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The development of long-lived luminescent nanoparticles for multiphoton lifetime 
imaging is of high interest in cancer research especially for in vivo experiments which 
allows for quantification of angiogenesis and cancer metastasis. Multiphoton imaging 
can reach up to several millimetres in depth detection, thus providing invaluable 
information on tumour vasculature and the microenvironment of the tumour. Detection 
of luminescence lifetimes is extremely sensitive to local environmental changes and is 
independent of probe concentration. Luminescent cyclometalated iridium(III) 
complexes were conjugated onto gold nanoparticles to produce novel multiphoton 
lifetime imaging nanoprobes. These nanoprobes show characteristic long luminescent 
lifetimes from the iridium(III) complex in the range of hundreds of nanoseconds and a 
short-lived signal on the scale of picoseconds from the gold, allowing for multichannel 
detection of these nanoprobes through lifetime imaging. This is the first report of 
multichannel phosphorescence and fluorescence lifetime imaging being applied to 
functionalised gold nanoparticle within cancer cells. The sensitivity of the iridium signal 
on the local environment of the cell was used to successfully map localisation within 
HeLa cells. The combination of the sensitivity of the iridium signal to the cellular 
environment together with the targeting nanoscaffold to guide delivery, offer 
opportunities for iridium nanoparticles to be used for targeting and tracking in in vivo 
models. The ability for these nanoprobes to selectively target cancer cells was 
investigated by conjugating monoclonal antibodies and SiRNA. Multiphoton lifetime 
imaging revealed uptake of these nanoprobes into cancer cells, and detection of 
luminescence lifetimes were sensitive to local changes in the environment. These 
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functionalised nanoprobes were investigated in applications for selectively targeting 
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CHAPTER 1. INTRODUCTION 
1. 1 Iridium(III) complexes for imaging applications 
1. 1. 1 Luminescence imaging 
Fluorescence based microscopy has revolutionised the way scientists visualise 
complex biological systems for biomedical applications. These optical imaging 
techniques have improved over the past few decades due to synthesis of imaging 
probes which enhance fluorescence signal for improved visualisation.1 The design of 
these fluorescent complexes are important and a lot of research has been carried out 
to optimise these probes over the past few decades. The factors that need to be 
considered in the design of a fluorescent probe are photophysical properties, uptake 
into cells, toxicity and solubility in biological media.2 Small-molecule organic probes 
have traditionally been used for in vitro imaging of cellular structures and biological 
events. This is because these probes can be easily modified for the selective targeting 
of specific organelles and proteins within cells.3, 4 However, these organic dyes can 
suffer from photobleaching, poor absorptivity and solubility in biological medium.5  In 
recent years research has shifted towards using heavy-metal transition metal 
complexes as biological imaging probes as they have many advantages over 
conventional organic dyes.6, 7 Transition metal complexes have favourable 
photophysical and electrochemical properties which makes them ideal candidates for 
optical and time-resolved imaging applications. There are several reasons why these 
luminescent transition metal complexes are desirable for bioimaging applications. 
Firstly, these complexes have extremely high photostability in comparison to organic 
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dyes which prevents photobleaching throughout prolonged exposure to irradiation. 
This is favourable for experiments requiring long-term observation of a biological 
specimen.8, 9 Secondly, they display intense and long-lived emission with a large 
Stokes shift in the visible region, which reduces the ability for these complexes to 
undergo self-quenching.10, 11 Many of these transition metal complexes display long-
lived phosphorescence with luminescence lifetimes on the time scale of nanoseconds 
to microseconds.12-14 Such long lifetimes can be utilised for eliminating background 
autofluorescence from biological samples by using time-resolved based techniques.15 
These techniques are extremely sensitive in comparison to emission-based 
microscopy methods.16 Lastly, these complexes have good solubility in water and high 
luminescence quantum yields. These transition metal complexes can be readily 
functionalised with ligands to selectively target organelles17, 18 and DNA19, 20 within 
cells.  
Many transition metal complexes have been studied as biological imaging reagents. 
The most commonly studied have been d6 heavy metal complexes based on Ru(II), 
Ir(III), Re(I) and Rh(III) centres and d8 heavy metal complexes based on Pt(II) 
centres.21 Iridium(III) cyclometalated complexes are popular luminescent probes for 
biological imaging,22 as their luminescent signal can be tuned by modification of their 
ligand framework,23 which also  influences localisation in cell organelles.24,25 In 
comparison to other d6 heavy metal complexes, luminescent iridium(III) complexes 
have longer luminescent lifetimes26, higher quantum yields and the iridium(III) metal 
centre can be functionalised with a wide range of cyclometalating ligands to tune their 
photophysical properties.27-30 These make iridium(III) complexes desirable for 
applications in fluorescence and time-resolved microscopy.  
1. Introduction 
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There are lots of examples in the literature of iridium(III) complexes being used as 
bioimaging probes. Huang et al. showed uptake of cationic iridium(III) complexes into 
the cytoplasm of living cells. This was the first example of an iridium(III) complex being 
used as a live cell imaging stain.31 The luminescence imaging showed that these 
cationic iridium(III) complexes had specificity for staining the cytoplasm of the cells 
over other organelles such as the nucleus and further analysis of the iridium 
luminescence revealed little to no signal localised within the nucleus (Figure 1.1). 
 
Figure 1.1. (Top) Chemical structure of iridium(III) complexes 1 and 2. (Bottom, 
left) Luminescence images (a and d) and bright-field images (b and e) of living 
HeLa cells incubated with 20 mM 1 (top) and 2 (bottom) in DMSO/PBS (pH 7, 1 
:49, v/v) for 10 min at 25 °C. (c and f) merged imaging of iridium signal and bright-
field images. ex = 405 nm. (Bottom, right) Luminescence images and 
luminescence intensity profiles (across the lines shown in (a and c) of HeLa cells 
incubated with 20 mM 1 or 2 in DMSO/PBS (pH 7, 1 :49, v/v) for 10 min at 25 °C. 
Signal-to-noise ratios (I2/I1) and cytoplasm-to-nucleus ratios (I2/I3) shown in the 
right hand column.31 
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Iridium(III) complexes have also been used to target specific biomolecules and 
substrates within cells, through the functionalisation of the iridium(III) centre with 
targeting ligands. This was seen in the research carried out by Lo et al. who developed 
the first luminescent iridium(III) polypyridine complexes as labelling reagents for 
biological substrates.32 They showed successful labelling of BSA and holo-transferrin 
present in human serum albumin to give luminescent bioconjugates. The group went 
onto study the interactions of iridium(III) polypyridine indole complexes with BSA and 
saw an emission enhancement and lifetime extension upon binding to BSA for all the 
complexes. Luminescence studies revealed that uptake of iridium(III) complexes (3a) 
mainly localised around the perinuclear region of HeLa cells (Figure 1.2, B).  
 
Figure 1.2. (A) Chemical structures of cyclometalated iridium(III) indole 
complexes. (B) (Left) Fluorescence, (Middle) Brightfield and (Right) overlaid 
images of HeLa cells incubated with complex 3a (5 M) at 37 °C for 1 hour. (C) 
Confocal images of HeLa cells incubated with (Left) Ir-BSA and (Right) Ir-TF at 
37 °C for 1 hour.32 
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To understand the mechanism of uptake, BSA was labelled with an amine specific 
luminescent iridium(III) polypyridine isothiocyanate complex (Ir-BSA). The 
luminescence images showed that uptake of Ir-BSA complex was mainly confined to 
the perinuclear region which was the same pattern of uptake as previously seen for 
complex 3a (Figure 1.2, C). Since the uptake of BSA into cells occurs through receptor 
mediated endocytosis33, 34, it was concluded that the iridium(III) polypyridine indole 
complexes follow the same mechanism of uptake. Since these cyclometalated 
iridium(III) complexes have desirable photophysical properties and have shown to be 
taken up readily into cells, studies have been done to investigate whether these 
complexes can be used to specifically target cellular organelles. Lo et al. designed a 
luminescent cyclometalated iridium(III) polypyridine poly(ethylene glycol) complex that 
localised within the mitochondrial region of HeLa cells (Figure 1.3).  
 
Figure 1.3. (Left) Luminescence images of HeLa cells incubated with complex 3a 
(100 M, ex = 405 nm) at 37 °C for 2 hour followed by incubation with (Middle) 
MitoTracker™ Deep Red (100 nM, ex = 633 nm) for 20mins at 37 °C. (Right) 





This was confirmed by co-incubating HeLa cells with the iridium(III) complex (100 M, 
2 hours, ex = 405 nm) and Mitotracker™ Deep Red (100 nM, 2 hours, ex = 633 nm). 
A high accumulation of iridium(III) PEG complex was found within the mitochondria 
which was seen through the co-localisation of the iridium signal and Mitotracker™ deep 
red signal in the luminescence images.35 Iridium(III) complexes have often been 
synthesised to target the mitochondria within cells and to track mitochondrial dynamics. 
Chao et al. synthesised four phosphorescent iridium(III) complexes (Ir1-Ir4) which 
showed high specificity for targeting mitochondria in live and fixed cells (Figure 1.4).  
 
Figure 1.4. Luminescence images of live HeLa cells incubated with 5 M Ir1-Ir4 
in DMSO and PBS for 1 hour at 37 °C, followed by 50 nM MitoTracker Red (Ir1 
and Ir2) and MitoTracker green (Ir3 and Ir4), respectively. Lane 1, luminescence 
images of Ir1-Ir4. Lane 2, luminescence images of MitoTracker Red and 
MitoTracker Green. Lane 3, merged images of iridium luminescence and 
MitoTracker luminescence. Lane 4, bright-field images and Lane 5 merged 
images of iridium signal, MitoTracker luminescence and bright-field.36 
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It was found that the emission properties could be tuned by modifying the ligands 
around the iridium(III) centre whilst retaining the specificity in targeting mitochondria in 
live cells. All the iridium(III) complexes were taken up into the mitochondria of the cells, 
which was identified through co-localisation of the iridium signal and Mitotracker™ 
red/green signals respectively which was seen in the luminescence images. ICP-MS 
revealed uptake of iridium(III) complexes was 80% into the mitochondria in comparison 
to other areas of the cell (cytoplasm and nucleus), indicating strongly of mitochondrial 
staining.36 The group furthered this research by synthesising mitochondria specific 
probes based on iridium(III) imidazo[4,5-f][1-10]phenanthroline derivatives which 
excelled at staining the mitochondria in comparison to commercially available 
mitochondrial stains (Figure 1.5). These iridium(III) complexes showed excellent 
photostability and selectively for staining the mitochondria during short incubation 
times.37 This work identifies the benefits of using transition metal complexes as 
luminescence and cell specific probes in biomedical applications. The desirable 
photophysical properties and selectivity for mitochondria led to these iridium(III) 
complexes being investigated as two-photon imaging probes which will be discussed 





Figure 1.5. Luminescence images of living HeLa cells incubated with 0.5 mM of 
MitoIr1-MitoIr6 in DMSO and DMEM for 15 minutes at 37 °C followed by 50 nM of 
MTR. Lane 1 luminescence images of MitoIr1-MitoIr6; lane 2 luminescence 
images of MTR and Lane 3 overlay of lane 1 and 2 and brightfield. Excitation 
wavelength: 405 nm (for all Ir(III) complexes) and 488 nm (for MTG).36  
 
Iridium(III) complexes have also been investigated for their abilities to selectively target 
and stain the nucleus of cells. Most commercially available nuclear dyes often suffer 
from photobleaching and the use of irradiation in the UV range (405 nm) which can 
cause damage to the cells after prolonged irradiation. These iridium(III) complexes can 
overcome these limitations as cells can be dosed with lower concentrations of the 
iridium(III) probes, they have shown to be highly photostable and irradiation can be 
done at longer visible wavelengths. Li et al. showed this by designing non-emissive 
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iridium(III) complexes that specifically light-up when binding to the nuclei of living cells 
(Figure 1.6, a).38 
 
Figure 1.6. (a) Luminescence images of living HeLa, FLS, KB and MSC cells 
incubated with 10 M LIr1 in DMSO/PSB PBS (pH 7.4, 1:99, v/v) for 10 min at 37 
°C (ex = 488 nm, em = 520 nm). (b) Intensified luminescence images (inset). (c) 
Luminescence intensity profile across the line shown in panel b corresponding 
to extracellular region (1), nuclear region (2) and cytoplasm (3 and 4).38 
 
They identified that the iridium(III) complex reacts with histidine and histidine-
containing proteins to form a luminescent emission product when localised in the 
nucleus of living cells. High specificity and accumulation was seen in the nucleus after 
only 10 minutes of incubation with iridium(III) complex, this was evident from the 
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luminescence intensity profile going across the whole cell (Figure 1.6, b and c) which 
showed iridium signal only present within the nucleus of the cells. This shows how 
selective these transition metal complexes can be in targeting organelles and DNA 
within cells by modifying the ligands that surround the metal core. 
1. 1. 2 Multiphoton imaging 
As discussed, emission based imaging methods such as standard fluorescence 
microscopy has been on the forefront for imaging biological samples with a variety of 
luminescence probes. However, the use of one-photon excitation presents many 
disadvantages for imaging thicker biological samples. This is because visible light is 
highly scattered within biological samples and tissues which limits the depth it can 
penetrate whilst still providing enough power to excite a fluorophore. Therefore, the 
field has moved to multiphoton microscopy which has become an invaluable tool in 
cancer research for in vivo applications such as studying angiogenesis and cancer 
metastasis, where these thick tissues are insufficiently studied by single-photon 
techniques.39,40. Hence, the design of luminescent probes that can undergo 
multiphoton excitation is of great interest in biomedical imaging and drug-delivery 
applications.  
Multiphoton microscopy uses fluorophores that are excited by the simultaneous 
absorption of two or more low energy photons. This differs from single-photon 
excitation which uses one high energy photon for excitation of a fluorophore. For two-
photon microscopy; the photons have half the energy needed for excitation in 
comparison to single-photon excitation and therefore light of twice the wavelength is 




Figure 1.7. Jablonski diagrams for (A) single-photon excitation and two-photon 
excitation. (B) Schematics of one-photon versus two-photon fluorescence 
emission.42  
 
The use of low energy photons over high energy photons provides many advantages 
of using multiphoton excitation over single-photon excitation. In multiphoton 
microscopy, excitation occurs in a small focal plane in thick samples as this focal point 
has a high enough photon density for the simultaneous absorption of two photons. 
Effectively, this means that out-of-focus fluorescence is significantly reduced which 
leads to less photobleaching and phototoxicity in cells.43 In comparison to single-
photon excitation which occurs throughout the sample both above and below the focal 
plane and generates more out-of-focus fluorescence which increases photobleaching 
and phototoxicity in cells (Figure 1.8, A).44 The use of longer, near infrared wavelengths 
allows for better depth of penetration in tissues. This is because visible light is often 
scattered in biological tissues which limits the depth of penetration, whereas biological 
1. Introduction 
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compounds absorb and scatter light significantly less at these longer near infrared 
wavelengths which are used in multiphoton excitation (Figure 1.8, B).45 
 
Figure 1.8. Advantages of multiphoton excitation in comparison to single-photon 
excitation. (A) Reduced out-of-focus light occurs in multiphoton excitation due 
to the small focus volume. For 1P, the excitation occurs above and below the 
focal plane whereas for 2P only occurs in a highly-localised area.44 (B) The 
biological optical window showing significantly less absorption between 700 – 
900 nm wavelengths from biological molecules within cells.45  
 
The design of fluorescent probes for multiphoton applications relies on fluorophores 
with the ability to undergo two-photon excitation and have a high two-photon 
absorption cross-section (σ2).  This is the probability for a compound to undergo two-
photon absorption (TPA).46 There have been significant developments in this field over 
the past couple of decades for designing two-photon absorbing materials with large 
two-photon absorption cross-sections.47 For this reason organic compounds are often 
used in multiphoton imaging, although these organic probes suffer for many limitations 
such as low photostability and poor solubility. Due to these limitations transition metal 
complexes have been investigated as multiphoton probes due to their desirable 
photophysical properties and cellular selectivity in addition to having large two-photon 
absorption cross-sections. Studies have shown that metal complexes based on Pt(II)48-
50, Ru(II)51-53 and Ir(III)53-55 can undergo multiphoton excitation with large two-photon 
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cross-sections. Iridium complexes have been extensively studied for their uses as 
multiphoton imaging probes as they have shown to exhibit desirable non-linear 
absorption properties and have rich photochemical properties. Additionally, these 
iridium complexes have long excited state lifetimes making them excellent candidates 
for lifetime imaging applications whilst still being able to benefit from multiphoton 
excitation.56-58 Another desirable property of iridium(III) complexes is the ability to 
readily modify the cyclometalated ligands to enhance their two-photon absorption 
cross-sections. Fan et al. showed that a series of triscyclometalated iridium complexes 
with different oligofluorene-substituted ppy ligands, displayed a range of high two-
photon absorption cross-sections (Figure 1.9).59  
 
Figure 1.9. (Left) Iridium(III) complexes studied for multiphoton absorption 
experiments. (Right) Two-photon absorption cross-sections calculated for each 
iridium(III) complex. TPA cross sections (1 GM = 10-50) were measured with a 





Amongst all the iridium(III) complexes, 2-cz displayed the highest TPA cross-section. 
This is to be expected with the iridium(III) complex containing three carbazole-
terminated trifluorenyl ppy ligands. This shows that the structural design of the ligands 
around the metal centre can have a major impact on the TPA properties. Edkins et al. 
went on to analyse the TPA cross-sections of neutral iridium(III) complexes with 
variations in the cyclometalating ligand, 2-phenylpyridine, and ancillary ligands. The 
results showed that these iridium(III) complexes displayed high TPA cross-sections at 
800 nm (Figure 1.10).60 
 
Figure 1.10. (Left) Two-photon absorption spectra (black, bottom abscissa, left 
ordinate) and single-photon (UV-Vis) spectra (red, top abscissa, right ordinate). 
Graphs have been annotated showing two-photon absorption cross-sections at 
800 nm. (Right) Corresponding structure of iridium(III) complex studied for these 
experiments.60 
 
There were little differences seen in TPA cross-sections between the iridium(III) 
complexes with the range being between 10 – 20 GM. This was improved by 
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implementing structural features known to increase the TPA in organic material.61 
Therefore, extending the π network conjugation within the framework of a molecule led 
to the synthesis of Ir(4-pe-2-ppy)2(acac) which displayed a TPA cross-section of 44 
GM at 800 nm. This was more than double the TPA cross-section recorded for 
Ir(ppy)2(acac), which was found to be 20 GM at 800 nm. This research showed that 
careful design of these iridium(III) complexes can lead to high TPA cross-section whilst 
still retaining desirable photophysical properties for a range of biomedical imaging 
applications. The ability to improve the TPA properties of these transition metal 
complexes through rational design of the conjugated ligands, would prove invaluable 
for multiphoton applications. 
A range of iridium(III) complexes have been designed for multiphoton microscopy and 
found to have high multiphoton absorption properties. Additionally, their ligands can be 
tuned for the selective targeting for organelles and biomolecules within cells. Wong et 
al. developed a heteroleptic iridium(III) complex that could specifically target the Golgi 
Apparatus in vitro using multiphoton microscopy. The results showed high 
accumulation of the phosphorescent iridium(III) complex within the Golgi Apparatus, 
which could be seen through complete co-localisation of the iridium signal with the 
Golgi stain using two-photon excitation (Figure 1.11). TPA cross-section was taken 
and found to be 340 GM at 750 nm, which is one of the highest recorded values for 




Figure 1.11. (TOP) Structure of Iridium(III) complex (2). (Bottom) (Left) Golgi 
marker Alexa Fluor 647 conjugates of HPA (Invitrogen L32452) (λex= 647 nm, 
band pass filter = 650 – 750 nm, 10 min exposure) in HeLa cells; (Middle) two-
photon microscopy images (ex = 700 nm, band pass filter = 500 – 640 nm; (Right) 
merged image.62 
 
Additionally, selectively targeting mitochondria is of high importance due to its 
proposed role in many diseases. This was demonstrated by Chao et al.  when two-
photon phosphorescent iridium(III) probes for detecting hypochlorite ions (ClO-) in 
mitochondria were developed. Multiphoton excitation is sought out for these 
applications because of the increased penetration depths achieved and reduced out-
of-focus fluorescence within the cells, making it easier to visualise mitochondria 
dynamics. The synthesised iridium(III) complex contained a diaminomaleonitrile group 
which specifically reacted with ClO- to form a carboxylate product (Figure 1.12, Top).63 
Studies have shown that abnormal levels of ClO- is linked to many diseases and 
therefore this shows the importance of developing probes that can specifically detect 
this reactive species within mitochondria.64-66 When this reaction occurred a significant 
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enhancement in phosphorescence intensity was observed under one-photon (405 nm) 
and two-photon (750 nm) excitation, with a TPA cross-section (σ2) of 78.1 GM being 
recorded. MitoTracker™ Green was used for co-localisation experiments between the 
Mitotracker and iridium signal. The results showed high specificity and sensitivity for 
detecting ClO- in the mitochondria through the fluorescence response of the iridium(III) 
probe (Figure 1.12, Bottom).  
 
Figure 1.12. (Top) Reaction mechanism of Ir-dmn with ClO-. (Bottom) Single-
photon and Two-photon microscopy images of exogenous ClO_ in HeLa cells. 
(a) OPM of cells incubated with MitoTracker Green for 30 min, ex = 488 nm, em 
= 500 – 540 nm; OPM (b) and TPM (e) image of cells pre-treated with NaClO (10 
M) for 1 h and then treated with Ir-dmn (10 μM) for another 1 h, ex = 405 nm 
(OPM)/750 nm (TPM), em = 580-620 nm; (d) Bright-field image of cells; (c) Overlay 
image of (a), (d) and (b); (f) Overlay image of (a), (d) and (e). Scale bar: 10 m.63 
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Chao et al. went on to develop iridium(III) complexes that could visualise and track 
mitochondria within living cells using multiphoton microscopy. Understanding the 
dynamics and functions of mitochondria could help answer many questions relating to 
diseases such as cancer, neurological disorders and aging. Single-photon and two-
photon fluorescence showed localisation of these iridium(III) complexes in the 
mitochondria by co-localisation of the iridium signal and MitoTracker™ Green signal. 
This was confirmed by ICP-MS which showed 80 – 90 % of the iridium(III) complexes 
localised within the mitochondria of the cells in comparison to other areas (cytoplasm 
or nucleus). The TPA cross-sections were found to be 60 – 65 GM at 750 nm, which 
is extremely high for iridium(III) complexes. However, the most important aspect of this 
work was to show the power of using two-photon excitation for imaging thick tissues, 
since the two-photon penetration depth is greater than that achieved through single-
photon excitation. To prove this, they used a 3D multicellular spheroid that contained 




Figure 1.13. (Top) Iridium(III) complexes; IrL1 – IrL5. (Bottom) (a) Single-photon 
microscopy (left) and two-photon microscopy (right) images of 3D multicellular 
spheroids after incubation with IrL2 (500 nM) for 0.5 hours. (b) Z-stack images 
were taken every 7 m sections along the Z-axis of an intact spheroid. (c) The 
merged images of Z-stack images of an intact spheroid. Excitation is 405 nm for 
single-photon excitation and 750 nm for two-photon excitation. Scale bar = 100 
m.67 
 
They found that with complex IrL2, luminescence signal could be seen down to depths 
of 90 m using single-photon excitation and 250 m using two-photon excitation. Two-
photon excitation allowed for strong phosphorescence signal to be detected deep 
within the spheroid which was not achievable with single-photon excitation, showing 
the importance of having a carefully designed probe for multiphoton imaging of 
tissues.67 This group then went on to investigate the uptake of iridium(III) complexes 
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specifically into mitochondria which was monitored by phosphorescence lifetime 
imaging, due to their desirable photophysical properties. Combining lifetime based 
imaging with multiphoton excitation has become a widely sought out tool for bioimaging 
due to its sensitivity of detection and complete elimination of background 
autofluorescence. Transition metal complexes are often used for multiphoton lifetime 
applications because they emit a long-lived excited state and are known to have high 
TPA cross-sections making them desirable candidates for this technique. 
1. 1. 3 Lifetime imaging 
Multiphoton lifetime imaging works by detecting the luminescence lifetimes of the 
transition metal probes which offers a more sensitive method of detection in 
comparison to emission based techniques. Fluorescence lifetime imaging microscopy 
(FLIM) detects the short-lived fluorescence lifetimes of a fluorophore within a sample. 
FLIM probes have been developed and are traditionally based on organic probes with 
short nanosecond lifetimes. There are a few examples of iridium(III) complexes being 
used as FLIM probes within cells. This was demonstrated in a peptide-iridium complex 
which was designed to selectively target CXR4 receptors on the surface of tumour 
cells, and could be visualised using fluorescence lifetime imaging (Figure 1.14).68 The 
FLIM images revealed clear specificity of these peptide conjugated iridium(III) 
complexes to the receptor of tumour cells, in comparison to unconjugated probes 




Figure 1.14. (A) FLIM image of MDAMB231CXCR4+ cells incubated with 1 m of 
peptide functionalised iridium(III) complex (8). The scale bar indicates the 
lifetime range (60 ns to 200 ns). (B) FLIM images of MDAMB231CXCR4+ cells 
without conjugates (8). The scale bar indicates lifetime range of 0 – 10 ns 
detected. 68 
 
Analysis of the lifetimes within the FLIM images revealed lifetimes of 60 – 200 ns for 
the conjugated probes and 0 – 10 ns for unconjugated probes. This can be seen 
visually within the FLIM images where the peptide iridium(III) complex can be seen 
accumulated around the cell membrane of cancer cells, whereas the unconjugated 
probe is dispersed on the bottom of the coverslip with no uptake into cells. One of the 
disadvantages of FLIM is detection of these nanosecond lifetimes are in the same 
range as the lifetimes detected from cellular autofluorescence (1 – 20 ns) which limits 
the probes’ sensitivity.69, 70 The advantage of using iridium(III) complexes is the ligands 
can be tuned for specific applications. Furthermore, most iridium(III) complexes exhibit 
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long-lived luminescence lifetimes which can extend into the millisecond range making 
them ideal candidates for phosphorescence lifetime imaging microscopy (PLIM). PLIM 
detects these long-lived lifetimes which can be completely gated from short-
nanosecond lifetimes associated with autofluorecence, expanding sensitivity and 
signal detection for these transition-metal complexes.71 Furthermore, this technique 
can be combined with multiphoton excitation which is advantageous for deep tissue 
imaging, as mentioned previously. Iridium(III) complexes are known to have long-lived 
phosphorescence lifetimes and can be excited by two-photon excitation to produce 
large TPA cross-sections. The power of detection by lifetime imaging of metal 
complexes72 has been demonstrated in iridium(III) complexes for biomedical 
applications such as imaging cellular organelles, cancer metastasis and hypoxia. 
Two-photon lifetime imaging has been demonstrated using iridium(III) complexes 
containing diphosphine ligands that could selectively target mitochondria for anticancer 
therapeutic applications.73 These iridium(III) complexes were shown to accumulate 
within the mitochondria of A549 cells which was confirmed by confocal microscopy, 
lifetime imaging and ICP-MS. It was found that the iridium(III) complexes have viscosity 
dependent lifetimes which allowed for detection of changes in the mitochondria 
microenvironment with high sensitivity. The viscosity changes within the mitochondria 
has shown to affect protein-protein interactions and has been associated with diseases 
such as diabetes and atherosclerosis. Being able to monitor the changes in 
mitochondrial viscosity has remained a challenge using other fluorescence microscopy 
techniques. The results showed the average luminescence lifetimes recorded within 
the mitochondria for Ir6 increased from 1,410 ns to 1,792 ns upon increase in 
mitochondrial viscosity (Figure 1.15, B). It is known that each separate mitochondrion 
1. Introduction 
 23 
within the same cell can respond differently to external stimuli74, 75, but detecting these 
individual organelles responses is extremely difficult and often limited. 
 
Figure 1.15. (A) Structure of iridium(III) complex, Ir6. (B) Mitochondria viscosity 
for Ir6-treated A549 cells detected by two-photon PLIM. The cells were treated 
with Ir6 (20 mm) and imaged at different time intervals. (C) Determination of 
mitochondria heterogeneity. A549 cells treated with Ir6 (20 mM) for 4 hours. 
The enlarged images are from the red boxes. The lifetime and viscosity are 
calculated from the spots in the red circle. ex = 750 nm (Ir6); em = 550 (Ir6).73 
 
Since PLIM is sensitive to local changes in environment, it can be used to determine 
the heterogeneity of mitochondria (Figure 1.15, C). The results revealed differences in 
lifetimes detected from the Ir6 complex in different areas within the mitochondria, this 
is highlighted in the insets which correspond to the red boxed present on the lifetime 
images. This shows how sensitive two-photon lifetime imaging can be for detecting 
small changes in the local microenvironment at a subcellular level. Iridium(III) 
complexes have the potential to be used as multiphoton lifetime imaging probes for in 
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vivo applications due to their high TPA cross-sections and long-luminescence lifetimes. 
The power of detection by lifetime imaging of metal complexes has been demonstrated 
in iridium(III) complexes in tumour imaging for cancer metastasis76 and  hypoxia.77 For 
these iridium(III) complexes to be successfully used for in vivo applications, their 
luminescence lifetimes need to be detected in thick samples, which requires a deeper 
penetration depth of the excitation light.  This was demonstrated by Chao et al. in which 
the penetration depth of multiphoton excitation allowed for imaging of 3D spheroids 
and phosphorescence lifetime imaging was sensitive enough to detect iridium(III) 
complexes within the mitochondria and multicellular tumour spheroids (MCTS) with 
complete elimination of background autofluorescence (Figure 1.16).78 
 
Figure 1.16. (a, e and i) Brightfield and (b, f and j) Two-photon excited PLIM 
images of iridium(III) complex in cells, 3D MCTSs and hippocampus slice. (c, g 
and K) kinetic traces from the selected regions of (b), (f) and (j). (d, h and l) 
Lifetime distribution for Ir(III) complexes = 730 nm. Scale bar = 20 m (a) and 200 




The images revealed a high accumulation of iridium(III) complexes into the 
mitochondria of cells which can be seen in cyan on the lifetime images (Figure 1.16, 
b). Long-luminescence lifetimes of around 460 ns were detected and found to be 
evenly distributed throughout the mitochondria. MCTSs were used as a model in these 
experiments to mimic the extracellular matrix of tumours. This is a more accurate 
representation of the tumour microenvironment and in understanding how the iridium 
probes behaves in this complex environment. The results showed that the lifetimes 
recorded for the iridium(III) complex seems to vary throughout the spheroid. This was 
to be expected as the oxygen levels within the spheroid change throughout (Figure 
1.16, f). The results showed that phosphorescence lifetime microscopy can be used 
for applications in oxygen sensing as well as tissue imaging. Since the aim of this work 
was to characterise these probes for tissue imaging, PLIM was carried out on 
iridium(III) complexes taken up in rat hippocampus tissue slices (Figure 1.16, j). PLIM 
could resolve the structural details of the tissue regions in much higher resolution than 
the corresponding wide-field image (Figure 1.16, j). The lifetime detected were found 
to be 1120 ns, which could be differentiated from the lifetimes recorded in cells (460 
ns), showing not only sensitivity to local environment changes but also selectively to 
different cell types. 
1. 2 Gold Nanoparticles for imaging applications 
1. 2. 1 Luminescence imaging  
Another novel area of research is looking at using nanoparticles and their applications 
in fluorescent bioimaging.79, 80 These nanoparticle probes have received a lot of 
interest for bioimaging because of their unique photophysical properties, ease of 
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synthesis and tuneable optical properties.81-83 Nanoparticles can be synthesised in 
various shapes and sizes and their surface can be functionalised with various ligands 
for selective targeting and drug delivery applications.84 There are many advantages for 
using nanoparticles over molecular probes. Most nanoparticles, such as gold 
nanoparticles, do not suffer from photobleaching, which is an inherit property of 
molecular dyes and they have shown to be non-toxic within cells.85 Nanoparticles can 
easily accumulate within cells and tissues and can be used to target specific molecular 
sites.86-88 The biggest advantage of using nanoparticles is that their surface can be 
used as a scaffold for the conjugation of biomolecules and synthetic ligands. The 
nanoparticles can be conjugated with luminescent probes for bioimaging 
applications,89, 90 biomolecules for selective targeting of specific receptors91, 92 or drug 
compounds for targeted delivery of these compounds into cells.93, 94 Nanoparticles 
have been used for many applications in biomedicine, from imaging to diagnostics to 
targeted cancer therapies.95, 96 To date a range of nanoparticles have been used 
including carbon nanotubes97-99, quantum dots100, 101, magnetic nanoparticles102, 103 
and gold nanoparticles.  
Gold nanoparticles (AuNPs) have often designed for biomedical imaging applications 
because they are readily taken up by cells with low cytotoxicity, tuneable optical and 
electrochemical properties and their surface can be easily modified with imaging 
probes104, 105 and biomolecules for targeting.106, 107 Whereas, in comparison to other 
nanoparticles such as upconverting nanoparticles108, 109 or Quantum Dots, the 
synthesis for these nanoparticles is often difficult and they have shown to exhibit high 
cytotoxicity within cells. The internalisation of gold nanoparticles has been investigated 
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by multiple microscopy techniques such as two-photon luminescence, scattering, 
lifetime imaging, electron microscopy and fluorescence microscopy. 
The most common technique employed is electron microscopy which provides high 
resolution imaging of gold nanoparticles to show localisation within cells. However, the 
drawback of this technique is the sample preparation which requires cells to be fixed 
and only thin sections are imaged. This means that this technique cannot be used for 
real-time imaging of cells in vivo, which is a major drawback. Optical based techniques 
overcome these limitations and can view nanoparticles within cells in real-time. Gold 
nanoparticles have been employed for optical imaging because of their unique 
fluorescence induced by single and two-photon excitation. Gold nanoparticles have a 
characteristic surface plasmon resonance (SPR) which can change based on the 
shape, size and surface coating of the nanoparticles. This SPR scattering properties 
allows these nanoparticles to be detected by both fluorescence and reflectance 
microscopy techniques using both single and multiphoton excitation wavelength.110, 111 
This was demonstrated by Ren et al. where 38 nm gold nanoparticles (AuNPs) were 
efficiently taken up into cancer cells, and the luminescence signal could be detected 
to identify single gold nanoparticles (surface not functionalised with any luminescent 




Figure 1.17 Bright-field images (a) and fluorescence images of HeLa cells 
incubated with 38 nm GNPs (b) before and (c) after 5 min photobleaching. The 
other two images in the same row for each imaging condition are shown to test 
reproducibility. Exposure time: 5 s.112 
 
The results showed that after photobleaching with a high laser intensity, the AuNPs 
could still be detected within cells and suffered no photobleaching. Irradiation with high 
laser powers meant that cell autofluorescence was removed, to leave only the 
luminescence signal of the gold nanoparticles within cells, which allowed for single 
particles to be detected over background signal. This would not be possible with many 
organic and inorganic probes which suffer from photobleaching during laser irradiation. 
However, even though the intrinsic luminescence of gold nanoparticles can be 
detected by reflectance microscopy, the emissive properties are sensitive to the size, 
shape and morphology of these particles making it difficult to predict its luminescence 
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in vitro and in vivo for their uses as reliable imaging probes. Therefore, research has 
shifted to developing luminescent nanoprobes by modifying the gold surface with 
luminescent probes which allows for bimodal imaging using the unique signature from 
the gold and the luminescence signal from the bioimaging probe. The large surface 
area of AuNPs allows for hundreds to thousands of luminescent agents to be attached 
to the surface. Often metal complexes are functionalised onto the gold surface for 
medical imaging such as positron emission tomography (PET), magnetic resonance 
imaging (MRI), single-photon emission computed tomography (SPECT) and 
fluorescence imaging. As discussed previously, transition metal complexes have 
desirable photophysical properties and their ligands can be easily modified with thiol 
containing groups for attachment onto gold nanoparticles. Our group have 
demonstrated the successful coating of AuNPs with transition metal complexes based 
on ruthenium(II) and iridium(III) centres for imaging applications.113, 114 This was 
demonstrated using ruthenium(II) coated gold nanoparticles which showed high 






Figure 1.18. (a) Confocal reflection microscopy image exc = 488 nm, em = 478-
498 nm and (b) confocal luminescence microscopy of ruthenium exc = 453 nm, 
em = 555-800 nm.115 
 
It was found that the unique signal for the gold SPR band could be detected by confocal 
reflectance microscopy and was found to completely co-localise with the fluorescent 
signal from the ruthenium(II) complex. After a 24 hour incubation single non-
aggregated particles were observed within the cancer cells showing the high stability 
of these nanoparticles within cells after internalisation. These results led to the 
development of more luminescent ruthenium(II) complexes for attachment onto gold 
nanoparticle and their cellular fate was investigated.116 Transition metal complexes 
based on iridium(III) centres have been functionalised onto the surface of gold 
nanoparticles and the applications for in vivo imaging of blood flood investigated. 
Iridium(III) coated nanoparticles have shown to produce brighter nanoparticles in 
comparison to ruthenium(II) coated nanoparticles, therefore making them ideal 
candidates for imaging in flow systems.117 However, the excitation wavelength of 
iridium(III) complexes is usually in the UV range making them less suitable for single 
photon techniques due to the high cellular autofluorescence present at these 
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wavelengths. Since these iridium(III) complexes have shown to excite using 
multiphoton excitation with high two-photon absorption cross-sections, iridium(III) 
functionalised nanoprobes have the potential to be effective multiphoton imaging 
probes for in vivo applications. Not only is the excitation in the near infrared range 
desirable for in vivo applications but the long-lived luminescence lifetimes of iridium(III) 
complexes would allow multiphoton lifetime imaging applications. At present, 
functionalising gold nanoparticles with iridium(III) complexes for multiphoton lifetime 
imaging has not be explored. 
1. 2. 2 Multiphoton imaging 
It has been found that gold nanoparticles can exert strong photoluminescence which 
is enhanced under two-photon excitation. Research has found that photoluminescence 
can be enhanced by a factor greater than 1 million by exciting the surface plasmon 
resonance band of gold nanorods118. Utilising this phenomenon has made these gold 
nanoparticles attractive contrast agents for two-photon imaging, which is a powerful 
technique that is becoming a widely sought out technique for in vivo experiments 
specifically for cancer diagnostics and detection. This technique can non-invasively 
image up to several millimetres in depth, which allows for deep tissue imaging of sub-
cellular structures providing us insight into cancer and cancer processes. 
Nanoparticles that can undergo two-photon excitation have been used for many 
applications to label free contrast agents119, 120, photodynamic therapy121, 122 and 
targeting cancer cells123. Gold nanorods are attractive options as two-photon 
luminescence (TPL) contrast agents because their rod like shape provides a 
characteristic longitudinal plasmon resonance which can be excited in the near-
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infrared region to provide enhanced photoluminescence.110, 124 Excitation in this region 
makes them suitable candidates for imaging thick tissue samples for in vivo 
applications due to the greater depths achieved in the NIR region with these 
techniques. Wang et al. demonstrated the use of single gold nanorods for in vivo 
imaging of blood vessels through the strong two-photon luminescence signal from the 
gold (Figure 1.19).124 
 
Figure 1.19. (Left) Properties of two-photon luminescence from gold nanorods 
(a) TEM image, (b) Power dependence studies and (c – e) Photoluminescence 
spectra from solution of gold nanorods at excitation 730 (c), 780 (d) and 830 (e) 
nm. (Right) In vivo imaging of single gold nanorods in mouse ear blood vessels 
(a) Transmission imaging highlighting two blood vessels. (b) Two-photon 
luminescence image of gold nanorods (red dots) in flow. (c) Overlay of 
transmission image (light blue) and a single-frame TPL image. (d) TPL intensity 
profile from the linescan in c.124 
 
The results showed that the two-photon luminescence recorded from a single gold 
nanorod was ~58 times brighter than the two-photon luminescence from a single dye 
molecule such as Rhodamine 6G. These gold nanorods displayed extremely high two-
photon absorption cross-sections of 2,320 GM at 830 nm, in comparison to Rhodamine 
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6G which has a two-photon absorption cross section of 40 GM at 830 nm excitation. 
This high TPA cross section combined with the lack of photobleaching makes these 
gold nanorods superior contrast agents for two-photon imaging for in vivo applications. 
The strong two-photon luminescence emitted by these gold nanorods meant they could 
be detected in vivo without interference from background autofluorescence. These 
single gold nanorods were presented throughout the blood vessel appearing as 
individual red dots which were rapidly cleared by 30 minutes of imaging (Figure 1.19, 
right, b). This work showed a great example of the enhanced two-photon intensity 
present from gold nanorods and how this effect can be utilised in biomedicine for 
imaging under two-photon excitation.   
Another advantageous property of gold nanoparticles is their surface can be 
functionalised with biomolecules for selective targeting of cancer receptors. Durr et al. 
synthesised antibody coated gold nanorods that could selectively targeted cancer cells 
overexpressing EGFR, which could be detected through strong two-photon 
luminescence. The two-photon images showed accumulation of these antibody coated 
gold nanorods around the cell membrane of cancer cells overexpressing EGFR, which 
is where EGFR proteins are present, showing a high degree of specificity. When 
compared to unlabelled cells, two-photon signal from the antibody coated gold 
nanorods could be seen throughout the cytoplasm of the cells with no specificity for 
the outer membrane (Figure 1.20). The two-photon luminescence signal detection 





Figure 1.20. (Top) Two-photon images of cancer cells placed on a coverslip from 
a cell suspension. (a) TPL image of unlabelled cells. (b) TPL image of nanorod-
labelled cells. (c) TPL image of non-specifically labelled cells. (Bottom) Two-
photon imaging of cancer cells embedded in a collagen matrix at increasing 
depths. (a) TPL imaging of unlabelled cells and (b) TPL imaging of nanorod-
labelled cells. Both samples require the same excitation power increase of 26% 
at each 20 M depth increment to maintain constant emission intensity.123 
 
Quantum dots have been used for multiphoton imaging due to their larger two-photon 
absorption cross-sections, however they suffer from disadvantages of high cytotoxicity 
and photo blinking.125, 126 Gold nanoparticles with their many shapes and sizes have 
often been investigated as two-photon contrast agents because of their strong two-
photon photoluminescence (TPPL) and high multiphoton absorption cross-sections. 
When compared to organic fluorophores, gold nanoparticles excel as an imaging agent 
as they do not photobleach under multiphoton excitation. They have proven to be 
biocompatible in cells and are non-toxic, making them perfect candidates for 
biomedical imaging applications. Many different types of gold nanoparticles have been 
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studied for two-photon luminescence applications including gold nanorods (AuNRs), 
nanocages (AuNCs), nanotriangles (AuNT) and nanospheres (AuNS). This has been 
demonstrated using spherical gold nanoparticles of various sizes where strong two-
photon luminescence (TPL) could be detected within 3D spheroids (Figure 1.21).127 
 
Figure 1.21. Two-photon images of HCT116 cell spheroids used for estimation 
of AuNP uptake in cell spheroids. (Top) control spheroid (Bottom) cell spheroid 
incubated with AuNP. ex = 800 nm and emission filters for GFP signal 505 – 545 
nm (green) and AuNP luminescence 618.5 – 675.5 nm (red). Scale bar: 50μm.127 
 
The TPL images showed distribution of AuNPs within the 3D spheroids by detecting 
the two-photon luminescence signal from the AuNPs which could be completely 
separated from the GFP signal. Being able to detect luminescence signal at these 
depths is not achievable through single-photon excitation. Interestingly, this work 
revealed that smaller spherical gold nanoparticles could penetrate deeper into the 
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spheroid than rod shaped gold nanoparticles. This is invaluable knowledge for 
researchers designing cancer targeting probes based on gold scaffold, where tumour 
penetration depth is of high importance. The intrinsic behaviour of gold nanoparticles 
has shown their importance in in vivo imaging using multiphoton excitation. Combining 
this desirable excitation wavelength with long-luminescence lifetimes can be achieved 
through conjugation of transition metal complexes to the gold nanoparticle surface. 
This will not only allow for increased penetration depths for imaging thick tissues but 
would allow for the mapping of localisation and interactions of these nanoprobes with 
biomolecules due to the luminescence lifetime of the probe being sensitive to changes 
in the local microenvironment. 
1. 2. 3 Lifetime imaging 
Fluorescence lifetime imaging is becoming interestingly popular as a technique used 
to image nanoparticles. These lifetime based methods detect short-lived fluorescence 
lifetimes (FLIM) or long-lived phosphorescence lifetimes (PLIM). Lifetime imaging 
works by using a pulsed laser to induce fluorescence (short) and phosphorescence 
lifetimes (long) from a sample which are collected simultaneously in two different 
channels and monitored using a TCSPC (Time-Correlated Single Photon Counting) 
detector. Detection of the luminescent lifetimes offers more sensitivity in comparison 
to emission based techniques due to the complete elimination of cellular 
autofluorescence. This is achieved by gating the short lived background fluorescence 
(couple of nanoseconds) and only collecting the long-lived fluorescence lifetimes of the 
nanoparticles. Another advantage of lifetime imaging over emission based methods, 
is that the detection of luminescence lifetimes is independent of probe concentration, 
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thus lower concentrations can be used for cellular experiments. These luminescence 
lifetimes can be sensitive to changes in local environment which is an advantage when 
studying localisation or interactions with cellular proteins. Most cells and tissues exhibit 
autofluorescence due to proteins, chemicals and endogenous fluorophores being 
excited in the UV and visible region. However, their chemical lifetime is usually short, 
in the picosecond to nanosecond range. Therefore, using nanoparticles which have 
long fluorescence lifetimes in hundreds of nanoseconds range, would allow for 
complete elimination of background autofluorescence. This was demonstrated by 
Shang et al. where dihydrolipoic acid (DHLA) capped gold nanoclusters (AuNCs) were 
synthesised and found to contain attractive properties of bright near-infrared 
luminescence, high colloidal stability and good biocompatibility in cells. These 
nanoclusters showed long luminescence lifetimes (>100 ns), which were greater than 
the lifetime of cellular autofluorescence, allowing them to be used as fluorescence 
lifetime imaging (FLIM) probes.128 The results showed that upon internalisation of 
DHLA-AuNCs in live HeLa cells the average lifetimes increased from 442  13 ns to 
656  10 ns, showing the sensitivity of lifetime based techniques in detecting changes 
of the AuNC probes microenvironment. The localisation of these gold nanoparticles 
could be investigated through analysis of the fluorescence lifetimes. It was found 





Figure 1.22. Intensity (A,C) and FLIM (B,D) images of cells only (A,B) and cells 
incubated with 100 g/ML DHLA-AuNCs for 1 h (C,D). Scale bar: 10 m.128 
This showed that FLIM could be used to provide information on the localisation of these 
particles and identify change in the local environment. Since lifetime based imaging 
has shown to be extremely sensitive to changes in the local environment, Shang et al. 
developed lipoic acid capped AuNCs to identify temperature changes in HeLa cells, 
through detection of the gold fluorescence lifetime.129 The results showed that an 
increase in temperature significantly reduced the fluorescence lifetime from 970 ns at 
14 C to 670 ns at 43 C, showing the sensitivity of using lifetime based imaging 




Figure 1.22. Typical FLIM image of HeLa cells with internalised AuNCs at four 
different temperatures.129 
1. 3 Functionalised nanoprobes for lifetime imaging applications 
As previously discussed, advantages of lifetime imaging over emission based methods 
include elimination of background autofluorescence, less photobleaching and reduced 
phototoxicity. Detecting the short lived lifetimes through FLIM still has its limitations as 
lifetime changes are often small and can overlap with cellular autofluorescence. 
Therefore, research has shifted onto looking at using phosphorescence lifetime probes 
which typically have long-lived lifetimes in the hundreds of nanoseconds to the 
microsecond range. These phosphorescent probes can be detected with complete 
elimination of background autofluorescence which typically has lifetimes ranging from 
picoseconds to nanoseconds. Transition metal complexes have often been employed 
1. Introduction 
 40 
as lifetime imaging probes due to their favourable photophysical properties. They have 
long-lived lifetimes phosphorescence lifetimes ranging from microseconds to 
milliseconds making them ideal candidates for phosphorescence lifetime imaging 
(PLIM). Transition metals have desirable properties for imaging probes as they have 
shown to have tuneable emissions from the visible to near-infrared range, high 
luminescence quantum yields and are photostable. Additionally, their long 
phosphorescence lifetime can be sensitive to local environment, meaning these 
probes can be used for mapping, localisation and detection of biological molecules and 
systems (oxygens, H2S, pH). Functionalising nanoprobes with transition metal 
complexes would allow for detection using phosphorescence lifetime imaging. 
Currently in the literature there are no examples of transition metal complexes being 
conjugated onto the surface of gold nanoparticles for phosphorescence lifetime 
imaging applications. There are examples of other types of nanoparticles utilising the 
long-lived phosphorescence lifetimes of iridium(III) complexes. These examples are 
present below. Yu et al. developed a dual emissive nanohybrid for ratiometric and 
luminescence lifetime imaging of intracellular hydrogen sulphide. The design consisted 
of a mesoporous silica nanoparticle (MSN) which was embedded with an iridium(III) 
complex and a specific merocyanine derivative which showed a unique dual emission 
(Figure 1.23).130 This was the first example of lifetime-based imaging of H2S in live 




Figure 1.23. (a) Design and architecture of the nanohybrid for the detection of 
H2S. (b) PLIM images (a – d) of 1 g mL-1 Cy2-MSNs/Ir1 in PBS (pH = 7.4) upon 
addition of different concentrations of HS-. (c) PLIM images in live HepG2 cells 
co-stained by 10 g mL-1 Cy2-MSNs/Ir1 (a) and cells pre-treated with 10 g mL-1 
Cy2-MSNs/Ir1 followed by incubation with HS- (600 M) for 8 min (b). 130 
It was found that upon addition of HS- the lifetime of Cy2-MSNs/Ir1 decreased from 
105 to 70 ns, whilst the phosphorescence lifetime of Ir1 remained the same (307 ns). 
The average lifetime of Cy2-MSNs/Ir1 was found to be 215 ns and upon addition of 
NaHS the lifetime was reduced from 215  1.3 ns to 135  0.7 ns (Figure 1.23, b, a – 
d). Further analysis was carried out in live HepG2 cells to identify lifetime changes of 
the functionalised nanoprobe. It was found that the luminescence lifetime of Cy2-
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MSNs/Ir1 detected within the cells was 414 ns, which was longer than in aqueous 
solution. Addition of HS- (600 M) was added to the media causing a decrease in 
luminescence lifetime to 366 ns, making this an ideal candidate for sensing and 
mapping HS- concentrations in vivo (Figure 1.23, c). 
Subsequently after this work, more research was carried out on developing 
nanoparticles which could be used for lifetime imaging with various applications. Zhang 
et al. developed a core-shell structured silica nanoparticle which contained two 
phosphorescent iridium(III) complexes which were immobilised in the inner solid core 
and the outer mesoporous layer of the nanoparticles respectively for the detection of 
exogenous and endogenous hypochlorite in live cells using ratiometric imaging and 
photoluminescence lifetime imaging microscopy.131 The first iridium complex was 
prepared as a reference compound that was unreactive towards ClO-, whereas the 
second iridium(III) complex was designed as the responsive compound as it was 
reactive towards ClO-. The photophysical properties of the core-shell structured 
nanoparticles SiO2@mSiO2-2 in aqueous solution showed strong phosphorescence 
for both complexes 1 and 2 and displayed phosphorescence lifetimes of 83 ns and 171 
ns, respectively. It was found that the lifetime of complex 2 increased from 171 ns to 
406 ns upon addition of ClO-, and not surprisingly the luminescence lifetime of the 
unreactive compound 1 remained unchanged. This elongation of the luminescence 
lifetime shows high potential for the SiO2@mSiO2-2 nanoprobe to be used as an 
intercellular sensing agent using PLIM microscopy. This was investigated in RAW 
264.7 cells treated with SiO2@mSiO2-2 for 2 hours at 37 C and the detected 




Figure 1.24. (a) (Top) Design concept of a ratiometric probe based on core-shell 
structured nanoparticles. (Bottom) Preparation of iridium(III) silane analogue 
from complex 1 and recognition mechanism of complex 2 towards ClO-.). (b) 
PLIM images of RAW 264.7 cells treated with SiO2@mSiO2-2 (120 g mL-1) for 2 
h at 37 C (Left), followed by treatment with NaClO (50 M) for 1 h (Middle), and 
RAW 264.7 cells stimulated with Lipopolysaccharide (LPS) and Phorbol 12-
myristate 12-acetate (PMA) and incubated with SiO2@mSiO2-2 (120 g mL-1) for 
2 h at 37 C (right).131  
Addition of NaClO (50 M) for 1 hour caused an extension in luminescence lifetime 
from 31 ns to roughly 91 ns. The cells were then stimulated to cause activation of RAW 
264.7 cells which saw a further extension in the luminescence of SiO2@mSiO2-2 to 
160 ns without any treatment with NaClO. This showed that endogenous ClO- led to 
more conversion of complex 2 to 2a compared to exogenous ClO-. These results all 
showed that this novel core-shell structure nanoparticle can be used for the sensitive 
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detection of endogenous and exogenous ClO- using phosphorescence lifetime 
imaging. Other nanoprobes based on mesoporous silica-coated core-shell 
upconverting nanoparticles (UCNPs) covalently have been functionalised with 
phosphorescent iridium(III) complex for applications in oxygen sensing. These 
nanoprobes showed sensitive luminescence lifetimes which increased when the 
environment changed from hypoxia into normoxia.131 These examples show the power 
of using iridium(III) coated nanoparticles for lifetime imaging applications, through 
detection of long-lived luminescence lifetimes which can be used to probe the cellular 
microenvironment. Combining the advantages of nanotechnology with the desirable 
photophysical properties of transition metal complexes not only allows for detection 
through multiple imaging techniques, but these sensitive lifetimes can be used to map 
localisation of these nanoprobes, understanding their interactions with biomolecules or 
sensing chemical changes within cells.  
1.4 Thesis outline 
This thesis outlines the design of luminescent iridium(III) complexes for the attachment 
onto 13 nm, 25 nm and 100 nm gold nanoparticles to create novel multiphoton lifetime 
imaging probes. Chapter three describes the modification of a previously synthesised 
iridium(III) complex with a hexyl chain to enhance the multiphoton properties. The 
attachment of these iridium(III) complexes onto the surface of gold nanoparticles was 
optimised and characterised to investigate the multiphoton excitation and lifetime 
properties of these functionalised nanoprobes. Due to the success in designing an 
iridium(III) functionalised nanoprobes with long-lived luminescence lifetimes and high 
two-photon absorption cross-sections, Chapter four details the cellular applications of 
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these luminescent nanoprobes. Multiphoton lifetime imaging was used to map the 
localisation of these functionalised nanoprobes in cancer cells by detecting short-lived 
signal from the gold nanoparticles and the long-lived luminescence lifetimes if the 
iridium(III) complex. This novel research was done in collaboration with Professor 
Stanley Botchway and Dr Andy Ward (Rutherford Appleton Laboratory). Chapter 5 
looks at further functionalising these iridium(III) coated nanoparticles with biomolecules 
for targeted delivery into cancer cells. This was achieved through the attachment of a 
monoclonal antibodies which selectively targets the tumour endothelial marker, 
CLEC14A as well as SiRNA complexes for gene silencing applications. Preliminary 
investigations were carried out to show uptake of these targeted nanoprobes into 
cancer cells which was detected by both fluorescence and phosphorescence lifetime 
imaging methods.  
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CHAPTER 2. GENERAL METHODS 
2. 1 Materials 
All chemicals, solvents and deuterated NMR solvents were purchased from Sigma 
Aldrich or Fisher unless stated otherwise. All reactions were done under a nitrogen 
atmosphere using a Schlenk line. Solvents were dried using 3Å molecular sieves under 
nitrogen.  
2. 2 Techniques for Characterisation 
2. 2. 1 NMR and Mass Spectrometry 
1H and 13C NMR spectra were recorded on a Brüker AVIII300 and AVIII400 
respectively. NMR spectra were processed using MestReNova. Electrospray mass 
spectroscopy was carried out on a Waters Micromass LCT- TOF mass spectrometer 
in a electrospray positive mode, using a nitrogen laser.  
2. 2. 2 UV/Vis absorption spectroscopy 
UV/Vis spectra were carried out on either a Varian Cary 50 or Cary 5000 spectrometer. 
UV-Vis spectra were collected at a 600 nm min-1 scan rate using a 1 cm path length 
quartz cuvette at room temperature. Baseline correction was carried out using a 
matching solvent in reference to the sample being analysed. Extinction coefficients 
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2. 2. 3 Steady-state and Time-resolved Spectroscopy 
Emission and excitation spectra were recorded on Edinburgh Instruments FLS920 
spectrometer fitted with a 450 W Xenon arc lamp as the illumination source. The 
detection source was an R928 visible Hamamatsu photomultiplier tube. The emission 
monochromator is fitted with a grating at 500 nm. 355 or 395 nm emission cut-off filters 
were used for all appropriate experiments. Edinburgh F900 software was used to 
record all data. 1 cm path length Quartz cuvettes were used for all experiments.   
 
Quantum yield (f) experiments were carried out using an integrated sphere attachment 
on Edinburgh Instruments FLS920 spectrometer. This method uses a reference 
standard measured against the sample (Equation 2.1) For the molecular probe in 
solution the reference standard was water (1% MeOH) measured against the sample, 
IrbpySS or IrC6 in water (1% MeOH). A different method is employed for the iridium 
functionalised gold nanoparticles. The reference standard was Z •AuNPs measured 
against the sample, IrbpySS •AuNP or IrC6 •AuNP. The reference standard (Z 
•AuNPs) was at a higher concentration than the sample and was diluted to the same 
concentration. This was monitored by UV/Vis and was completed when the SPR peaks 




Equation 2.1. Calculation for Quantum Yield (f) experiments. 
Spectral scans of the emission region (E), recorded from 450 – 700 nm and excitation 
scatter region (S), recorded from 365 – 385 nm of the sample (s) and reference 
standard or solvent (r).  




Figure 2.1. Absorption spectra of (left) sample, IrC6 •AuNP25 (dotted line) and 
reference, Z •AuNP25 (solid line). (Right) Expanded region showing SPR overlap 
of sample and reference. 
 
Luminescence lifetime (t) experiments were carried out using an Edinburgh 
instruments EPL-376 nm picosecond pulsed diode laser as the excitation source. A 
time-correlated single-photon counting module on Edinburgh instruments was used to 
record data along with the R928 visible Hamamatsu photomultiplier tube. Lifetimes 
were fitted using Edinburgh Instruments FAST software. Luminescence lifetimes were 
fitted to three components unless stated otherwise with an error of ± 10 %. The 
luminescence lifetimes were fitted with a chi-squared (c2) value between 1 – 1.3.  
2. 2. 4 Dynamic Light Scattering and Zeta Potentials 
Dynamic light scattering (DLS) and Zeta potential measurements were acquired using 
a Malvern Zetasizer nano ZSP. Samples were recorded using a 1 cm disposable 
cuvette for size analysis and a folded capillary cell for zeta potential measurements. 
Samples were run using a standard operating procedure (SOP). For the SOP, 
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refractive index: 1.33, Absorption: 1.00, dispersant: water, temperature: 25 °C, cell: 
DTS0012 disposable cuvette (DLS) and folded capillary cell (Zeta Potentials). 
Instrument was left to equilibrate at 25 °C for 180 seconds before measurements were 
recorded. For DLS samples, 3 measurements were recorded containing 15 runs each, 
the average was then presented. For Zeta potential samples, 10 runs were recorded 
containing runs between 10 - 100, the average was then presented. Data was recorded 
and processed on the Malvern Zetasizer software. Polydispersity index is calculated 
from the equation below, where the standard deviation (s) of the particle diameter is 
divided by the mean particle diameter. 





2. 2. 5 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS was carried out at the chemistry department in the University of Warwick. ICP-
MS data was recorded on a 7500cx ICPMS with an integrated auto-sampler (Agilent). 
For all samples the metal concentrations were determined using PlasmaCal calibration 
standards (QMX laboratories), with R2 values >0.999 linear calibration curves. For all 
nanoparticle samples the solutions are digested in ultrapure aqua regia. Preparation 
of AuNPs for ICP-MS can be found in Chapter 3, Section 3.4.5.  
2. 3. Microscopy Techniques  
2. 3. 1 Transmission Electron Microscopy (TEM) 
TEM images were acquired on a JOEL 1200 EX transmission electron microscope, 
using a Gatan camera, at Materials and Metallurgy department at the University of 
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Birmingham. Samples were prepared on a 200-mesh formvar-coated copper grid (Agar 
Scientific). Images were acquired using Gatan software, but converted to TIFF files for 
analysis on ImageJ, Software version 1.49. Preparations of AuNPs for TEM can be 
found in Chapter 3, Section 3.4.4. 
2. 3. 2 Total Internal Reflectance Fluorescence Microscopy (TIRF)   
Total internal reflection microscopy (TIRF) was constructed around an inverted Nikon 
Ti-U microscope. Fluorescence excitation was obtained from an Omicron laser hub 
containing a 405 nm, 488 nm and 561 nm continuous wave lasers and fibre coupled 
to the TIRF-M unit. The laser light was focused and collimated at the back aperture of 
a x100 oil immersion, NA 1.49 objective. Fluorescence emission was detected using 
an electron multiplying charged-coupled device (EMCCD, iXon, Andor) camera. 
Images were analysed as TIFF files in ImageJ software, version 1.49. 
2. 3. 3 Fluorescence and Phosphorescence Lifetime Microscopy (FLIM/ PLIM)  
Multiphoton excitation at 760 nm was used to acquire all images. The lifetime signals 
were detected by an adapted Becker & Hickl DCS120 laser scanning system coupled 
to a SPC150 time correlated single photon counting PCI card and a PMC-100 detector. 
The same card was also used to correlate the x,y pixel positions for the FLIM 
acquisition. The multichannel lifetime collection set up in the two windows was 
constructed around a Nikon Ti-E microscope. The multiphoton used a pulse modulated 
Titanium: Sapphire laser (Mira F-900, Coherent, UK) with 76 MHz repetition rate and 
200 fs pulse. This was used to image live HeLa cells stained with IrC6 •AuNPs. An 
water immersion x60 objective was used for all samples. Emission light was collected 
using a bandpass (BG39) filter. PLIM and FLIM data collected were analysed in 
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SPCImage (Becker & Hickl software, version 5.0). The data was fitted to an 
exponential decay model.  
2. 3. 4 Confocal microscopy 
Confocal microscopy was performed using a Leica TCS SP8 upright confocal laser 
scanning system using a 40x water immersion objective lens. Solid-state laser 405 nm 
with 26 % laser intensity was used. An AOBS spectral detector and gateable hybrid 
(Hy-D) PMT detector was used with the following ex/em ranges: lexc = 405 nm, lem = 
550 - 800 nm for Iridium luminescence and lexc = 405 nm, lem = 425 - 475 nm for 
Hoechst acquisition. Z-stacks slice widths were performed as stated in the Iridium and 
Hoechst channel images. Processing and visualization of 3D images was performed 
by the image processing software FIJI (ImageJ Version 1.52b). 
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        CHAPTER 3. DESIGN OF IRIDIUM(III) COMPLEXES FOR LABELLING GOLD 
NANOPARTICLES 
3. 1 Introduction 
Luminescent iridium(III) complexes are highly researched due to their rich 
photophysical properties such as intense emission in the visible range, long-lived 
luminescence lifetimes and high photostability.1-3 The desirable photophysical 
properties of iridium(III) complexes not only makes them excellent candidates for 
cellular imaging but for uses in organic light-emitting diodes (OLEDs)4, 5, dye-sensitised 
solar cells,6, 7 and biosensing probes.8, 9 These iridium(III) complexes can be 
functionalised with a range of ligands which can enhance their physical and chemical 
properties. These ligands can be synthesised to interact with biomolecules within cells, 
target specific cellular organelles or contain anticancer properties.10-12 An increasing 
amount of iridium(III) complexes which are cationic or lipophilic have been designed 
for cellular imaging applications and have shown to be readily taken up into the cell 
and even localisation in specific regions of the cell.11, 13-15 Kenneth Lo’s group was the 
first to look at using cyclometalated iridium(III) complexes for luminescence imaging of 
biological substrates back in early 2000s.16 Since then his group have developed a 
vast range of iridium(III) complexes for various biological imaging applications.9, 17  
The lipophilicity of iridium(III) complexes is closely related to the efficient cellular 
uptake into cells.18 Huang et al. increased the lipophilicity of iridium(III) complexes 
through fluorination of the C^N ligand and found this increased the uptake of these 
iridium(III) complexes into the cytoplasm of cells in comparison to their chloro 
counterparts (Figure 3.1).19 Zwitterionic iridium(III) complexes [(Ir(N^C)2(Hdcbpy)] 
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have also been studied for cellular uptake experiments and have shown to selectively 
stain the cytoplasm of KB cells. It was also found that the emission intensity detected 
within the cytoplasm increases as the lipophilicity of the iridium(III) complexes 
increases.20 
 
Figure 3.1. (Top) Chemical structure of iridium(III) complexes 1 and 2. (Bottom)(a 
and d) Confocal luminescence and (b and e) brightfield images of living HeLa 
cells incubated with 20 mM (a, b, c) 1 or (d, e, f) 2 in DMSO/PBS (pH 7, 1 : 49, v/v) 
for 10 min at 25 1C. Overlays of luminescence and brightfield images are shown 
in (c) and (f) for 1 or 2, respectively (lex = 405 nm).20 
 
 
The lipophilicity of iridium(III) complexes has been investigated through 
functionalisation of different lengths alkyl chains onto the N^N ligand of iridium(III) 
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complexes.21 The lipophilicity of the complexes is referred to as log Po/w (Po/w = n-octan-
1-ol/water partition coefficient) which is determined by reverse-phase HPLC. The 
lipophilicity of iridium(III) complexes [[Ir(N^C)2(Me-bpy-CONH-CnH2n+1)]+ where n = 18, 
10, 2, was found to be 8.79, 4.42 and 0.44 respectively. For the most part there was 
an increase in uptake as the iridium(III) complexes increased in lipophilicity, however 
the most lipophilic compound [Ir(N^C)2(Me-bpy-CONH-C18H37)]+ showed the lowest 
amount of uptake into cancer cells, which was not expected. It was proposed that the 
higher molecular weight could hinder the probes ability to penetrate the cell membrane 
for uptake into cells. Secondly, the large alkyl chain on the ligand could cause the 
iridium(III) complex to undergo self-aggregation in cell media. Since this iridium(III) 
complex contained a very hydrophobic octadecyl chain, its interactions with serum 
binding proteins was examined and found to increase upon binding to human serum 
albumin (HSA). This means that these iridium(III) complexes not only display high 
uptake into cells and desirable photophysical properties, but the attachment of an alkyl 
chain opens up the possibility for these probes to be used as luminescent sensors for 
probing hydrophobic biological interactions within cells. This shows how important it is 
to carefully design these metal complexes for the appropriate biomedical application.  
Over the past decade there has been increasing interest in using gold nanoparticles 
(AuNPs) for biomedical applications such as bioimaging, therapeutics, diagnostics and 
drug delivery due to their unique photophysical and chemical properties.22, 23 Research 
has shown that the size, shape, morphology and surface profile can be easily modified 
to enhance biocompatibility and targeting abilities of these gold nanoparticles in vitro 
and in vivo.24, 25  In addition, these gold nanoparticles have shown to be inert in a 
cellular environment and their high surface area allows for modification with various 
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ligands for targeting (antibodies, peptides and DNA) and drug delivery (doxorubicin26, 
27, siRNA). This was demonstrated by Firer et al. who showed that a peptide-drug 
conjugate could be attached to the surface of gold nanoparticles to enhance their 
chemotherapeutic efficiency within cells.28 Since gold has a high electron density, 
imaging techniques such as electron microscopy can be used to visualise these 
functionalised nanoparticles in cells.29, 30 However, these electron microscopy methods 
are often limited to fixed imaging over live cell imaging studies . Therefore, researchers 
have looked at attaching luminescent probes onto the surface of gold nanoparticles 
which further extends their uses in biomedical applications.  
As previously discussed, these iridium(III) complexes have shown to be suitable for 
imaging applications with their desirable photophysical properties. The ligands can be 
functionalised to interact with targeting ligands Furthermore, the ligands can be 
modified for attachment onto the surface of gold nanoparticles. Conjugation of these 
luminescent iridium(III) complexes onto the surface of gold nanoparticles has shown 
to add desirable biological properties such as increased uptake efficiency, cellular 
distribution and aqueous solubility, making these nanoprobes extremely powerful for 
biomedical imaging applications. Furthermore, utilizing the chemical and photophysical 
properties gold nanoparticles and iridium(III) complexes together allows for multimodal 
detection of these nanoprobes within cells. Despite all the advantages of 
functionalising gold nanoparticles with iridium(III) complexes, there are very limited 
examples in the literature. Apart from our group, the only examples of iridium 
functionalised gold nanoparticles have been carried out by Mayer et al. Their first paper 
showed that bifunctional heteroleptic iridium(III) complexes could be used as a 
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reducing agent for tetrachloroauric acid and a capping agent for small sized gold 
nanoparticles (2 – 3 nm) (Figure 3.2).31  
 
Figure 3.2. Mechanism of the reduction and capping process: (i) Deprotection in 
a basic medium; (ii) reduction by the reaction media.31 
 
 
They found that the iridium(III) complex displayed strong luminescence with a lmax at 
537 nm, however no luminescence was observed upon conjugation of these 
complexes to the gold nanoparticle surface. It was proposed that the short distance 
between the iridium(III) complex and the gold surface caused quenching of the 
luminescence signal. Similar effects from quenching of gold has previously been 
observed on ruthenium functionalised gold nanoparticles.32, 33 Since these nanoprobes 
displayed no luminescence, their applications as bioimaging probes were not explored. 
More recently, Mayer et al. synthesised iridium(III) complexes for functionalisation onto 
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gold and silver nanoparticles.34 The iridium(III) complex was synthesised containing a 
modified 1,10-phenanthroline ligand with a pyridine end which is already known as a 
capping agent to stabilise metal nanoparticles (Figure 3.3). 
 
Figure 3.3. Structure of iridium(III) complex containing an anchoring group for 
conjugation onto gold nanoparticles.34 
 
 
The iridium(III) complex was conjugated onto the surface of 5 – 6 nm gold 
nanoparticles by a ligand exchange reaction, at low concentrations to avoid particle 
aggregation. The results showed the first example of functionalising gold nanoparticles 
with iridium(III) complexes without loss of luminescence signal upon conjugation. This 
was shown through photophysical characterisations of both the iridium(III) complex in 
solution and iridium functionalised gold nanoparticles. It was found that upon excitation 
at 340 nm both Ir2 and NPAu-Ir2 were luminescent with an emission lmax of 630 nm. 
However, there was a significant reduction in signal intensity upon conjugation of Ir2 
onto the gold surface. It was proposed that the spectral overlap between the SPR band 
of the gold (516 nm) and the luminescence of Ir2 (lmax =633 nm) was the cause of this 
substantial quenching of the luminescence signal.34 Previous work from the 
Pikramenou group has shown iridium(III) complexes being synthesised for conjugation 
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onto larger, 100 nm sized particles and their applications for in vivo monitoring of blood 
flow explored (Figure 3.4).35 
 
 
Figure 3.4. Luminescent iridium-coated gold nanoparticles for imaging blood 
flow in murine tissues.35 
 
 
The results showed that luminescence signal from the iridium could be detected within 
vessels without any interference from cellular autofluorescence. Development of 
iridium(III) functionalised gold nanoparticles for bioimaging applications is still an 
emerging field. The aim of this thesis is to develop iridium(III) complexes that can be 
functionalised onto the surface of gold nanoparticles for their uses as multichannel 
luminescence lifetime imaging probes. Furthermore, a biorecognition molecule will be 
conjugated to gold nanoparticles alongside the iridium(III) complex allowing for both 
imaging and therapeutic applications.  
3. 1. 1 Chapter Summary 
This chapter will talk about the synthesis and photophysical characterisations of two 
iridium complexes and iridium functionalised nanoprobes. These iridium functionalised 
nanoprobes need to be fully characterised to identify their potential as two-photon 
lifetime imaging agents. Two iridium probes were synthesised for this work, the first 
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has previously been defined in the Pikramenou group and contains a bipyridine ligand 
with leg longs for attachment onto gold nanoparticles, IrBpySS. The second probe 
sees the modification of IrBpySS with a hexyl chain on the phenyl pyridine ligands, 
IrC6 (Figure 3.5). The incorporation of the hexyl chain was designed to increase 
hydrophobicity of the iridium complex which would increase the permeability across 
the cell membrane. These iridium probes were conjugated onto AuNPs and their single 
and two photon properties investigated for their use as bioimaging probes.  
 
Figure 3.5. Schematic for the conjugation of IrBpySS (Left) and IrC6 (Right) onto 
AuNPs.  
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3. 2 Results and Discussion 
3. 2. 1 Cyclometalated iridium(III) complexes 
3. 2. 1. 1 Synthesis 
Two iridium complexes were synthesised for this work. The iridium complex, IrBpySS 
and the modified IrC6 were synthesised and fully characterised. Both the iridium 
complexes were conjugated onto AuNPs by methods previously established in the 
Pikramenou group36, 37, these were then characterised and investigated as imaging 
probes. Both complexes contain the surface active bipyridine ligand with thiol active 
groups for the attachment onto gold nanoparticles. IrC6 contains a phenyl pyridine 
ligand which has been modified with a hexyl chain to increase the hydrophobicity of 
the complex. The iridium dimers, [Ir(ppy)2(µ-Cl)]2 and [Ir(ppy-C6)2(µ-Cl)]2 were 
synthesised according to a method developed by Watts et al.38 For IrbpySS, A mixture 
of iridium trichloride hydrate and 2-phenyl pyridine was refluxed in 2-ethoxyethanol and 
water, the precipitation was collected and fully characterised (Scheme 3.1). For IrC6, 
the 2-phenylpyridine ligand was modified with a hexyl chain based on the method 
developed by Ackermann et al.39 This involves the direct alkylation of 1-bromohexane 
onto the ortho C-H position on the 2-phenylpyridine. This ligand was then refluxed with 
Iridium trichloride hydrate in 2-ethoxyethanol and water. The precipitate was collected 
and fully characterised (Scheme 3.2). 
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Scheme 3.1. Synthesis of [Ir(ppy)2(µ-Cl)]2 
 
 
Scheme 3.2. Synthesis of [Ir(ppy-C6)2(µ-Cl)]2 
 
 
The final iridium(III) complexes were synthesised by refluxing the iridium dimer with 
the bipyridine ligand in 2-ethoxyethanol and then precipitating the 
hexafluorophosphate salt out in water. The synthesis for IrbpySS and IrC6 can be seen 
in scheme 3.3 and 3.4 respectively, the synthesis for the bipyridine ligand can be found 
in the experimental section for this chapter.  These iridium probes were fully 
characterised by 1H and 13C NMR and ESI+ MS (Appendix) and agree with previously 
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published work.40.An ion exchange mechanism was carried out to convert the PF6 
counter ion to the chloride ion for increased solubility in water which is required for 
attachment onto nanoparticles.   
 
Scheme 3.3. Synthesis of IrBpySS 
 
Scheme 3.4. Synthesis of IrC6 
3. 2. 1. 2 Photophysical Characterisation 
The photophysical properties of the two iridium complexes have been studied in 1% 
MeOH in water and degassed MeOH for comparison. These probes have been 
designed for conjugation onto gold nanoparticles for their use as biological cellular 
imaging probes. Therefore, it is important to study the photophysical properties of 
these iridium complexes in conditions which are closely related to this application.  
After being converted to the chloride ion, the Iridium probes are made up to a 
concentration of 1 mM in Methanol. The absorption, steady state emission and 
excitation spectra of IrC6 and IrbpySS was recorded in water (1% MeOH), at a 
concentration of 30 µM. Both the iridium complexes display similar photophysical 
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characteristics. The IrC6 complex absorbs in the UV-Vis region and exhibits intense 
bands at 230 nm and 260 nm arising from the spin allowed 1LC (p-p*) transition of both 
the C^N and N^N ligands.41, 42 The absorption profiles show a tail with shoulders at 
300 nm and 350 nm with the profile extending into the visible range (450 nm) (Figure 
3.6).  
 
Figure 3.6. Absorbance spectra of 30 µm (left) IrbpySS and (right) IrC6 in water 
(1% MeOH).  
 
 
This is attributed to the spin allowed 1MLCT transition state, which corresponds to 
previous assignments.2 The absorption profiles for these iridium complexes are similar 
to the parent compound [Ir(ppy)2bpy] + which has been extensively studied.1, 43 
Excitation of a solution of IrbpySS and IrC6 in water at 375 nm produced a broad peak 
emission spectra in the visible range of 400 – 750 nm. The luminescence spectra have 
a lmax at 570 nm and 580 nm for IrbpySS and IrC6 respectively (Figure 3.7). This is 
attributed to the triplet charge transfer state which usually has contributions from 
3MLCT and 3LMCT.44-46 The iridium(III) complexes were found to display strong 
luminescence signal upon excitation at 375 nm and 405 nm (Appendix). 
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Figure 3.7. Photophysical characterisations of Iridium complexes in water. 
Excitation spectra (dotted line) lem = 570 nm and 580 nm for IrbpySS and IrC6 
respectively and luminescence spectra (solid line) of 30 µM (left) IrbpySS and 
(right) IrC6 in water (1% MeOH). lexc = 375 nm. Spectra have been corrected for 
PMT and instrument response. 
 
The excitation spectrum showed characteristics of the absorption spectra, revealing 
that excitation in the visible range up to 450 nm is possible to provide emission. This 
makes these iridium complexes suitable candidates for conventional light microscopy. 
The photophysical properties upon addition of a Zonyl FSA surfactant was investigated 
and it was found that a 5 nm and 10 nm bathochromic shift was observed in emission 
for IrbpySS and IrC6, respectively (Figure 3.8). This differs from the effect of the Zonyl 
FSA surfactant on previously studied ruthenium complex (RuS12), where no significant 
shift was observed upon addition of the surfactant.33 The shift is indicative of an 
interaction of the iridium probe with the Zonyl FSA surfactant, changing the 
environment around the iridium complex and affecting the charge transfer transitions. 
This is more predominant for IrC6 because the hydrophobic chain on the complex 
causes a greater interaction with the surfactant.  
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Figure 3.8. Luminescence spectra of (left) 30 µM IrbpySS (Right) 30 µM IrC6 in 
water. The solid line represents the iridium complex in water and the dotted line 
is with 10 µL 10% Zonyl FSA. lexc = 350 nm. Spectra have been corrected for PMT 
and instrument response and normalised.  
 
To further understand the effects of the Zonyl FSA surfactant on the photophysical 
properties of the iridium complexes, the luminescence lifetimes were analysed and 
both complexes were found to have 3 components in the lifetime fitting. The 
luminescence lifetimes for IrbpySS and IrC6 in water and with the addition of 10% 
Zonyl FSA can be found in Table 3.1. 
Table 3.1. Lifetimes recorded for IrbpySS and IrC6 in water and with the addition 
of Zonyl FSA surfactant (10% in water). Lifetimes were recorded using a 376 nm 
laser and were fitted with a c2 between 1 and 1.1. 
 
Lifetimes under different conditions (ns) 
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Both Iridium complexes show a multi-exponential decay in the observed luminescence 
lifetime. The iridium complexes in water display long luminescence lifetimes in the 
nanosecond range. The data agrees with phenyl-pyridine iridium(III) complexes 
previously studied.3, 47 IrbpySS has a lifetime of 310 ns and a luminescence quantum 
yield of 3 %. IrC6 showed a slightly longer luminescence lifetime of 430 ns and a 
luminescence quantum yield of 4 %. Upon addition of Zonyl surfactant (10% in water), 
IrbpySS shows an increase in luminescence lifetime by 71 % in comparison to the 
complex in water. This agrees with the results seen for RuS12 where the luminescence 
lifetime increased from 280 ns to 350 ns, resulting in an increase of 25%. This increase 
was attributed to the surfactant interacting with the ruthenium complex and protecting 
it from 3O quenching.48 A similar effect is happening with IrbpySS where the iridium 
complex is being protected from the environment, increasing the luminescence 
lifetime. This affect is not seen for IrC6, where the luminescence lifetime decreased by 
26 % when compared to the free metal complex in water. Previous studies have shown 
that the luminescence properties of iridium complexes containing different length 
hydrophobic alkyl chains, were affected in the presence of different surfactants. It was 
found that the iridium complexes, based on the phenylpyridine ligand, containing 
hydrocarbon chain lengths of 18 and 10 (IrC18 and IrC10, respectively) had long 
luminescence lifetimes of 390 ns (IrC18) and 210 ns (IrC10) in 1 % aqueous methanol, 
which agrees with the results for IrC6. This is attributed to the polar medium causing 
the hydrocarbon chains to “wrap” around the complex cores resulting in a hydrophobic 
local environment. When these complexes were placed in the presence of a neutral 
surfactant, a red-shift in emission was seen along with a decrease in luminescence 
lifetime by 84 % for IrC18 and 71 % for IrC10. It was reasoned that the surfactant then 
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caused “unwrapping” of the hydrophobic chains around the core, therefore reducing 
the hydrophobic local environment.21  
To summarise, excitation of these iridium complexes at 375 nm leads to broad 
emission peak within the visible range. The emission comes from the triplet charge 
transfer state which usually has contributions from 3MLCT and 3LMCT. The 
luminescence lifetime recorded in 1 % aqueous methanol leads to long luminescence 
lifetimes of 310 ns and 430 ns for IrbpySS and IrC6, respectively. When studying the 
effects of the Zonyl surfactant on the luminescence properties of these iridium 
complexes, it was found that the luminescence lifetime increased by 71 % for IrbpySS 
and decrease by 26 % for IrC6 in comparison to the metal complex in water. The 
quantum yields recorded were 3 % for IrbpySS and 4 % for IrC6.  
3. 2. 2 Gold Nanoparticles (AuNPs) 
3. 2. 2. 1 Synthesis  
Monodisperse 13 nm AuNPs (AuNP13) were synthesised following a previously 
published method, in which modifications were made.49 This method synthesises 
colloidal gold nanoparticles following the reduction of tetrachloroauric acid (HAuCl4) 
with trisodium citrate (Na3Ct), a well-documented method which was first reported by 
Turkevich et al in 195150 and later refined by Frens in 197351. This protocol has been 
extensively used over the past six decades and became known as the “Turkevich 
Synthesis”, which yields 15 nm spherical gold nanoparticles with a narrow size 
distribution. This method has been modified and optimised by numerous groups to 
create AuNPs in a wide range of sizes from 5 – 150 nm.52, 53 Grabar et al.54 modified 
the method to produce a large range of AuNP sizes which have showed to be stable 
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and non-toxic in water. The method shows the reduction of Au3+ à Au0 in water by 
adding sodium citrate to form 13 nm AuNP seeds at a high concentration (9 nM), 
labelled direct synthesis of AuNPs. This method was previously used in the 
Pikramenou group55; however, it was found that the AuNPs produced had a large size 
distribution and a low reproducibility. Therefore, a new method of gold nanoparticle 
synthesis was followed, known as the inverse Turkevich method, which has shown to 
drastically improve the size distribution and PDI in solution. In this method Au3+ salt is 
reduced by Na3Ct, and the size of the nanoparticles is determined by the ratio of these 
reactants. The Au3+ salt is added into a mixture of citric acid and sodium citrate, which 
is the reverse order in comparison to the original Turkevich method56.  It is identified 
that Na3Ct has three important roles in the synthesis, (1) the reduction of Au(III) à 
Au(0), (2) citrate capping of the AuNPs (stabilising the AuNPs) and (3) pH mediator 
(modifies the reactivity of Au species in solution).57 During the reaction sodium citrate 
oxidises to acetonedicarboxylate (ADC) which was found to be a kinetically faster 
reducing agent for HAuCl4 than sodium citrate. ADC organises the gold ions into 
polymolecular complexes delivering a large local concentration of gold precursor which 
facilitates the reduction of Au3+ à Au0. The formation of the ADC-Au+ complex 
selectively facilitates the disproportionation of AuCl à Au0 which accelerates the 
nucleation and growth to AuNPs58 (Figure 3.9). This accelerated rate of reaction means 
a faster nucleation rate which in turn gives us the narrow size distribution.  
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Figure 3.9. Mechanism of the Turkevich Synthesis showing (a) Redox reaction 
of citrate and the Au(III) precursor to yield Au(I) ions and acetonedicarboxylate 
(ADC). (b) Organisation of Au(I) ions in polymolecular complexes, (c) 
Disproportionation of Au(I) to Au(0) and Au(III) and (d) nucleation and growth of 
Au(0) to AuNPs.49  
 
 
The actual growth mechanism of the gold nanoparticle synthesis is still poorly 
understood, with many different papers hypothesising different theories as to what is 
occurring. The reasoning being that there is limited in situ techniques that are able to 
follow the reactions that are occurring.59 The summary of the growth mechanism 
proposed in the Turkevich method can be found below (Figure 3.10) 
 
Figure 3.10. Summary of the growth mechanism used in the Turkevich method.60 
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There are four steps in the formation of AuNPs from the initial gold precursor. As 
discussed, the first step is the reduction of the gold salt from Au(III) à Au(0) which 
forms small clusters of the gold monomer. These clusters go on to form small seed 
particles (r <1.5 nm). The remaining gold ions are attracted to these seed particles and 
attach in the electronic double layer (EDL) causing further reduction. These then grow 
forming monodisperse, stable AuNPs in solution. Since this reaction is highly 
dependent of pH control, the rate of reaction was increased by lowering the pH, which 
increases the reactivity of Au3+. This is done by creating a buffer solution of citric acid 
and sodium citrate.60 
For this work, AuNPs were synthesised using the inversed Turkevich method 
producing monodisperse 1.53 nM AuNP13. EDTA was added to the reaction mixture 
and found to significantly improve the shape uniformity of the AuNPs.49 Through this 
method, the produced AuNPs showed improved size distributions, better 
reproducibility and consistently low polydispersity indexes (PDI) of <0.15 in 
comparison to the previous method of synthesis. These AuNP13 are then grown to 
produce AuNP25 (0.65 nM), AuNP50 (73 pM) and AuNP100 (37 pM) stabilised with 
citrate anions, following a previously published protocol.61 This seeded growth method 
allows for growth to larger sized gold nanoparticles whilst retaining their spherical 
shape (Figure 3.11). This method allows for high reproducibly with narrow size 
distributions and low PDIs of <0.1, forming mono-stable AuNPs in water.   
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Figure 3.11. Seed mediated growth mechanism for AuNPs producing AuNP25 
(0.65 nM), AuNP50 (73 pM) and AuNP100 (37 pM). 
 
The AuNPs were then fully characterised by UV/Vis spectroscopy, dynamic light 
scattering (DLS), Zeta potential measurements and transmission electron microscopy 
(TEM).  
3. 2. 2. 2 Nanoparticle characterisations  
UV/Vis spectroscopy was used to measure the characteristic surface plasmon 
resonance (SPR) band of AuNP13, AuNP25 and AuNP100 in water which was found 
to have a  lmax (H2O) at 517, 519 and 556 nm respectively (Figure 3.12). The SPR 
band is characteristic to the shape, size and morphology of gold nanoparticles and 
indicates particle aggregation and surface modification.22, 62  
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Figure 3.12. UV/Vis spectra of citrate stabilised nanoparticles in water. 
 
 
AuNP13, AuNP25 and AuNP100 were sized by DLS and their number and intensity 
distributions reported (Table 3.2 and Figure 3.13). The intensity distribution measures 
the amount of scattered light from the particles, whereas number distribution is derived 
from the intensity distribution using Mie theory.63 The particle scattering intensity is 
proportional to the square of the molecular weight, this means that any larger particles 
and aggregates present in the sample will dominate the distribution, causing the results 
to be weighted towards measuring larger particles. The number distribution is 
proportional to the intensity distribution, meaning that the presence of larger particles 
and aggregates in the sample will not be displayed in the number distribution, which 
provides a more accurate representation of particle size.64, 65 The polydispersity Index 
(PDI) is the measure of the average uniformity of particles in a solution. If the PDI 
values are large, this indicates a large size distribution and can often be an indication 
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of particle aggregation. A PDI of less than 0.1 indicates that particles in solution are 
fully monodisperse.66 The PDI calculations can be found in Chapter 2, Section 2.2.4. 
Table 3.2. Dynamic Light Scattering (DLS) for AuNPs in water. Results displayed 
are Size by Number Distribution, Size by Intensity Distribution and 
Polydispersity Index (PDI). 
 
 Number Distribution (nm) Intensity Distribution (nm) PDI 
AuNP13 13 ± 3 19 ± 5 0.07 
AuNP25 18 ± 5 27 ± 8 0.05 
AuNP100 80 ± 20 101 ± 25 0.03 
 
Figure 3.13. Dynamic Light Scattering (DLS) Data showing sizing by (Top) 
Number Distribution and (Bottom) Intensity Distribution. Results displayed are 
for AuNP13 (red), AuNP25 (green) and AuNP100 (Blue).  
 
 
The nanoparticles were sized by Transmission Electron Microscopy (TEM). TEM 
images show sizes of 15 nm, 25 nm and 95 nm for AuNP13, AuNP25 and AuNP100 
respectively (Figure 3.14). TEM images show highly uniform, spherical particles which 
is in good agreement with the DLS results, for all three nanoparticle sizes.  
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Figure 3.14. Transmission Electron Microscopy (TEM) images of (a) AuNP13, (b) 
AuNP25 and (c) AuNP100. Images were acquired on Joel 2100 EX TEM. Scale 
bars are 15 nm, 25 nm and 100 nm respectively. 
 
 
Zeta-potentials is a measure of the stability of particles in solution. It is measured by 
sending an electric field through the sample to measure the electrostatic or charge 
repulsion/attraction between particles, which is the factors that affect stability of 
particles in solution. For colloidal nanoparticle systems Zeta-potential values of > ± 30 
mV are classed as highly stable in solution.67 The Zeta-potentials of the citrate coated 
nanoparticles were measured and found to be -33 ± 13 mV, -30 ± 12 mV and -33 ± 12 
mV for AuNP13, AuNP25 and AuNP100 respectively (Figure 3.15). These results 
show highly stable nanoparticles in solution with an overall similar negative charge for 
all three sizes, which is to be expected due to the nanoparticles being capped with 
citrate ions. 
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Figure 3.15. DLS data showing the absolute Zeta-Potential measurements for 
AuNP13 (red), AuNP25 (green) and AuNP100 (green) in water.  
 
3. 2. 3 Iridium(III) functionalised gold nanoparticles 
3. 2. 3.1 Synthesis and nanoparticle characterisations 
The iridium complexes (IrbpySS and IrC6) were conjugated onto gold nanoparticles 
by attachment of the thiol group on the bipyridine ligand onto the surface of the gold.68-
70 However, because the solution of citrate coated gold nanoparticles is negatively 
charged, addition of the iridium complexes which carry a positive charge of +2, would 
cause complete aggregation of the nanoparticles due to the loss of electrostatic 
repulsions which would destabilise the solution (Appendix). Therefore, prior to coating 
with the IrbpySS and IrC6 complexes, the nanoparticles were pre-coated with a 
fluorinated surfactant, Zonyl FSA (Scheme 3.5). The surfactant directly replaces the 
negative citrate ions on the gold surface which prevents the particles from aggregating. 
The Zonyl FSA surfactant has been shown to increase the stability and lipophilicity of 
gold nanoparticles in solution.71, 72 
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Scheme 3.5. Schematic for the procedure of coating AuNPs with the fluorinated 
surfactant (Zonyl FSA). 
 
A change in the SPR provides information on changes to the surface, shape and size 
of the nanoparticles. When coating with surfactants and metal complexes the lmax shift 
in absorption is monitored. This shift represents a change to the gold surface, which 
means that there been attachment onto the gold. Molecules which chemically bond to 
the surface of gold can be detected by the observed change they induce in electron 
density on the surface, which results in a shift in SPR lmax.73 Addition of Zonyl FSA (10 
% in water) causes a shift in the surface plasmon resonance (SPR) by 2 nm, 3 nm and 
1 nm making the recorded value 519 nm, 521 nm and 557 nm for AuNP13, AuNP25 
and AuNP100 respectively. These particles are then isolated by centrifugation to give 
Z •AuNP13, Z •AuNP25 and Z •AuNP100. These particles were sized to ensure no 
aggregation had occurred upon addition of the surfactant, the results can be seen 
below (Table 3.3, Figure 3.16). The results show an increase in size and PDI in 
comparison to citrate AuNPs, which confirms the presence of Zonyl FSA to the surface 
of the nanoparticles. 
 
3. Design of iridium complexes for labelling gold nanoparticles 
 87 
Table 3.3. Dynamic Light Scattering (DLS) for AuNPs in water. Results displayed 
are Size by Number Distribution, Size by Intensity Distribution and 
Polydispersity Index (PDI). 
 
 Number Distribution (nm) Intensity Distribution (nm) PDI 
Z •AuNP13 17 ± 4 26 ± 8 0.24 
Z •AuNP25 22 ± 6 38 ± 18 0.14 
Z •AuNP100 87 ± 21 107 ± 24 0.02 
 
 
Figure 3.16. Dynamic Light Scattering (DLS) data showing sizing by (Top) 
Number Distribution and (Bottom) Intensity Distribution. Results displayed are 
for Z •AuNP13 (red), Z •AuNP25 (green) and Z •AuNP100 (Blue).  
 
 
Zeta-potentials were measured and found to be -66 ± 21 mV, -56 ± 13 mV and -68 ±16 
mV for Z •AuNP13, Z •AuNP25 and Z •AuNP100 respectively (Figure 3.17). The 
results show an increase in negative potential compared to the citrate stabilised 
nanoparticles, increasing the stability of the nanoparticles in solution.  
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Figure 3.17. DLS data showing the absolute Zeta-Potential measurements for Z 
•AuNP13 (red), Z •AuNP25 (green) and Z •AuNP100 (Blue). 
 
The iridium complexes (IrbpySS and IrC6) were then added to the colloid suspension 
of gold nanoparticles (Scheme 3.6). Gold nanoparticles were concentrated from their 
stock solutions to the concentrations stated below for the coating protocol.  
 
Scheme 3.6. Schematic for the procedure of coating Z •AuNPs with Iridium 
complexes. 
 
A solution of IrbpySS and IrC6 in MeOH (1 mM) was titrated in 5 µL and 2.5 µL aliquots, 
for IrbpySS and IrC6 respectively, into an aqueous solution of 4.5 nM for Z •AuNP13 
(1 mL) and the SPR shift monitored within the visible region (Figure 3.18). The shift in 
SPR shows a modification on the gold surfaces and allows us to identify the full 
saturation of the gold surface with the iridium complexes.  
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Figure 3.18. UV/Vis titration of Iridium complexes into 4.5 nM Z •AuNP13 in water 
(1 mL). (Left) 1 mM IrbpySS titrated in 5 µL aliquots and (right) 1 mM IrC6 titrated 
in 2.5 µL aliquots.   
 
 
As the complex is titrated into a solution of gold a red shift is seen, this shift stops as 
the surface is fully saturated with the iridium complex. Addition of 20 µL, 1mM IrbpySS 
and 22.5 µL, 1mM IrC6 into 4.5 nM Z •AuNP13 resulted in an 8 nm (525 nm) and 5 nm 
(522 nm) shift in lmax (H2O), respectively.  A similar coating was seen for the addition 
for iridium complexes into Z •AuNP25 and Z •AuNP100. Addition of 20 µL, 1mM 
IrbpySS and 40 µL, 1mM IrC6 into 1.6 nM Z •AuNP25 resulted in a 6 nm (525 nm) 
shift in lmax (H2O) for both complexes (Figure 3.19).  
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Figure 3.19. UV/Vis titration of Iridium complexes into 1.6 nM Z •AuNP25 in water. 
(Left) 1 mM IrbpySS and (right) 1 mM IrC6 titrated in 2.5 µL aliquots for both. 
 
 
Addition of 20 µL, 1mM IrbpySS and 30 µL, 1mM IrC6 into 30 pM Z •AuNP100 resulted 
in a 6 nm (562 nm) and 2 nm (558 nm) shift in lmax (H2O) respectively (Figure 3.20).   
 
Figure 3.20. UV/Vis titration of Iridium complexes into 30 pM Z •AuNP100 in 
water. (Left) 1 mM IrbpySS and (right) 1 mM IrC6 titrated in 2.5 µL aliquots for 
both. 
 
The iridium coated nanoparticles were isolated by size exclusion chromatography to 
produce IrbpySS •AuNP13, IrC6 •AuNP13, IrbpySS •AuNP25, IrC6 •AuNP25, IrbpySS 
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•AuNP100 and IrC6 •AuNP100. Upon isolation of these nanoparticles the SPR lmax 
(H2O) maximum remains unchanged showing that the surface coating remains the 
same upon removal of excess metal complex, and no aggregation has occurred for all 
three sizes of nanoparticles. DLS shows that the size of the AuNPs does not 
significantly change when coated with IrbpySS and IrC6 (Table 3.4 and Figure 3.21). 
The slight increase in size and PDI is indicative of the iridium complex being present 
on the nanoparticles, which would increase the hydrodynamic size.  
Table 3.4. Dynamic light scattering data for IrC6•AuNP in water, showing 
polydispersity index (PDI), size by number (nm) and size by intensity (nm). 
 
 PDI Size by number (nm) Size by intensity (nm) 
IrbpySS •AuNP13 0.24 14 ± 4 25 ± 8 
IrC6 •AuNP13 0.27 17 ± 4 28 ± 10 
IrbpySS •AuNP25 0.21 26 ± 10 32 ± 17 
IrC6 •AuNP25 0.18 22 ± 6 30 ± 16 
IrbpySS •AuNP100 0.02 95 ± 30 123 ± 34 
IrC6 •AuNP100 0.02 89 ± 22 109 ± 25 
 
Figure 3.21. Dynamic Light Scattering (DLS) data showing sizing by (Top) 
Number Distribution and (Bottom) Intensity Distribution. Results displayed are 
for IrC6 •AuNP13 (red), IrC6 •AuNP25 (green) and IrC6 •AuNP100 (Blue).  
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Zeta-potentials were measured and found to be -32 ± 15 mV, -35 ± 20 mV and -42 ± 
24 mV for IrC6 •AuNP13, IrC6 •AuNP25 and IrC6 •AuNP100 respectively (Figure 
3.22). The results showed a decrease in negative potential in comparison to the Z • 
AuNPs, which had a zeta-potential of -66 ± 21 mV, -56 ± 13 mV and -68 ±16 mV for Z 
•AuNP13, Z •AuNP25 and Z •AuNP100 respectively. This was to be expected as the 
iridium complex holds an overall positive charge. The iridium(III) complex could cause 
displacement of the Zonyl FSA surfactant since the disulphide bond on the iridium 
complexes have a higher affinity for binding to the gold nanoparticles. Therefore, upon 
addition of IrC6, this would decrease the overall negative potential of the solution.  
 
Figure 3.22. DLS data showing the absolute Zeta-Potential measurements for 
IrC6 •AuNP13 (red), IrC6 •AuNP25 (green) and IrC6 •AuNP100 (Blue). 
 
TEM show spherical particles with estimated diameters of 15 nm for IrC6 •AuNP13, 25 
nm for IrC6 •AuNP25, and 95 nm for IrC6 •AuNP100 respectively. IrbpySS coated 
particles were sized and found to be 19 nm for IrC6 •AuNP13, 30 nm for IrC6 •AuNP25, 
and 102 nm for IrC6 •AuNP100 respectively (Figure 3.23). 
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Figure 3.23. Transmission Electron Microscopy (TEM) images of (top) IrbpySS 
•AuNPs and (bottom) IrC6 •AuNPs. (A) 13 nm AuNPs, (B) 25 nm AuNPs (C) 100 
nm AuNPs. Images were acquired on Joel 2100 EX TEM. Scale bars are 15nm, 25 
nm and 100 nm respectively. 
 
 
Elemental composition of the nanoparticles by inductively coupled plasma mass 
spectroscopy (ICP-MS) was carried out to calculate the number of iridium complexes 
per nanoparticle (Table 3.5), in which the calculation can be found in the Appendix. 
The results show a high coating of iridium complexes onto Z •AuNPs, with thousands 
of iridium complexes per AuNPs. There is a higher number of IrC6 complexes per 








3. Design of iridium complexes for labelling gold nanoparticles 
 94 
Table 3.5. Elemental composition of nanoparticles by ICP-MS, showing number 
of iridium complexes per AuNPs. 
 
Sample Number of Iridium complexes per AuNPs 
IrbpySS •AuNP13 1200 
IrC6 •AuNP13 1400 
IrbpySS •AuNP25 2300 
IrC6 •AuNP25 3200 
IrbpySS •AuNP100 15000 
IrC6 •AuNP100 22000 
    
3. 2. 2. 2 Photophysical characterisations  
The photophysical properties of these functionalised nanoparticles were investigated 
to identify any changes in behaviour of the iridium complexes when conjugated to the 
surface of gold nanoparticles. The luminescence properties were characterised by 
steady state and time resolved spectroscopy. The luminescence spectra of IrbpySS 
•AuNPs and IrC6 •AuNPs were recorded and compared to that of the metal complex 
in solution (Figure 3.24). 
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Figure 3.24. Steady-state emission spectrum lexc = 375 nm (solid line), UV/Vis 
absorption spectra (dashed line) and excitation spectra, lem = 580 nm for 
IrbpySS •AuNPs and lem = 590 nm IrC6 •AuNPs (dotted line) of (A) 4.5 nM IrbpySS 
•AuNP13, (B) 1.6 nM IrbpySS •AuNP25, (C) 30 µM IrbpySS •AuNP100, (D) 4.5 nM 
IrC6 •AuNP13, (E) 1.6 nM IrC6 •AuNP25 and (F) 30 pM IrC6 •AuNP100. Spectra 
corrected for PMT and instrument response.  
 
 
These nanoprobes are highly emissive upon excitation at 350, 375 and 405 nm, with 
a lmax at 580 nm for IrbpySS •AuNPs and a lmax at 590 nm for IrC6 •AuNPs. The 
emission has red shifted by 10 nm for both iridium functionalised nanoparticles in 
comparison to the free complex in water, which has an emission lmax at 570 nm for 
IrbpySS and lmax at 580 nm for IrC6. This effect was seen when the surfactant was 
added to the iridium complexes in aqueous solution where a 5 nm and 10 nm shift was 
seen for IrbpySS and IrC6 respectively. The shift is even more enhanced for IrbpySS 
•AuNPs, this could be due to an increased interaction of the complex with Zonyl FSA 
when they are both locked onto the surface of the nanoparticle, leading to a greater 
shielding effect in comparison the complex free in solution. The excitation spectra 
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displayed the iridium characteristic bands which are responsible for the observed 
emission and are similar for all three sizes of nanoparticles with both iridium 
complexes. The luminescent lifetimes of the functionalised AuNPs are summarised in 
Table 3.6.  
Table 3.6. Luminescent lifetimes of iridium functionalised gold nanoparticles in 
comparison to the complexes free in solution. Luminescent lifetimes were fitted 
with a c2 between 1 and 1.1.  
 



























   
The luminescent lifetime of IrC6 •AuNPs and IrbpySS •AuNPs are similar for all three 
sizes.  The luminescence lifetime were analysed with three components for both IrC6 
•AuNPs, IrbpySS •AuNPs and the free metal complex in solution. A short component 
of 25 – 50 ns was observed at a small percentage of 1 – 5 % for all sets of nanoparticles 
and the metal complexes in water. The long component of the IrC6 •AuNPs (~ 335 ns) 
decreases by 22 % when compared to the IrC6 in solution, whereas the opposite effect 
is seen for IrbpySS •AuNPs which showed an increase of 38% - 58 % in comparison 
to IrbpySS in solution. These results follow the same trend that was seen from the 
addition of Zonyl® FSA to the metal complexes in solution (3.2.1.2). The luminescence 
lifetimes of the IrbpySS •AuNPs reflect the same increase in lifetimes as was seen 
from the addition of Zonyl® FSA to IrbpySS in water, where an increase of 71 % was 
seen. This same effect has been seen in previously published methods, in which the 
lifetime of IrbpySS.Au increased from 130 ns (83 %) to 245 ns (86 %) upon addition of 
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Zonyl® FSA, Zonyl® FS-300 and PEG.74 The luminescence lifetimes of the IrC6 
•AuNPs follows the same trend for the increase in lifetimes that was seen from the 
addition of Zonyl® FSA to IrC6 in solution, where a decrease of 22 % was seen 
(3.2.1.2). This shows that the decrease in lifetime is from the Zonyl surfactant 
environment rather than any quenching from the gold nanoparticles. This is also 
evident in the observed lmax shift in the emission spectra of the nanoparticles in 
comparison with the IrC6 molecular probe. The quantum yields were measured using 
an integrated sphere with Zonyl coated gold nanoparticles being the reference sample, 
in which the SPR peak was diluted to match the SPR peak of IrC6 coated nanoparticles. 
The quantum yields for IrC6 •AuNP13 and IrC6 •AuNP25 were found to be 5 %. This 
was a small increase in quantum yield in comparison to the metal complexes in solution 
which were found to be 4%. 
3. 3 Conclusions 
Modification of previously designed iridium(III) complexes (IrbpySS) with a hexyl chain 
on the phenyl pyridine ligands led to the successful synthesis of IrC6 molecular probe. 
The incorporation of the hexyl chain was designed to increase hydrophobicity of the 
iridium complex which would increase the permeability across the cell membrane, and 
therefore it was important to have the optimal photophysical properties for imaging 
applications. These were measured for IrC6 and compared to IrbpySS, and the results 
showed desirable properties for bioimaging applications with intense emission in the 
visible range and long-lived luminescent lifetimes. These luminescent iridium 
complexes were successfully conjugated to gold nanoparticles of different sizes and 
found to retain their long-lived luminescence lifetimes and emission profiles. The 
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fluorinated surfactant used to stabilise the gold nanoparticles led to a reduction in the 
luminescence lifetime of IrC6 in water, but no further decrease was seen upon 
conjugation to the different sized nanoparticles. The opposite affect was seen for 
IrbpySS functionalised gold nanoparticles. The long-lived luminescence lifetimes 
recorded make these iridium functionalised nanoparticles suitable for two-photon 
lifetime imaging probes, which will be investigated in Chapter 4. Going forward, only 
the IrC6 probe is investigated for lifetime imaging studies. This is due to the inefficient 
excitation of IrbpySS under multiphoton excitation. Furthermore, design of these 
nanoprobes for both imaging and selective targeting will be explored through 
conjugation of biomolecules to the surface of different sized gold nanoparticles 
(Chapter 5).  
3. 4 Experimental section 
3. 4. 1 Synthesis of iridium(III) complexes 




The synthesis is from the method developed by Hong et al. A solution of 4,4’-
dimethoxy-2,2’-bipyridine (5.12 g, 23.7 mmol) in glacial acetic acid (295 mL) was 
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added to a hydrobromic acid (48 % w/v, 41 mL, 362.5 mmol) dropwise and refluxed for 
24 hours under N2. The solution was cooled to room temperature and the solvent 
removed in vacuo, affording an off-white solid. The solid was dissolved in H2O (250 
mL) and neutralised with aqueous ammonia solution (31% by weight) dropwise. The 
precipitate was filtered, washed with H2O (50 mL) and ice cold acetone (4 x 10 mL) 
and dried at 60 °C for 1 hour to give a white solid (2.06 g, 73.9% yield). δH(300 MHz; 
D2O/NaOH) 4.75 (2H, br s, OH), 6.37 (2H, dd, J = 5.7, 2.5, H-2), 6.84 (2H, d, J = 2.5, 
H-4), 7.84 (2H, d, J = 5.8, H-3). δC(100 MHz; D2O/NaOH) 115.75 (C-2), 114.52 (C-4), 





Potassium bicarbonate (14.12 g, 141.1 mmol) was suspended in a solution of 5-amino-
1-pentanol (5.04 g, 48.8 mmol) in H2O: THF (70 mL, 1:1). The white suspension was 
cooled in an ice bath to 0-10 °C, to which di-tert-butyl dicarbonate (11.12 g, 51.0 mmol) 
dissolved in H2O:THF (80 mL, 1:1) was added dropwise over 15 minutes, maintaining 
the temperature between 0-10 °C. The solution was then heated to 50 °C and stirred 
for 24 hours under N2. The organic phase was separated and concentrated in vacuo 
forming a white microsuspension. The suspension was dissolved in H2O:Et2O (150 
mL, 2:1) and the organic layer separated. The aqueous layer was washed with Et2O 
(50 mL), and the combined aqueous layers were dried (Na2SO4), filtered, and the 
solvent removed in vacuo to give a clear oil N-Boc-5-amino-1-pentanol (7.73 g, 90%); 
δH(300 MHz; CDCl3) 1.28-1.58 (6 H, m, H-2,3,4), 1.37 (9 H, s, H-8),  1.72 (1 H, s, OH), 
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3.11 (2 H, q, H-5), 3.63 (2 H, t, H-1) and 4.59 (1 H, s, NH); δC(100 MHz; CDCl3) 22.9 
(C-2), 28.3 (C-8), 29.7 (C-3), 32.1 (C-4), 40.3 (C-1), 62.1 (C-5), 79.0 (C-7) and 156.2 




N-(Boc)-5-amino-pentanol (7.80 g, 38.4 mmol) and para-toluene sulfonyl chloride (8.97 
g 47.1 mmol) were dissolved in anhydrous CH2Cl2 (50 mL) under an atmosphere of N2 
and cooled to 0-5 °C. Anhydrous Pyridine (11 mL, 149.0 mmol) was added dropwise 
over 5 minutes, maintaining the temperature between 0-5 °C. The solution was heated 
to room temperature and stirred for 24 hours. The mixture was concentrated in vacuo 
until it yielded a white suspension. The suspension was added to H2O:Et2O (100 mL 
1:1) and separated, followed by washing the organic layer with aqueous NaHCO3 (50 
mL) and brine (50 mL). The solution was dried (Na2SO4), filtered, and the solvent was 
removed in vacuo to give a clear oil (9.75 g), which was triturated in hexane (50 mL). 
The solid was filtered and washed with cold hexane (2 x 30 mL) to afford a white solid 
N-Boc-5-amino-1-tosylpentane (5.61 g, 45%); δH(300 MHz, CDCl3) 1.32-1.43 (4 H, m, 
H-6,7), 1.45 (9 H, s, H-1), 1.68 (2 H, dd, H-5), 2.47 (3 H, s, H-13), 3.04-3.12 (2 H, m, 
H-4), 4.04 (2 H, t, H-8), 4.51 (1 H, s, NH), 7.37 (2 H, d, H-11) and 7.81 (2 H, d, H-10); 
δc(300 MHz, CDCl3) 21.6 (C-13), 22.6 (C-7), 28.4 (C-1), 28.5 (C-6), 29.4 (C-5), 40.2 
(C-8), 70.4 (C-4), 79.1 (C-2), 127.89 (C-11), 129.9 (C-10), 133.1 (C-12), 144.8 (C-9) 
and 156.0 (C-3); MS (ESI+) m/z: 380.2 (M+Na)+. 
 




N-(Boc)-5-amino-1-tosylpentane (6.67 g, 15.7 mmol), 4,4’-dihydroxy-2,2’-bipyridine 
(0.94 g, 4.9 mmol) and Potassium carbonate (2.22 g, 15.8 mmol) was suspended in 
acetone (210 mL) with a catalytic amount of 18-crown-6 and heated to 60 °C and stirred 
for 36 hours. The reaction mixture was hot filtered and cooled to 0 -5°C to afford a 
white precipitate which was washed with cold acetone (2x 20 mL) to yield a yellow solid 
(1 g, 1.45 mmol, 35%); δH(300 MHz; CDCl3) 1.47 (18 H, s, H-1), 1.52-1.63 (8 H, m, H-
6,7), 1.84-1.87 (4 H, m, H-5), 3.10-3.25 (4 H, m, H-4), 4.15 (4 H, t, H-8), 4.58 (2 H, s, 
NH), 6.84 (2 H, dd, H-10), 7.96 (2 H, d, H-13) and 8.48 (2 H, d, H-11); δc(300 MHz; 
CDCl3) 23.3 (C-7), 28.4 (C-1), 28.6 (C-6), 29.8 (C-5), 40.4 (C-8), 67.8 (C-4), 77.3 (C-
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4,4’-di-(N-(Boc)-5-amino-1-pentoxy)-2,2’-bipyridine (0.97 g, 1.7 mmol) was dissolved 
in trifluoroacetic acid (14.9 mL) was stirred under N2 for 1 hour. The solvent was 
removed in vacuo, before separation (20 mL NaOH (1M)/ 20 mL chloroform). The 
aqueous layer was washed with chloroform (6 x 10 mL), and the combined organic 
extracts were dried (Na2SO4) and filtered. The solvent was removed in vacuo to give 
a white solid (0.26 g, 86%); δH (300 MHz; CDCl3) 1.48 (4 H, s, NH2), 1.37-1.55 (8 H, 
m, H-3,4), 1.72-1.81 (4 H, m, H-2), 2.73 (4 H, t, H-1), 4.07 (4 H, t, J = 6.4, H-5), 6.86 
(2 H, dd, H-7), 7.87 (2 H, d, J = 2.6, H-10) and 8.50 (2 H, d, H-8); m/z (ES) 359.2 
([M+Na]+, 100 %) 
 
4,4’-di-(5-lipoamido-1-pentoxy)-2,2’-bipyridine (bpySS) 
α-lipoic acid (0.48 g, 2.3 mmol) and 1-hydroxybenzotriazole hydrate (0.36 g, 2.7 mmol) 
in anhydrous DMF (8.8 mL) was cooled to 0-5 °C, upon which 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (0.41 g, 2.6 mmol) was added and stirred for 
1 hour, maintaining this temperature. After EDC had dissolved the solution was 
warmed to room temperature and stirred for a further 1 hour. A solution of N-
ethylmorpholine (N-EM) (0.27 g, 2.4 mmol), and 4,4’-di-(5-amino-1-pentoxy)-2,2’-
bipyridine (0.35 g, 9.8 mmol) in anhydrous DMF (12.3 mL) was added to the reaction 
mixture and stirred for 14 hours. The crude product was slurried in CHCl3 (50 mL) and 
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filtered again, before washing with CHCl3 (4 x 10 mL) to give a pale yellow powder 
bpySS (0.215 g, 20%); (δH (300 MHz; CDCl3) 1.30-1.58 (12 H, m, H-7,8,13), 1.54-1.68 
(8 H, m, H-14,15), 1.74-1.90 (6 H, m, H-9, H-17’), 2.10 (4 H, t, H-12), 2.38-2.50 (2 H, 
m, H-17), 2.98-3.16 (4 H, m, H-18, 18’), 3.22 (4 H, dd, H-10), 3.44-3.53 (2 H, m, H-16), 
4.06 (4 H, t,  H-6), 5.48 (2 H, s, NH), 6.75 (2 H, dd, H-4), 7.87 (2 H, d, H-2) and 8.38 
(2 H, d, H-5); δC (100 MHz; CDCl3) 23.4 (C-8), 25.4 (C-13), 28.6 (C-14), 28.9 (C-7), 
29.4 (C-9), 34.7 (C-15), 36.6 (C-12), 38.5 (C-18), 39.3 (C-10), 40.3 (C-17), 56.5 (C-
16), 67.7 (C-6), 106.7 (C-2), 111.3 (C-4), 150.2 (C-5), 157.8 (C-1), 166.1 (C-3), and 
172.7 (C-11); m/z (ES) 757.2 ([M+Na]+, 100 %). 
 
Tetrakis(2-phenylpyridine-C2,N')(µ-dichloro)diiridium 
The synthesis was based on the method of Watts et. al.38 Iridium trichloride hydrate 
(0.340g) and 2-phenylpyridine (0.79g) and dissolved in a mixture of 2-ethoxyethanol 
(30 mL) and water (10 mL) and refluxed for 24 h.  The solution was cooled to room 
temperature affording a white precipitate. The precipitate was washed with 95% 
ethanol (60 mL) and acetone (60 mL) and dissolved in anhydrous DCM (75 mL) and 
filtered producing [Ir(ppy)2Cl]2 (0.428 g, 72%). δH (300 MHz; CDCl3) 5.96 (1H, d J = 
7.8), 6.59 (1H, t J = 7.4), 6.78 (2H, dd, J = 16.2, 7.0), 7.51 (1H, d J = 7.8), 7.76 (1H, 
dd J = 11.8, 5.2), 7.90 (1H, d J = 7.7) and 9.27 (1H, d, J = 5.8); MS (ESI+) m/z: 1077.7 
[M-Cl]+. 




IrbpySS was synthesised via a modified method outlined by Slinker et al. Briefly, 
[Ir(ppy)2Cl]2 (66.6 mg, 0.06 mmol) and bpySS (100.8 mg, 0.14 mmol) was suspended 
in ethylene glycol (6.5 mL) and heated to 150 °C for 19 hours. The yellow mixture was 
cooled to room temperature, upon which H2O (150 mL) was added, and the mixture 
heated to 60-70 °C. Saturated aqueous ammonium hexafluorophosphate (1 g in 2.5 
mL H2O) was added, immediately forming a yellow precipitate, which was cooled on 
ice, filtered and washed with H2O. The solid was dissolved in minimal acetone and the 
solvent removed in vacuo to give [Ir(ppy)bpySS]PF6 (103.8 mg, 61%); δH (300 MHz; 
d6-acetone) 1.24-1.61 (20 H, m, H-8,9,10,14,16), 1.64-1.83 (6 H, m, H-15,18’), 2.0 (4 
H, t, H-13), 2.22-2.39 (2 H, m, H-18), 2.92-3.17 (8 H, m, H-11,19), 3.35-3.49 (2 H, m, 
H-17), 4.2 (4 H, t, J = 6.4, H-7), 6.22 (2 H, dd, H-k), 6.76 (2 H, td, H-j), 6.9 (2 H, td, H-
i), 6.97 (2 H, s, NH), 7.01-7.10 (4 H, m, H-5,d), 7.67 (2 H, d, H-6), 7.70-7.75 (4 H, m, 
H-e,h), 7.80 (2 H, dd, H-c), 8.10 (2 H, d, H-b) and 8.3 (2 H, d, H-3); m/z (ES+) 1235.4 
([M-Cl]+).  
The pH of a suspension of two spatulas of Dowex 1x8 50-100 Mesh in deionised water 
(30mL) was lowered to 1 using HCl (10%) and stirred for 1 hour. The Dowex was 
filtered in vacuum and washed with deionised water (20mL) and methanol (50mL). The 
Dowex was resuspended in MeOH (~30mL). A solution of [Ir(ppy)2bpySS]PF6 
(~0.005g, in 5mL of MeOH) was added and the mixture is stirred for 2 hours. The 
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Dowex was filtered off, and the resin was washed with MeOH until colourless. The 
solution was dried and made to a concentration of 1mM with MeOH to give a solution 
of [Ir(ppy)2bpySS]Cl. λmax (H2O)/nm (ε/dm3.mol−1cm−1); [Ir(C6-ppy)2bpySS]Cl: 229sh 
(24472), 258 (23568), 298sh (12216), and 354sh (4722). Emission λmax = 570 nm, 
t = 30 ns (8%), 100 ns (33%), 430 ns (49%), f = 4 %. Upon addition of 10% Zonyl FSA. 
Emission λmax = 580 nm, t = 35 ns (1 %), 140 ns (56 %), 530 ns (44 %), f = 3 %. 
3. 4. 1. 2 Synthesis of IrC6 
 
2-(hexylphenyl)-pyridine 
The synthesis was based on the method of Ackermann et. al.39 A suspension of 
[RuCl2(p-cymene)2] (15.4 mg, 0.025 mmol, 2.5 mol%), 1-AdCO2H (54.1 mg, 0.30 
mmol, 30 mol%), K2CO3 (276 mg, 2.00 mmol), 2-phenylpyridine (155 mg, 1.00 mmol), 
and 1-bromo-n-hexane (495mg, 3.00mmol) in NMP (4mL) was stirred for 48h at 130 
ºC under N2. EtOAc (100 mL) and H2O (100 mL) were added to the cold reaction 
mixture. The aqueous phase was extracted with EtOAc (4 x 50 mL). The combined 
organic layers were washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried over 
Na2SO4, and concentrated in vacuum. The remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc 3:1) to yield 2-(hexylphenyl)-pyridine 
(163 mg, 68%) as a light yellow oil. δH(300 MHz; CDCl3) 0.73 (t, J = 6.8 Hz, 3H, H-
18), 1.16 – 1.03 (m, 6H, H-15,16,17), 1.36 (dt, J = 15.3, 7.7 Hz, 2H, H-14),  2.74 – 2.50 
(m, 2H, H-13), 7.37 – 6.99 (m, 6H, H-1,2,5,6,8,10), 7.64 (td, J = 7.7, 1.8 Hz, 1H, H-9), 
8.60 (d, J = 5.7 Hz, 1H, H-11); δC (100 MHz; CDCl3) 14.1 (C-18), 22.5 (C-17), 29.1 (C-
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15), 31.3 (C-14), 31.5 (C-16), 32.9 (C-13), 121.6 (C-8), 124.11 (C-2), 125.7 (C-10), 
128.3 (C-5), 129.7 (C-6,1), 136.1 (C-9), 140.4 (C-4), 140.8 (C-3), 149.1 (C-11), 160.4 




The synthesis was based on the method of Watts et. al.38 Iridium trichloride hydrate 
(0.235 g, 0.79 mmol) and 2-(2’-hexylphenyl)pyridine (0.71  g, 2.92 mmol) was 
dissolved  in  a  mixture  of 2-ethoxyethanol (20 mL) and water (10 mL) and refluxed 
for 24 h.  The solution was cooled to room temperature affording a yellow precipitate.  
The precipitate was washed with 95% ethanol (25 mL) and methanol (50 mL) to give 
yellow crystals of [Ir(C6-ppy)2Cl]2 (0.290 g, 0.205 mmol, 53%). δH (300 MHz; CDCl3) 
0.84 (H1, t, J = 6.9 Hz, 12H), 1.28 (H2-3, dd, J = 8.8, 5.0 Hz, 16H), 1.39 (H4, dd, J = 
12.9, 6.6 Hz, 8H), 1.71 – 1.51 (H5, m, 8H), 3.09 – 2.60 (H6, m, 8H), 5.58 (H10, dd, J 
= 7.7, 1.0 Hz, 4H), 6.33 (H9, t, J = 7.6 Hz, 4H), 6.47 (H8, d, J = 7.3 Hz, 4H), 6.65 (H16, 
t, J = 6.3 Hz, 4H), 7.65 (H15, t, J = 7.1 Hz, 4H), 7.89 (H14, d, J = 8.4 Hz, 4H), and 9.26 
(H17, dd, J = 5.8, 1.4 Hz, 4H). δC (100 MHz; CDCl3) 14.2 (C1), 22.7 (C2), 29.6 (C4), 
30.4 (C5), 31.8 (C3), 35.6 (C6), 121.5 (C16), 122.1 (C15), 124.8 (C8), 128.0 (C9), 
128.5 (C10), 135.7 (C14), 140.5 (C12), 141.8 (C7), 148.3 (C11), 152.7 (C17) and 168.4 
(C13). NMR assignments were confirmed by COSY, HSQC, and HMBC. 




[Ir(C6-ppy)2bpySS]PF6 was also synthesized via a modified method outlined by Slinker 
et al. [Ir(C6-ppy)2Cl]2 (0.040 g, 0.028 mmol) and bpySS (0.053 g, 0.057 mmol) was 
suspended in ethylene glycol (10 mL) and heated to 150 °C for 24h. The yellow mixture 
cooled to room temperature, upon which H2O (50 mL) was added, and the mixture 
heated to 60−70 °C. Saturated aqueous ammonium hexafluorophosphate (1 g in 2.5 
mL H2O) was added, forming an orange precipitate that was left on agitation for 1 hour. 
The solution was cooled on ice, filtered, and washed with H2O. The solid was dissolved 
in minimal acetone and the solvent removed in vacuum. The residual solid was triturate 
in n-hexane and vacuum filtered to give [Ir(C6-ppy)bpySS]PF6 (0.0944 g). λmax 
(MeCN)/nm (ε/dm3.mol−1cm−1) 223 (46961), 258 (40567), 297sh (19366) 322sh 
(12850) and 353sh (7493); δH (300MHz; CDCl3) 0.92 (t, J = 6.2 Hz, 6H), 1.42 – 1.27 
(m, 12H), 1.52 – 1.42 (m, 8H), 1.66 – 1.52 (m, 12H), 1.77 – 1.67 (m, 8H), 1.87 (d, J = 
3.1 Hz, 8H), 2.31 – 2.20 (m, 4H), 2.73 (d, J = 4.2 Hz, 4H), 3.03 (t, J = 7.2 Hz, 4H), 3.28 
(d, J = 4.0 Hz, 4H), 3.90 (s, 2H), 4.02 (s, 2H), 4.27 (t, 4H), 6.06 (d, J = 7.4 Hz, 2H), 
6.76 (t, J = 7.4 Hz, 2H), 6.90 – 6.78 (m, 4H), 7.02 (d, J = 3.9 Hz, 2H), 7.53 (d, J = 5.8 
Hz, 2H), 7.69 (d, J = 4.6 Hz, 2H), 7.77 (t, J = 7.6 Hz, 2H), 8.00-8.05 (m, 4H); δC (100 
MHz; CDCl3) 14.1 (C-q), 22.7 (C-p) 22.9 (C-3), 23.6 (C-9), 28.2 (C-10) 28.7 (C-n), 29.4 
(C-m), 30.2 (C-4), 31.7 (C-o), 35.9 (C-5,7), 39.2 (C-l), 63.8 (C-13), 65.3 (C-11), 69.4 
(C-1), 110.6 (C-18), 115.2 (C-j), 122.6 (C-c), 123.2 (C-d), 126.0 (C-16), 129.7.8 (C-h/i), 
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137.4 (C-b), 141.4 (C-f), 141.9 (C-k), 149.1 (C-a), 150.3 (C-15), 153.6 (C-19), 157.5 
(C-e), 167.4 (C-17), 167.9 (C-9), and 216.2 (C-6); NMR assignments were confirmed 
by COSY, HSQC, and HMBC.  
The pH of a suspension of two spatulas of Dowex 1x8 50-100 Mesh in deionised water 
(30mL) was lowered to 1 using HCl (10%) and stirred for 1 hour. The Dowex was 
filtered in vacuum and washed with deionised water (20mL) and methanol (50mL). The 
Dowex was resuspended in MeOH (~30mL). A solution of [Ir(C6-ppy)2bpySS]PF6 
(~0.005g, in 5mL of MeOH) was added and the mixture is stirred for 2 hours. The 
Dowex was filtered off, and the resin was washed with MeOH until colourless. The 
solution was dried and made to a concentration of 1mM with MeOH to give a solution 
of [Ir(C6-ppy)2bpySS]Cl. λmax (H2O)/nm (ε/dm3.mol−1cm−1); [Ir(C6-ppy)2bpySS]Cl: 229sh 
(24472), 258 (23568), 298sh (12216), and 354sh (4722). Emission λmax = 580 nm, 
t = 40 ns (6%), 170 ns (45%), 430 ns (49%), f = 4%. Upon addition of 10% Zonyl FSA. 
Emission λmax = 590 nm, t = 40 ns (6%), 150 ns (35%), 320 ns (62%), f = 4%. 
3. 4. 2 Synthesis of gold nanoparticles (AuNPs) 
AuNP13. The protocol for synthesizing 13 nm AuNPs was based on the published 
method Turkevich et al.49 in which glassware used was washed with aqua regia 
(HCl:HNO3, 3:1) and dried in the oven.  A solution of trisodium citrate dihydrate 
(60.6mg, 0.21 mmol), citric acid (13.6 mg, 0.07 mmol) and ethylenediaminetetraacetic 
acid (EDTA) (1.6 mg, 0.004 mmol) in 100 mL ultrapure water was vigorously stirred 
and brought to reflux. This was left to reflux for 15 minutes, before rapid addition of a 
solution of gold(III)chloride trihydrate (HAuCl4.3H2O) (8.6 mg, 0.020 mmol) in 25 mL of 
ultrapure water. After refluxing for a further 15 minutes, the heat was turned off and the 
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solution left to cool to room temperature, forming 1.53 nM AuNP13. lmax(H2O): 517 nm 
(SPR). Diameter 13 ± 3 nm (DLS number distribution), PDI = 0.07, z-potential = -33 ± 
13 mV. The final concentration of AuNP13 was changed by centrifuged at 10, 000 g 
for 30 minutes. The supernatant was decanted and the pellet was redispersed in 
ultrapure water to form a 4.5 nM solution of AuNP13.   
AuNP25 and AuNP100. The protocol for the formation of AuNP25 and AuNP100 was 
modified using a previously published method.61 Three stock solutions were prepared; 
5 mM HAuCl4.3H2O, 57 mM ascorbic acid and 34 mM trisodium citrate dihydrate in 
water. AuNP13 (34 mL, 1.53 nM) were diluted to 40 mL with ultrapure water and 
vigorously stirred. The three solutions were diluted to 1 mM, 2.85 mM and 0.85 mM in 
ultrapure water for HAuCl4.3H2O, ascorbic acid and trisodium citrate dehydrate 
respectively. The three solutions (HAuCl4.3H2O and ascorbic acid, trisodium citrate 
dehydrate) were added simultaneously to the vortex of the solution via a peristaltic 
pump over 25 minutes. The solution was refluxed for 30 minutes forming 0.65 nM 
AuNP25. lmax(H2O): 519 nm (SPR). Diameter 18 ± 5 nm (DLS number distribution), 
PDI = 0.05. z-potential = -30 ± 12 mV. The AuNP25 were then centrifuged at 10, 000g 
for 30 minutes and redispersed in ultrapure water to remove excess ascorbic acid and 
concentrated to give 1.6 nM AuNP25. AuNP25 (9 mL, 0.65 nM) were diluted to 40 mL 
with ultrapure water and vigorously stirred. The three solutions were diluted to 1 mM, 
2.85 nM and 0.85 nM in ultrapure water for HAuCl4.3H2O, ascorbic acid and trisodium 
citrate dehydrate respectively. The two solutions (HAuCl4.3H2O and ascorbic acid, 
trisodium citrate dehydrate) were added simultaneously to the vortex of the solution 
via a peristaltic pump over 25 minutes. The solution was refluxed for 30 minutes 
forming 70 pM AuNP50. lmax(H2O): 527 nm (SPR). Diameter 46 ± 10 nm (DLS number 
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distribution), PDI = 0.03. z-potential = -33 ± 17 mV. The AuNP50 (40 mL, 70 pM) was 
left to vigorously stir. The three solutions were diluted to 4 mM, 12 nM and 3.4 nM in 
ultrapure water for HAuCl4.3H2O, ascorbic acid and trisodium citrate dehydrate 
respectively. The two solutions (HAuCl4.3H2O and ascorbic acid, trisodium citrate 
dehydrate) were added simultaneously to the vortex of the solution via a peristaltic 
pump over 25 minutes. The solution was refluxed for 30 minutes forming 35 rM 
AuNP100. lmax(H2O): 556 nm (SPR). Diameter 80 ± 20 nm (DLS number distribution), 
PDI = 0.03. z-potential = -33 ± 12 mV. The AuNP100 were taken and centrifuged at 
10, 000 g for 90 s. The supernatant was decanted and the pellet was redispersed in 
ultrapure water.  
3. 4. 3 Attachment of iridium(III) complexes to AuNPs 
Z •AuNP13. 10% Zonyl FSA solution in ultrapure water (3 µL) was added to 4.5 nM 
AuNP13 (1 mL) and sonicated for 10 minutes. This was centrifuged at 10, 000g for 30 
minutes, the supernatant was decanted and the pellet was resuspended in ultrapure 
water (1 mL) to form Z •AuNP13. lmax(H2O): 519 nm (SPR). Diameter 17 ± 4 nm (DLS 
number distribution), PDI = 0.24. z-potential = - 66 ± 21 mV.  
IrbpySS •AuNP13. IrC6 (20 µL, 1 mM) was titrated into 4.5 nM solution of Z •AuNP13 
(1 mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution of IrbpySS •AuNP13. lmax(H2O): 522 nm (SPR). Diameter 
14 ± 4 nm (DLS number distribution), PDI = 0.24. z-potential was not recorded. ICP-
MS results show 12,00 complexes per AuNP13. 
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IrC6 •AuNP13. IrC6 (22.5 µL, 1 mM) was titrated into 4.5 nM solution of Z •AuNP13 (1 
mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution of IrC6 •AuNP13. lmax(H2O): 525 nm (SPR). Diameter 17 
± 4 nm (DLS number distribution), PDI = 0.27. z-potential = - 32 ± 15 mV. ICP-MS 
results show 1,400 complexes per AuNP13. 
Z •AuNP25. 10% Zonyl FSA solution in ultrapure water (3 µL) was added to 1.6 nM 
AuNP25 (1 mL) and sonicated for 10 minutes. This was centrifuged at 10, 000g for 30 
minutes, the supernatant was decanted and the pellet was resuspended in ultrapure 
water (1 mL) to form Z •AuNP25. lmax(H2O): 521 nm (SPR). Diameter 22 ± 6 nm (DLS 
number distribution), PDI = 0.14. z-potential = -56 ± 13 mV.  
IrbpySS •AuNP25. IrC6 (20 µL, 1 mM) was titrated into 1.6 nM solution of Z •AuNP25 
(1 mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution of IrbpySS •AuNP25. lmax(H2O): 525 nm (SPR). Diameter 
26 ± 10 nm (DLS number distribution), PDI = 0.21. z-potential was not recorded. ICP-
MS results show 23,00 complexes per AuNP25. 
IrC6 •AuNP25. IrC6 (40 µL, 1 mM) was titrated into 1.6 nM solution of Z •AuNP25 (1 
mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution of IrC6 •AuNP25. lmax(H2O): 525 nm (SPR). Diameter 22 
± 6 nm (DLS number distribution), PDI = 0.18. z-potential = -35 ± 20 mV. ICP-MS 
results show 3,200 complexes per AuNP25. 
Z •AuNP100. 10% Zonyl FSA solution in ultrapure water (3 µL) was added to 30 pM 
AuNP100 (1 mL) and sonicated for 10 minutes. This was centrifuged at 10, 000g for 
90 seconds, the supernatant was decanted and the pellet was resuspended in 
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ultrapure water (1 mL) to form Z •AuNP100. lmax(H2O): 556 nm (SPR). Diameter 87 ± 
21 nm (DLS number distribution), PDI = 0.02. z-potential = -68 ± 16 mV. 
IrbpySS •AuNP100. IrC6 (20 µL, 1 mM) was titrated into 30 pM solution of Z • AuNP100 
(1 mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution IrbpySS • AuNP100. lmax(H2O): 558 nm (SPR). Diameter 
95 ± 30 nm (DLS number distribution), PDI = 0.02. z-potential not recorded. ICP-MS 
results show 15,000 complexes per AuNP100.  
IrC6 •AuNP100. IrC6 (30 µL, 1 mM) was titrated into 30 pM solution of Z • AuNP100 (1 
mL) with sonication in between. A Sephadex G-10 size exclusion column was 
performed to give a solution IrC6 • AuNP100. lmax(H2O): 562 nm (SPR). Diameter 89 
± 22 nm (DLS number distribution), PDI = 0.02. z-potential = -42 ± 24 mV. ICP-MS 
results show 22,000 complexes per AuNP100.  
3. 4. 4 Preparing AuNPs for TEM  
TEM imaging was carried out on Citrate •AuNPs, IrbpySS •AuNPs and IrC6 •AuNPs. 
For all nanoparticle samples 20 µL was added to a 200-mesh formvar-coated grid TEM 
grid and left to dry for 1 hour. Excess liquid was removed using filter paper. Samples 
prepared were 4.5 nM Citrate •AuNP13, IrbpySS •AuNP13 and IrC6 •AuNP13, 1.6 nM 
Citrate •AuNP25, IrbpySS •AuNP25 and IrC6 •AuNP25 and 30 pM Citrate •AuNP100, 
IrbpySS •AuNP100 and IrC6 •AuNP100.  
3. 4. 5 Preparing AuNPs for ICP-MS 
Standard solutions were prepared containing the metals which were to be detected 
through ICP-MS (Gold and Iridium) in a series of concentrations from 0, 10, 25, 50, 
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100, 250, 500, 1000 ppb. These were used to calibrate the system and to calculate 
the metal content for each iridium functionalised AuNPs.  
IrbpySS •AuNPs and IrC6 •AuNPs were prepared as outlined in Section 3.4.3. The 
AuNP samples were dissolved in minimal ultrapure Aqua Regia (3 HCl: 1 HNO3), 
which was added in small aliquots until samples were fully digested. These samples 
were left to stir overnight at room temperature to ensure that the gold nanoparticles 
had fully digested. These samples were analysed at the University of Warwick to 
determine the number of iridium complexes per gold nanoparticle. In order to 
determine the gold concentration, a 1:200 dilution was done into 4% ultrapure Nitric 
Acid. 
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CHAPTER 4. IRIDIUM NANOPARTICLES FOR MULTICHANNEL 
LUMINESCENCE LIFETIME IMAGING, MAPPING LOCALISATION IN LIVE 
CANCER CELLS 
4. 1 Introduction 
The effective sensitivity of single-photon fluorescence microscopy is often limited by 
out-of-focus light, especially in thick samples such as tissues.  Therefore, multiphoton 
microscopy is often employed and is fast becoming the most widely used optical 
microscopy for in vivo experiments.1, 2 Multiphoton imaging has led to breakthroughs 
in medical diagnostics, specifically in quantification of angiogenesis and cancer 
metastasis, reaching to several millimetres in depth detection, thus providing 
invaluable information on tumour vasculature and tumour microenvironment.3-5 A 
limitation to using intensity based methods is the high concentrations of luminescent 
probes needed to visualise subcellular structures, which can be toxic and generates a 
high background signal. Therefore, researchers have started looking at lifetimes based 
techniques as a more sensitive method of detection in comparison to emission based 
methods. Utilising the advantages of multiphoton excitation and combining this with 
lifetime imaging has revealed a wealth of additional information, which is independent 
of the probe concentration but sensitive to local changes of the environment.6, 7  
Lifetime based techniques are advantageous over emission based techniques 
because they allow for complete elimination of background autofluorescence which is 
only a couple of nanoseconds, by using time-gating methods.8-10 This means that long 
phosphorescence and fluorescence lifetimes can be detected separately from 
background autofluorescence. Luminescence lifetimes are detected independent of 
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probe concentration,11 meaning lower concentrations can be used in comparison to 
emission based techniques, where high loading is needed in cells. There are currently 
two types of imaging methods that utilize the luminescence lifetimes of chemical and 
biological imaging probes. Fluorescence lifetime imaging microscopy (FLIM) uses 
probes that contain short nanosecond fluorescent lifetimes, typical around 1 – 10 ns.12 
These short nanosecond lifetimes are within the range of lifetimes detected from 
cellular autofluorescence lifetimes, so research has shifted into looking at 
phosphorescent probes for phosphorescence lifetimes imaging microscopy (PLIM). 
These probes have long-lived luminescence lifetimes extending into the microsecond 
range, due the spin-forbidden triplet excited state.13 Therefore there is a strong interest 
in developing phosphorescent probes with long excited state lifetimes, which can be 
gated from short-lived signals associated with autofluorecence, expanding sensitivity 
in signal detection.14  
Transition metal complexes are ideal candidates for phosphorescence lifetime imaging 
as they emit from a long-lived triplet excited state, have high two-photon absorption 
cross-sections and have previously been found to function effectively as biological 
imaging probes for fluorescence emission based microscopy due to their desirable 
photophysical properties. Despite this, there are only a few examples in the literature 
utilising these desirable properties of transition metal complexes for their use in 
phosphorescence lifetime imaging. This was seen by using ruthenium(II) complexes 
as PLIM probes to study nuclear DNA in both fixed and live cells.11 The results showed 
that DNA-bound ruthenium(II) complexes exhibited longer luminescence lifetimes of 
185 ns in comparison to that of unbound ruthenium(II) complexes present in the 
cytoplasm which displayed a lifetime of 124 ns (Figure 4.1). 
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Figure 4.1. (Left) Phosphorescence lifetime images (PLIM) and (Right) confocal 
images of fixed, permeabilized MCF7 cells treated with complex 1 (100 µm, 45 
minutes, PBS buffer).11   
 
The cytoplasmic staining appears to show weak emission from the ruthenium(II) 
complexes in comparison to the nuclear staining which can be seen in the confocal 
image. However, the corresponding lifetime image shows a lot of detail within the 
cytoplasm and further analysis was carried out to identify the small changes in lifetimes 
between the two regions of the cells. This shows how sensitive the detection is for 
lifetime imaging techniques and highlights the limitations of emission based methods. 
The ability to detect these differences in the phosphorescent probes luminescence 
lifetime within cells will lead to more sensitive way of mapping localisation patterns, 
understanding interactions with biological targets and probing the cellular 
microenvironment. The latter was demonstrated by Baggaley et al. which showed the 
first example of oxygen sensing in cells using a heteronuclear Ir(III)-Ln(III) luminescent 
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complex, in which lifetime changes were monitored by PLIM.15 They showed some 
very promising results with the Ir(III) luminescence lifetime decreasing upon increasing 
volumes of O2 levels within HeLa cells, showing that the probe is sensitive to local 
changes in environment. The recorded lifetimes were 435, 520, 586 and 664 ns for a 
relative oxygen concentration of 100 %, 50%, 21 % and 0 % respectively. These 
changes in lifetimes correspond to the visual change seen in the lifetime images, where 
the colour shifts from orange to blue in the lifetime images (Figure 4.2). 
 
Figure 4.2. (Left) Schematic representation of dyad Ir-Gd phosphorescence 
complex. (Right) Two-photon phosphorescence lifetime (lex = 760 nm) imaging 
of Ir-Gd stained HeLa cells (50 µm, 18 h, fixed) under varying concentrations of 
O2. Scale bar = 10 µm.15  
 
Combining both phosphorescence and fluorescence lifetime imaging is highly 
advantageous for samples containing multiple labels and is made possible through 
time-gated methods (FLIM/PLIM).16 The technique has been demonstrated 
successfully in the literature on cyclometalated platinum(III) complexes which showed 
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variable lifetimes from the nanosecond range to the millisecond range depending on 
the probes localisations within cells.16 Through this technique the short nanosecond 
lifetimes could be detected by FLIM and the long-lived lifetimes detected by PLIM, with 
no overlap of the emitting signals. The results showed that discrimination between 
fluorescent and phosphorescent labels in multiply stained cells and tissues could be 
achieved using this method (Figure 4.3).  
 
Figure 4.3. (Top) Two-photon images of live CHO-K1 cells co-labelled with PtL1 
Cl and Hoechst. (a and c) Intensity images, (b and d) lifetime maps for short 
nanosecond lifetimes and (c and d) correspond to long-lived emission from PtL1 
Cl. (Bottom) Skin epidermis co-labelled with PtL2 Cl and DAPI. (e) Time-gated 
intensity images demonstrate separation of short-lived emission of 
DAPI/autofluorescence from PtL2 Cl. (f) Emission spectra from epidermis: 
unlabelled (black), labelled with DAPI (blue) or PtL2 Cl (green), co-labelled with 
PtL2 Cl and DAPI (red).16 
 
 
The lifetime images show that short-lived lifetimes from DAPI and cellular 
autofluorescence can be completely separated from PtL2 long-lived signal which can 
be seen visually in Figure 4.3, e. This was a novel approach which used the powers of 
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multiphoton excitation and both lifetime imaging methods on transition metal 
complexes. To date, there are no examples in the literature for using multiphoton 
excitation and FLIM/PLIM imaging on transition metal complexes coated on gold 
nanoparticles.  
Gold nanoparticles have unique optical properties and can easily incorporate more 
than one type of imaging or targeting agent, which allows them to be used as 
multifunctional nanoplatforms for both imaging and cancer therapies.17-19 The gold 
nanoparticle scaffold is ideal as a multimodal probe which can be detected by electron 
microscopy techniques as well as reflectance microscopy, which is highly 
advantageous for 100 nm gold nanoparticles to be detected as single, non-aggregated 
particles within the microscope diffraction limit.20, 21 Even though the characteristic 
surface plasmon resonance of the gold nanospheres has been used extensively as 
signal detection,22 there is little investigation in monitoring gold nanoparticles by 
lifetime imaging.23 We have been interested in the development of nanosized probes 
based on gold scaffold and luminescent transition metal complexes in order to translate 
the attractive luminescent properties of the metal complexes to the nanosized probe.24-
26  
4. 2 Chapter Summary 
This chapter looks at the synthesis of iridium(III) coated nanoparticles for multichannel 
lifetime imaging using multiphoton excitation and the design of novel nanoprobe based 
on a luminescent iridium complex with long legs for attachment to gold. The previous 
chapter discussed the synthesis and photophysical characterisations of two iridium 
functionalised nanoparticles (Scheme 4.1). It was previously shown that the distance 
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of the luminescent centre from the gold nanoparticle enhances the lifetime properties 
of the ruthenium probes.25 Incorporating  the hexyl chain on the phenyl pyridine was 
designed to increase hydrophobicity of the iridium complex and stabilization onto gold, 
increasing signal and therefore proposing better permeability across the cell 
membrane.27, 28 
 
Scheme 4.1. Summary of the photophysical properties of IrbpySS •AuNPs and 
IrC6 •AuNPs 
 
Detection of the characteristic long luminescence lifetime of the iridium complex and 
the short-lived lifetime detected from the gold resonance signal was monitored by 
lifetime imaging microscopy. Different sizes of gold nanoparticles (13 nm, 25 nm and 
100 nm) were functionalised with the iridium(III) probe and their uptake in live HeLa 
cells was analysed using lifetime imaging, optical microscopy and electron based 
techniques. The results of nanoparticle localisation in cells are also supported by Total 
Internal Reflection Fluorescence Microscopy (TIRF), electron microscopy as well as 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) analysis.   
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4. 3 Results and Discussion  
4. 3. 1 Iridium functionalised AuNPs as multiphoton lifetime imaging probes 
4. 3. 1.1 Multiphoton properties 
The photophysical properties of these iridium functionalised nanoprobes were 
characterised to assess their ability to undergo multiphoton excitation for multiphoton 
lifetime imaging applications. The multiphoton absorption cross-sections and power 
dependence analysis of the luminescence upon excitation at 760 nm was examined. 
The two-photon luminescence spectra of IrC6 in MeOH and IrC6 •AuNP25 were 
successfully recorded and compared to their corresponding single-photon 
luminescence spectra. The results showed that two-photon excitation at 760 nm 
produced a nearly identical emission spectra as produced by single-photon excitation 
(Figure 4.4). 
 
Figure 4.4. Emission spectra produced from one photon excitation  lexc = 375 nm 
(dotted line) and two-photon excitation lexc = 760 nm (solid line) for (Left) IrC6 
and (Right) IrC6 •AuNP25 in agarose gel. Spectra have been normalized. 
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Whilst trying to obtain the two-photon luminescence spectra for IrC6 •AuNP25 in water, 
some issues arose. Two-photon excitation was attempted in solution, however it 
appeared nanoparticles were moving in and out of focus due to Brownian motion in 
solution which meant an emission spectra could not be recorded using this method. 
Therefore, an immobilisation technique was carried out to record the two-photon 
luminescence spectra, which allowed us to calculate the two-photon absorption cross-
sections and power dependence. The IrC6 •AuNP25 (1.6 nM, 1 mL) were immobilised 
in 0.1% agarose gel, and a luminescence spectra was generated using multiphoton 
excitation. This meant that the two-photon luminescence spectra for IrC6 •AuNP25 had 
to be recorded in agarose gel. A solution of 0.1 % agarose gel containing no iridium 
functionalised nanoparticles was excited at 760 nm and found to produce no 
luminescence. Power dependence studies determines the ability for the compound to 
undergo two-photon excitation by measuring the luminescence intensity at increasing 
laser powers. For IrC6 •AuNP25 immobilised in 0.1 % agarose gel, the laser 
dependence studies were carried out on four different areas and the average 
presented (Figure 4.5). 
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Figure 4.5. (Left) Two-photon luminescence spectra taken at increasing laser 
power for (Top) IrC6 and (Bottom) IrC6 •AuNP25 using 760 nm excitation. (Right) 
Power dependence studies showing log-log plot of integrated emission intensity 
versus laser power. Slope calculated as 2.30, R = 0.9959 for (Top) IrC6 and 2.06, 
R = 0.9944 for (Bottom) IrC6 •AuNP25.  
 
A log-log plot of the integrated emission intensity versus laser power shows quadratic 
dependence for both the IrC6 probe and IrC6 •AuNP25. The slope was calculated and 
found to be 2.30 and 2.06 for IrC6 and IrC6 •AuNP25 respectively, indicating strongly 
that a two-photon process is occurring.29 The two-photon absorption cross-sections 
(s2) were calculated using the results from the highest laser power (0.069 mW for both 
IrC6 (MeOH) and IrC6 •AuNP25 (0.1% agarose gel). The two-photon absorption cross-
section were calculated using the equation below, where r and s stand for the reference 
standard and sample respectively, s2 for two-photon absorption cross-section, c for 
concentration, Il and FIl are the fluorescence intensity at the wavelength l for two-
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photon and one-photon, respectively. åFL describes the integrated intensity of the 
one-photon fluorescence spectra and f is the one-photon fluorescence quantum yield, 














This equation compares the luminescence intensity of the samples to a reference 
standard, Rhodamine B in Methanol31. The recorded cross-sections are in units of 
Goeppert-Mayer (GM) where 1 GM = 10-50 cm4 s photon-1. The results showed an 
absorption cross-section of 38 GM for the IrC6 in methanol and 2 x 103 GM per particle 
for IrC6 •AuNP25. The absorption cross-section calculated for IrC6 agrees with similar 
iridium compounds.32, 33 The absorption cross-section calculated for IrC6 •AuNP25, is 
unusually high for any iridium-based luminescence signal and is therefore attributed to 
the enhancement by the gold nanoparticles surface plasmon resonance. Jiang et al. 
investigated the two-photon absorption properties of non-aggregated gold 
nanoparticles (40 nm) and aggregated gold nanoparticles. They found that the two-
photon absorption cross-section increased from 4 x 102 GM to 5 x 103 GM when the 
particles aggregated. The increase was attributed to the enhanced plasmon coupling 
in the aggregated particles, which lead to an increase in two-photon absorption.34 It is 
evident from our results that upon immobilisation of IrC6 •AuNP25 in 0.1% agarose 
gel, the nanoparticles have come together to form clusters or ‘aggregates’ of 
nanoparticles. The nanoparticles are in close spatial proximity to each which causes 
an enhancement in the plasmon resonance band, which is reflected in the high two-
photon absorption cross-section.35 These studies have shown the potential for these 
nanoprobes to be used as multiphoton lifetime imaging probes. This will be explored 
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in the following section, where uptake into HeLa cells will be investigated using two-
photon lifetime microscopy and characterisation of the lifetimes detected will be used 
to map localisation in cells.   
4. 3. 2 Multichannel luminescence lifetime imaging  
Two-photon lifetime imaging works by detecting the characteristic long-lived lifetimes 
and short lifetimes in two separate channels. A pulsed Titanium: Sapphire (Ti: Sa) laser 
is used to induce fluorescence lifetimes (short) and phosphorescence lifetimes (long) 
from a sample which are collected simultaneously in two different channels. During the 
on-time the laser excites fluorescence and allows phosphorescence to be built up, 
when the laser is switched off the true phosphorescence is obtained, all within the 
same pixel dwell time (Figure 4.6).36  
 
Figure 4.6. Principles of PLIM/ FLIM set up 
Therefore, the PLIM channel detected the long-lived signal from the iridium complex 
and the FLIM channel identified the presence of AuNPs within the cell by detecting the 
characteristic SPR band of the gold. The co-localisation of these two signals revealed 
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uptake of these iridium functionalised nanoparticles with no decomposition of particles 
when inside the cell.  
To investigate the potential of these nanoprobes as lifetime imaging agents, live HeLa 
cells were treated with IrC6 •AuNP13, IrC6 •AuNP25 and IrC6 •AuNP100. HeLa cells 
were dosed with a final concentration of 0.45 nM, 0.16 nM and 3 pM for IrC6 •AuNP13, 
IrC6 •AuNP25 and IrC6 •AuNP100 respectively. Cells dosed with IrC6 •AuNP13 and 
IrC6 •AuNP100 were incubated for 5 hours and cells dosed with IrC6 •AuNP25 for 3 
hours. Two-photon lifetime imaging was carried out at Rutherford Appleton 
Laboratories (RAL), in which long and short lifetimes were detected in two different 
channels. One channel was set to detect the long component of the iridium signal in 
the hundreds of nanoseconds range (PLIM) and the second channel was set to detect 
a short-lived signal in the tens of picosecond range (FLIM). The lifetimes obtained from 
the two channels were analysed separately for all three sizes of nanoparticles. The 
long-lived lifetimes detected in the PLIM channel were fit to three components for all 
samples and the lifetimes displayed in the PLIM channel are from the t3 lifetime 
component. 
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Figure 4.7. Two-photon phosphorescence lifetime analysed on SPCImage 
(Becker & Hickl software, version 5.0). (Left) Intensity image and (right) TP PLIM 
lifetime image displaying the t3 component coloured in RGB. Blue cross hairs 
showing iridium gold nanoparticles. Lifetime decay for the long-lived iridium 
signal, fitted to three components to give a c2 of 1.24.   
 
The short-lived lifetimes detected in the FLIM channel were fit to one component. 
These short-lived picosecond lifetimes have been attributed to the characteristic SPR 
band of the gold nanoparticles. An example of the PLIM and FLIM lifetime decay plots 
that are extracted from the lifetime images are shown in Figure 4.7 (PLIM) and 4.8 
(FLIM). This is an example dataset to show the lifetime decay plots extracted from a 
specific coordinate (blue crosshairs) within the images. 
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Figure 4.8. Two-photon fluorescence lifetime analysed on SPCImage (Becker & 
Hickl software, version 5.0). (Left) Intensity image and (Right) TP FLIM image 
displaying short-lived lifetimes coloured in RGB. Blue cross hairs showing 
iridium gold nanoparticles. A sharp peak is shown in the lifetime decay plot 
which is attributed to the short-lived signal from the gold. Lifetime decay is fitted 
to one component to give a c2 of 1.54.   
 
The two-photon PLIM and FLIM images in live HeLa cells are shown below for IrC6 
•AuNP13 (Figure 4.9), IrC6 •AuNP25 (Figure 4.10) and IrC6 •AuNP100 (Figure 4.11). 
The lifetime images from the FLIM channel can be seen on the left-hand side of the 
intensity image, with its corresponding colour map in picoseconds. The images from 
the PLIM channel are on the right-hand side of the intensity image and its 
corresponding colour map is in nanoseconds.  
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Figure 4.9. Two-photon images showing detection of the long-lived 
phosphorescence (PLIM) and short lived fluorescence (FLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.45 nM IrC6 •AuNP13 for 5 
hours. (a) FLIM image showing detection of lifetimes in the range 20 – 2500 ps 
(colour map on the left). (b) Intensity image and (c) PLIM images showing 
detection of lifetimes in the range of 450 – 1500 ns (colour map on the right). lexc 
= 760 nm, scale bar = 10 μm.  
 
 
Figure 4.10. Two-photon images showing detection of the long-lived 
phosphorescence (PLIM) and short lived fluorescence (FLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.16 nM IrC6 •AuNP25 for 3 
hours. (a) FLIM image showing detection of lifetimes in the range 20 – 1600 ps 
(colour map on the left). (b) Intensity image and (c) PLIM images showing 
detection of lifetimes in the range of 470 – 1100 ns (colour map on the right). lexc 
= 760 nm, scale bar = 10 μm.  
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Figure 4.11. Two-photon images showing detection of the long-lived 
phosphorescence (PLIM) and short lived fluorescence (FLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 3 pM IrC6 •AuNP100 for 5 
hours. (a) FLIM image showing detection of lifetimes in the range 20 – 500  s 
(colour map on the left). (b) Intensity image and (c) PLIM images showing 
detection of lifetimes in the range of 450 – 2500 ns (colour map on the right). lexc 
= 760 nm, scale bar = 10 μm.  
 
 
The PLIM images revealed strong signal from the long-lived luminescence lifetimes 
within HeLa cells which could be detected using multiphoton lifetime imaging. The 
lifetimes detected were in the hundreds of nanoseconds range, positively identifying 
the characteristic lifetime of iridium in HeLa cells. A control of Z •AuNP13 in HeLa cells 
was carried out to show no long-lived lifetimes detected in the PLIM channel 
(Appendix). The colour map shows a range of lifetimes detected from blue (short 
nanosecond lifetimes) to orange (long nanosecond lifetime). The range of lifetimes 
detected are similar for IrC6 •AuNP13 and IrC6 •AuNP25 which show a range between 
~450 – 1500 ns. This is different for IrC6 •AuNP100 where the lifetime range extends 
to 2500 ns. The lifetime range present in the PLIM images shows lifetimes detected 
which are in the same range as the characteristic lifetimes recorded for IrC6 in water 
and the IrC6 •AuNPs in solution (Figure 4.9, 4.10 and 4.11, c). It should be noted that 
detection in the nanosecond range revealed lifetimes which were longer than the 
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iridium nanoparticles in solution. This is due to the probe interacting with cellular 
proteins, causing the lifetimes to extend. This will be discussed in detail later in the 
chapter. The FLIM images (Figure 4.9, 4.10 and 4.11, a) show detection of short-lived 
lifetimes in the range of ~20 – 1600 ps for IrC6 •AuNP13 and IrC6 •AuNP25 and ~20 – 
500 ps for IrC6 •AuNP100. The fitting of the lifetime decay suggests this signal is 
coming from the gold. Interestingly, the short-lived signal detected within HeLa cells is 
slightly different for each size of nanoparticles as they appear to have different patterns 
of uptake. In the next figure, the PLIM and FLIM lifetime images have been false 
coloured yellow and magenta so the signals can be overlaid. This overlap of the short-
lived and long-lived lifetime signals can be seen in Figure 4.12, c. 
 
Figure 4.12. Two-photon lifetime microscopy showing multichannel detection of 
lifetimes present in PLIM and FLIM channels. (a) PLIM image showing long-lived 
lifetime signal (False coloured yellow), (b) FLIM images showing short-lived 
lifetime signal (False coloured magenta) and (c) Overlay of the PLIM and FLIM 
channels. lexc = 760 nm, scale bar = 10 μm.  
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The results for IrC6 •AuNP13 in HeLa cells show detection of short-lived lifetimes from 
the gold nanoparticles within the cytoplasm by FLIM and the long-lived lifetimes from 
the iridium in the PLIM channel. When overlaid the gold and iridium signals detected 
from the two channels appear to fully co-localise. This differs from the results of IrC6 
•AuNP25 and IrC6 •AuNP100 in HeLa cells, where the gold signal from the FLIM 
channel has only been detected in certain areas of the cell and does not fully co-
localise with the iridium signal detected in the PLIM channel. It is proposed that in 
areas where strong gold signal has been detected for IrC6 •AuNP25, is where gold 
nanoparticles have localised together within the cell, giving strong resonance signal 
which can be detected. The areas where there is iridium signal detected within the 
cytoplasm, but appears to be no gold signal, could be due to the small sized 25 nm 
gold nanoparticles not having a strong enough resonance to be detected in the FLIM 
channel. This is not the case for IrC6 •AuNP13 in HeLa cells because the cells were 
loaded with a much higher concentration of IrC6 •AuNP13 (0.45 nM for 5 hours) in 
comparison to IrC6 •AuNP25 (0.16 nM for 3 hours) allowing for more nanoparticles to 
enter the cells, which in turn provides a stronger resonance signal which can been 
detected in the FLIM channel. The FLIM images of IrC6 •AuNP100 in HeLa cells shows 
strong signal around the cellular membrane, where the gold nanoparticles have 
localised.  
The results from PLIM and FLIM images shows that uptake of IrC6 •AuNP13 and IrC6 
•AuNP25 into HeLa cells mainly in the cytoplasm of the cell but also shows uptake 
around the cellular and nuclear membranes. These nanoparticles could be localised 
within endosomes or lysosomes, but further studies would need to be carried out to 
confirm uptake into these cellular compartments. The uptake for IrC6 •AuNP100 differs 
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from IrC6 •AuNP13 and IrC6 •AuNP25 with more clusters forming around the cell 
membrane, which is evident from the gold signal detected in the FLIM channel. The 
clustering of gold nanoparticles could be due to the larger size of nanoparticles slowing 
down uptake and confining the nanoparticles to the cellular membrane, which slows 
down uptake due to steric hindrance and receptor saturation, where the larger gold 
nanoparticles block the receptors, stopping their uptake into cells.37  
4. 3. 1. 3 Mapping the localisation of IrC6 •AuNPs in cancer cells  
Further analysis of the PLIM images was carried out to identify whether localisation of 
these nanoprobes in cells could be mapped by detecting the changes in 
iridium t3 lifetime signal present in different regions of the HeLa cells. Looking at the 
lifetime variations of the iridium coated nanoparticles the areas chosen for mapping 
were the cytoplasm, nucleus and clusters of gold nanoparticles (Table 4.1). The 
lifetime variations were mapped by taking the average lifetimes in 10 different regions 
within the cytoplasm, nucleus and clusters of gold nanoparticles.  
Table 4.1. Lifetimes detected within different cellular regions for each cell 
sample. Lifetimes were collected from 4 different coordinates within each 
cellular region and an average lifetime calculated.  
 





Cytoplasm 650 ± 80 ns 660 ± 75 ns 660 ± 60 ns 
Nucleus 790 ± 90 ns 740 ± 80 ns 750 ± 80 ns 
Cluster 590 ± 80 ns 590 ± 75 ns 580 ± 65 ns 
In Solution (Long component for 
comparison) 340 (47%) 330 (53%) 340 (54%) 
 
The results showed that iridium luminescence lifetimes in the cytoplasm of HeLa cells 
extends to 650 ns, 660 ns and 660 ns with a standard deviation of ± 75 ns for IrC6 
•AuNP13, IrC6 •AuNP25 and IrC6 •AuNP100 respectively. These average lifetimes 
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observed for the iridium long component show an increase of ~320 ns from the 
lifetimes recorded for IrC6 •AuNPs in water. The largest increase in lifetimes recorded 
was in the nucleus of the cell. The luminescence lifetimes recorded in the nucleus were 
790 ns, 740 ns and 750 ns with a standard deviation of ± 85 ns. These lifetimes showed 
an increase of ~420 ns from the IrC6 •AuNPs recorded in water. The clusters of gold 
nanoparticles have an average lifetime of 590 ns, 590 ns and 580 ns with a standard 
deviation of ± 75 ns. These lifetimes are longer than IrC6 •AuNPs recorded in water, 
with an increase of ~250 ns being recorded. This extension in luminescence lifetime 
proves that aggregation has not occurred upon uptake of IrC6 •AuNPs within HeLa 
cells. It is known that aggregation of gold nanoparticles causes quenching of the iridium 
luminescence lifetime, and therefore a decrease would have been seen. This was 
shown on a solution of IrC6 •AuNP25, forced into aggregation by addition of 50 mM 
Tris Buffer and the luminescence lifetimes recorded. The aggregation of IrC6 •AuNP25 
in water was confirmed by a visual colour change from red to purple and broadening 
of the SPR peak by UV/Vis (Appendix).  The lifetimes of aggregated particles in 
solution were found to be 45 ns (4 %), 170 ns (63 %) and 300 ns (33 %). This showed 
an increase in the contribution of the shorter component to 170 ns (63 %), in 
comparison to 160 ns (42 %) for IrC6 •AuNP25 in water and a decrease in the long 
component to 300 ns (33 %), in comparison to 330 ns (53 %) for IrC6 •AuNP25 in 
water. These recorded lifetimes are much shorter than the lifetimes observed for the 
clustered gold nanoparticles in cells, for all three sizes of nanoparticles, which was 
recorded at ~590 ns. This data provides evidence to show that these gold 
nanoparticles within HeLa cells are non-aggregated nanoparticles but most likely gold 
nanoparticles which have been coated in proteins causing an increase in the 
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luminescence lifetime. It is therefore concluded that the AuNPs have localised together 
during uptake to form clustering of nanoparticles within the cell rather than aggregation 
of nanoparticles. This is supported by electron microscopy which showed a high 
content of gold nanoparticles being detected within vesicles inside the cells. Notably, 
the iridium lifetime observed from these clusters of nanoparticles within the cells is 
longer than that recorded for IrC6 •AuNPs in solution.  
To map the localisation of iridium functionalised nanoparticles within HeLa cells, a 
colour map has been created to highlight the areas of interest based on the average 
lifetimes recorded from the cytoplasm, nucleus and the clusters of gold nanoparticles. 
The lifetime range 700 – 1000 ns highlights the longest lifetimes found in the nucleus, 
which can be seen in red. The lifetime range 600 – 690 ns coloured in green highlights 
the lifetimes recorded from the cytoplasm and the lifetime range 450 – 590 ns, coloured 
in blue highlights the lifetimes recorded from the clusters of gold nanoparticles. The 
results can be seen in Figure 4.13, below.    
 
Figure 4.13. Mapping the iridium signal of iridium-coated nanoparticles in live 
HeLa cells: IrC6 •AuNP13 (left), IrC6 •AuNP25(middle) and IrC6 •AuNP100 (right).; 
Image of signal with a lifetime range of 700 – 1000 ns (red), 600-690 ns (green) 
and 450-590 ns (blue). HeLa cells incubated with 0.16 nM IrC6 •AuNP25 for 3 
hours and 0.45 nM IrC6 •AuNP13 and 3 pm IrC6 •AuNP100 for 5 hours.  lexc = 
760 nm, scale bar = 10 μm. 
 
4. Iridium nanoparticles for multichannel luminescence lifetime imaging, mapping localisation 
in live cancer cells 
 142 
IrC6 •AuNP13, IrC6 •AuNP25 and IrC6 •AuNP100 show a similar pattern, with uptake 
mainly being within the cytoplasm of the cells. Uptake appears to be evenly distributed 
within the cytoplasm, as seen in green. The images show areas of clustering being 
formed around the cell outer and inner nuclear membranes. This is more predominant 
for IrC6 •AuNP100 which shows more clusters of nanoparticles around the outer cell 
membrane. The PLIM images show that these cluster of gold nanoparticles seem to 
be accompanied with lifetimes highlighted in the range of 450 – 590 ns, presented in 
blue. The lifetime variation at this range shows more clustering of nanoparticles seen 
for IrC6 •AuNP25 in comparison to the clustering detected in IrC6 •AuNP13. Long-lived 
lifetimes which extend past 700 ns were detected in the nucleus of the cells for both 
IrC6 •AuNP13 and IrC6 •AuNP25, this is coloured red in the PLIM images.  These 
results positively confirm through detection of the long-lived iridium signal, that 
functionalised gold nanoparticles are localising within the nucleus of cells. 
Interestingly, the longer lifetimes detected in the range of 700 – 1000 ns seem to be 
the most predominant lifetimes present in all the PLIM images. It is proposed that the 
extension of luminescence lifetime for IrC6 •AuNPs within the cell is due to the 
iridium(III) complex interacting with proteins and biomolecules. Multiphoton lifetime 
imaging has shown to be extremely sensitive in detecting these changes in iridium 
lifetimes which has allowed us to successfully map gold nanoparticle localisation within 
HeLa cells. 
4. 3. 1. 4 Lifetime analysis of IrC6 •AuNPs in cancer cells  
To further understand the changes in iridium luminescence lifetimes of these 
nanoparticles in HeLa cells, the lifetimes of IrC6 •AuNPs were recorded in full cell 
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culture media (Dulbecco modified Eagle’s Medium (DMEM), 10% Fetal Bovine Serum 
(FBS) and 5% penicillin-streptomycin-glutamine) and FBS serum (90 % v/v) to emulate 
the conditions in a cell (Table 4.2). 
Table 4.2. Lifetimes recorded for samples in water, cell media and FBS serum. 
Lifetimes were recorded using a 376 nm laser and were fitted with a c2 between 
1 and 1.1.   
 Lifetimes under different conditions (ns) 
































 The results showed a large increase in luminescence lifetimes for iridium 
nanoparticles when measured in cell media and FBS serum for all sizes of 
nanoparticles.  The largest increase in lifetimes was seen for IrC6 •AuNP25 in cell 
culture media and serum which showed lifetimes of 145 ns and 232 ns respectively. 
The SPR of IrC6 •AuNP25 were checked by UV/Vis to prove no aggregation had 
occurred when placed in cell media (Figure 4.14). 
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Figure 4.14. Nanoparticle SPR in cell media. Absorption spectra of IrC6 •AuNP25 
in cell media highlighting the SPR peak (right) to show non-aggregated particles 
in cell media. lmax = 527 nm, indicating a shift of 2 nm from IrC6 •AuNP25 in water, 
but showing no aggregation. 
 
We postulate that the long lifetimes of the iridium nanoparticles in cells reflect their 
interaction with cellular chemicals and proteins. The lifetime of the molecular complex 
IrC6 is also affected by cell culture media and FBS although the increase is not as 
enhanced as seen on the nanoparticles. 
4. 3. 1. 5 Assessing nuclear uptake of IrC6 •AuNPs in cancer cells  
To positively identify uptake of IrC6 •AuNPs into the nucleus of HeLa cells, Z-stacks 
were acquired in both fluorescence and phosphorescence lifetime channels.  For these 
experiments, HeLa cells were dosed with 0.16 nM IrC6 •AuNP25 for 3 hours and 
images were acquired every 2.5 microns in depth, obtaining four slices through the 
nucleus. The intensity images show the HeLa cells in the whole field of view, with a 
red box highlighting the nuclear region of the cell analysed (Figure 4.15).  
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Figure 4.15. (Top) Intensity images of live HeLa cells dosed with IrC6 •AuNP25 
for 3 hours. Images increase by 2.5 µm up the cell from Image 2. (Bottom) Nuclear 
stacks of HeLa highlighting the nucleus as marked by a red box in top image. 
 
Further lifetime analysis was carried out on the nuclear region highlighted by the red 
box in the intensity images. The corresponding phosphorescence and fluorescence 
lifetime images in this nuclear region can be seen in Figure 4.16. 
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Figure 4.16. (Left) Intensity image, (middle) Long-lived lifetimes showing Iridium 
signal in nucleus, colour coded lifetimes showing blue: 450 – 590 nm, green: 600 
– 690 nm and red: 700 – 1000 nm. (Right) Short-lived lifetimes showing gold 
detection in the nucleus, tm: 20 – 120 ps. Top to bottom corresponds to Image 2, 
2b, 2c and 2d, which corresponds to the intensity images in Figure X. lexc = 760 
nm, scale bar = 20 μm. 
 
It should be noted that normally for a Z-Stack more than four steps would be taken, 
however since the microscope was not set up for Z-stack acquisitions during this visit 
only four steps were manually taken. Nonetheless, this was enough to show that the 
lifetimes detected for iridium and gold are present within the nucleus. The PLIM images 
show long-lived signal from the iridium within the nucleus of the cell in all four images, 
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which can be seen in red. The shorter lifetimes in blue can be seen around the cell 
nuclear membrane as the steps go through the cell, which are identified as the clusters 
of gold nanoparticles. The long-lived lifetimes appear strongly in the nucleus, but these 
start to fade as you get to the top of the cell. To show that the signal is coming from 
fully coated iridium nanoparticles, the corresponding FLIM images have been shown. 
This has positively identified short-lived picosecond lifetimes coming from the gold 
nanoparticles, by detecting the sharp peak decay. Detection of the short-lived signal 
from the gold in the FLIM channel alongside detection of long-lived signal from the 
iridium in the PLIM channel, positively identifies iridium functionalised gold 
nanoparticles within the nucleus. This is the first time this technique has been used for 
dual channel imaging showing localisation of gold nanoparticles within the nucleus of 
cancer cells. It should be noted that the previous lifetime images (Figure 4.12), showed 
no FLIM signal in the nucleus. This is because the weak signal detected in the nucleus 
meant that the binning had to be increased to get a good fitting, which was done when 
an ROI (region of interest) was created over the nucleus. To prove this was true 
FLIM/PLIM signal coming from the gold nanoparticles within the nucleus, the decay 
plots of a coordinate within the nucleus have been shown in Figure 4.17. 
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Figure 4.17. Two-photon fluorescence lifetime analysed on SPCImage (Becker & 
Hickl software, version 5.0). Blue cross hairs are placed on a spot where there 
are iridium gold nanoparticles. Lifetime decays are shown for (left) a sharp peak 
decay which can be seen in the lifetime plot which is attributed to the short-lived 
signal from the gold. (Right) The long-lived characteristic lifetime from the 
iridium signal. The short-lived and long-lived lifetime signals are detected in two 
separate channels, allowing for multichannel detection of these nanoparticles in 
cells.    
 
Analysis of the FLIM and PLIM for the IrC6 •AuNP100 in HeLa cells showed very weak 
signal detected in the nucleus for both the gold and iridium. This is because these 
larger particles have shown to localise around the cell membrane and cytoplasm and 
therefore it is expected that there would be less signal in the nucleus for these sized 
particles. This technique has shown to be sensitive to the detection of the smaller sized 
gold nanoparticles in the nucleus. This is a great achievement over emission based 
techniques where detecting localisation in the nucleus can be challenging as it requires 
higher concentrations and longer accumulation times to detect the nanoparticles.  
Detecting short-lived picosecond lifetime signal and long-lived nanosecond lifetime 
signals simultaneously in two separate channels has allowed us to positively identify 
the uptake of iridium coated gold nanoparticles into cancer cells. This is novel work 
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which has for the first time has used this multichannel detection for iridium 
functionalised gold nanoparticles. Uptake into the nucleus was investigated further 
using confocal microscopy and inductively coupled plasma mass spectroscopy (ICP-
MS). Confocal microscopy was carried out to provide further evidence of nanoparticle 
localisation within the nucleus (Figure 4.18).  
 
Figure 4.18. (Top) Widefield confocal luminescence images of IrC6 •AuNP25 in 
HeLa cells (3 h incubation). (a) Iridium-based luminescence image λexc = 405 nm, 
λem = 550 - 800 nm, (b) Hoechst based luminescence image (nucleus) λexc = 405 
nm, λem = 425 - 475 nm and (c) overlay of iridium and Hoechst luminescence 
images.  Scale bar 50 μm. (Bottom) Orthogonal view Z-stacks of the red-dashed 
inset box. (a) and (b) correspond to orthogonal views of nanoparticle clusters at 
two locations. Main image shows central z-stack slice, with xz plane below 
and yz plane-right. Images show nuclear localised iridium luminescence from 
clusters of nanoparticles within the central z-planes containing the nuclear 
Hoechst stain (white arrows). Z-stack is 10.4 µm thick, comprising 14 slices, slice 
width 0.7 μm. Scale bar 20 μm. This work was carried out by Dr Sunil Claire.  
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Hela cells were treated with 0.16 nM IrC6 •AuNP25 for 3 hours. Prior to imaging the 
HeLa cells were treated with Hoechst 33258, a dye which binds to double stranded 
DNA and emits a blue fluorescence when excited at 405 nm. Z-stacks were acquired 
throughout the cells revealing iridium and Hoechst signals in the nucleus. The iridium 
signal is collected in the yellow channel, in which the IrC6 •AuNP25 are excited using 
a 405 nm laser and the emission collected from 550 – 800 nm. The Hoechst dye is 
collected in the blue channel upon excitation with the 405 nm laser, collecting the 
emission from 425 – 475 nm. The images show the iridium luminescence localising 
within the whole cell, evenly distributed throughout the cytoplasm. There are areas 
within the cytoplasm where brighter spots can be seen in the iridium channel (Figure 
4.18, top, a). This “spot” like pattern is evidence of nanoparticle accumulation within 
the cytoplasm. The images appear to show nanoparticle accumulation within the 
nucleus of some HeLa cells. To investigate this an orthogonal Z-stack of a HeLa cell 
marked with a red box was acquired. The Z-stack shows nuclear localised iridium 
luminescence from clusters of nanoparticles within the central z-planes containing the 
nuclear Hoechst stain (Figure 4.18, bottom, white arrows). This was carried out on two 
different nanoparticle clusters in that region and both showed localisation within the 
nucleus of the cell from the Z-stack.  
To further evidence the accumulation of nanoparticles in the nucleus, ICPMS was 
carried out on HeLa cells in which the organelles were separated for analysis. This 
method consists of treating HeLa cells with 0.16 nM IrC6 •AuNP25 for 6 and 24 hours. 
HeLa cells were pelleted by centrifugation and cell fractions were isolated using a 
Mitochondrial isolation kit. The cell fractions isolated for analysis were cytoplasm, 
vesicles, mitochondria and nucleus. The samples were analysed by ICP-MS to identify 
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the concentration of gold (ppb) within the cell organelles, the results can be seen in 
Figure 4.19. The samples were done in triplicate and the average gold content 
presented. 
 
Figure 4.19. ICPMS results of Au content in isolated mitochondria and vesicles 
following fractionation of HeLa cells loaded with IrC6 •AuNP25 for 6 and 24 hours 
as indicated. Cell dosing and digestion carried out by Sunil Claire. 
 
The results show a low concentration of gold nanoparticles detected in mitochondria 
and vesicles after 6 hours of incubation with IrC6 •AuNP25, which is to be expected. 
The concentration of gold (ppb) detected increases after 24 hours, due to more 
particles accumulating within the cell, with the highest concentration being found in 
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vesicles. This is supported by data acquired using electron microscopy, where 
nanoparticles could be seen localising within the vesicles of cells and is a known 
occurrence of nanoparticle uptake from literature.38-40 After 24 hours, high 
accumulation of nanoparticles was seen in the mitochondria of the cells. There are 
examples of iridium(III) complexes in the literature that have been designed with 
specific targeting for accumulation within the mitochondria.41-43 So, it is interesting that 
IrC6 •AuNP25 shows high accumulation within the mitochondria with no targeting 
ligand present on the complex. This could be due to the high 2+ charge of the 
iridium(III) complex, which explains the accumulation in the mitochondria. During the 
cell fractionation it was found that the nucleus couldn’t be extracted by itself and 
instead contained mostly cytoplasm within the fraction, therefore the results obtained 
from this were invalid and not presented. Since this was a preliminary study, future 
work would be carried out to repeat the nucleus fractionation to identify whether 
particles were accumulating in the nucleus. Further characterisation would need to be 
carried out on the nanoparticle location within the mitochondria and vesicles, to fully 
understand the pattern of uptake. 
4. 3. 2 Optical and electron microscopy of IrC6 •AuNPs in cancer cells 
To further analyse the internalisation of the IrC6 •AuNP25 we used total internal 
reflectance fluorescence (TIRF) microscopy and transmission electron microscopy 
(TEM). TIRF provides high-resolution imaging of the cell surface44, 45, which allowed 
us to determine localisation of these nanoparticles throughout the cell as TIRF angle 
is varied (Figure 4.20).  
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Figure 4.20. Total internal reflectance fluorescence (TIRF) microscopy of 0.16 nM 
IrC6 •AuNP25 in HeLa cells after incubation of 3 hours. a) Bright field, (b-f) TIRF 
images. lexc = 405 nm. Plane increase from 1-5 is going upwards through the cell 
and away from the cover glass 
 
 
Clear bright white spots in the luminescence image (planes 1-5) are attributed to 
iridium luminescence from the non-clustered gold nanoparticles on planes moving 
upwards from the imaging dish. This shows nanoparticle localisation within the cell 
more specifically in the cytoplasm and around the cell membrane, which is in good 
agreement with the lifetime imaging studies and confocal microscopy. Most importantly 
the images show clearly non-aggregated nanoparticles with good resolution. TIRF 
microscopy is governed by the evanescent wave with the resolution restricted to 200 
nm depth, providing information inside the cell membrane only and not within the whole 
cell. TIRF clearly shows non-clustered, single nanoparticles in each plane, which is in 
good agreement with the other imaging data collected. 
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Electron microscopy shows IrC6 •AuNP25 appear as dark spheres located throughout 
the cytoplasm of the cell (Figure 4.21). They appear to be individual spheres 
suggesting that no aggregation occurs upon uptake. The nanoparticles are localised 
into vesicles suggesting the mechanism of uptake is endocytosis, this is also supported 
by the ICPMS data which showed high gold accumulation of nanoparticles in vesicles 
as well as mitochondria and cytoplasm. This data agrees with previous studies looking 
at uptake of ruthenium(II) functionalised nanoparticles in cancer cells.46 A high loading 
of iridium(III) functionalised gold nanoparticles can be seen within the vesicles, 
confirming that the nanoparticles are taken up together and accumulated in the same 
space as single particles. Since these nanoparticles have localised in one place, at 
lower magnifications they appear to have formed clusters of nanoparticles within the 
cell. This supports the two-photon lifetime images where clusters of nanoparticles 
could be seen within the cytoplasm of the cell that still retained long luminescence 
lifetimes of the functional nanoprobes. Long luminescent lifetimes were also seen 
within the nucleus of the cell, however the TEM images revealed no nanoparticles 
uptake within the nucleus. This could be because electron microscopy requires thin 
sections of the cell to be imaged, and with short incubation times, it makes it harder to 
identify nuclear uptake using TEM. 
 
Figure 4.21. TEM images of sectioned HeLa cells which were incubated with 0.16 
nM IrC6 •AuNP25 for 3 hours. Zoomed in images (b-d). 
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4. 4 Conclusions 
We have shown that iridium(III) functionalised gold nanoparticles displayed two-photon 
luminescence in agreement with the single-photon luminescence spectra. The power 
dependence studies revealed strongly that a two-photon absorption process was 
occurring for the IrC6 probe in solution and IrC6 •AuNPs in agarose gel. The two-
photon absorption cross-section of IrC6 •AuNP25 was measured and found to be much 
higher than the molecular probe in solution, which was attributed to enhancement from 
the gold nanoparticles. Two-photon lifetime imaging of IrC6 •AuNP25 in cancer cells 
demonstrated that detection can be performed in two channels, one for the long 
luminescence lifetime signal of the iridium complex in hundreds of nanoseconds and 
the other for the short lifetime signal from the gold in tens of picoseconds. The two 
channel detection showed clearly the iridium and gold signal for all nanoparticle sizes 
investigated, with uptake being seen in the cytoplasm and cell membrane. The lifetime 
images allowed us to visualise the pattern of uptake for the different sized 
nanoparticles. It was found that IrC6 •AuNP25 and IrC6 •AuNP13 showed a similar 
pattern in uptake, whereas IrC6 •AuNP100 located mainly around the cell plasma 
membrane. The lifetime images revealed that upon uptake these gold nanoparticles 
were localising in clusters within some areas of the cytoplasm, which could be seen 
for all three sizes of nanoparticles. It is unclear from the lifetime images whether the 
iridium(III) functionalised gold nanoparticles were localising within vesicles in the 
cytoplasm of the cells, but this pattern of uptake was identified from the TEM images. 
Investigation into the luminescence lifetimes within the cell revealed detection of long 
and short lifetimes within the cytoplasm and nucleus of the cells, which identified 
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nanoparticle uptake in these regions. Further investigations revealed remarkably long 
lifetimes detected within the nucleus showing an average of 740 ns, which was an 
increase of 410 ns in comparison to IrC6 •AuNP25 in solution. The lifetime of the cluster 
of nanoparticles were recorded and found to be ~450 – 590 ns, which showed that 
these were non-aggregated particles as this is an enhancement from the IrC6 •AuNPs 
in solution. This “clustering” seen from the nanoparticles was also confirmed by 
electron microscopy, which showed a high accumulation of single gold nanoparticles 
within vesicles in the cytoplasm. Nuclear localisation of small non-aggregated 
nanoparticles is challenging but the sensitivity of the luminescence lifetime signal 
demonstrated nuclear localisation by detecting the long-lived lifetimes, which was more 
dominant for the IrC6 •AuNP13 and IrC6 •AuNP25. There was no signal detected in 
the nucleus for IrC6 •AuNP100, which is to be expected since the size restricted the 
localisation to the cell membrane. The cells were also dosed with a much lower 
concentration of IrC6 •AuNP100 which had a final concentration of 3 pM within the 
cells. The lifetimes of IrC6 •AuNPs in cell media, serum and FBS were independently 
examined, the luminescent lifetimes elongated in comparison to nanoparticles in water, 
this effect was attributed to interactions of the nanoparticles with biomolecules. 
Confocal microscopy showed nanoparticle accumulation within the cytoplasm and 
confirm nanoparticle uptake into the nucleus. The results from ICPMS showed that 
gold was accumulating within vesicles in the cytoplasm, which agrees with the electron 
microscopy data. This technique also showed that after 24 hours a high gold content 
was detected within mitochondria. Unfortunately, this technique could not be used to 
confirm nuclear uptake, this method would be improved for future investigations. 
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Overall, the iridium-coated nanoparticles are introduced as novel nanoprobes for 
multiphoton lifetime imaging providing multichannel detection for independent 
monitoring of the gold scaffold and the iridium signal. The long-lived lifetime signal is 
sensitive to the cell environment, providing local information which can be used for 
gating specific biomolecular interactions and tracking nanoparticles in in vivo models. 
4. 5 Experimental section 
4. 5. 1 Cell culture and Nanoparticle dosing  
4. 5. 1. 1 Live cell imaging 
Human cervical epithelioid cancer cells (HeLa cells) obtained from Public Health 
England (catalogue number 93021013) were used in all experiments. HeLa cells were 
maintained and grown in complete Dulbecco’s Modified Eagle Medium (DMEM) 
without phenol red supplemented with 10% Fetal Bovine Serum (FBS), 2 mM 
glutamine, 100 units/mL penicillin and 0.4 mg/mL streptomycin. Cells were grown as 
monolayer in vented cap T75 flasks at 37 °C in a humidified atmosphere of 5 % CO2 
incubator. A day prior to dosing with nanoparticles, HeLa cells were counted with 
Biorad automated cell counter and viability determined by trypan blue exclusion. Cells 
were seeded at a density of 100,000 cells per 35 mm MaTek glass dishes and allowed 
to attach overnight in a humidified 5 % CO2 atmosphere. For nanoparticle dosing, cell 
media was removed and the dishes washed twice with phosphate buffered saline 
(PBS) at pH 7. HeLa cells were dosed for 5 hours for IrC6 • AuNP13 (0.45 nM) and 
IrC6 • AuNP100 (3 pM) and 3 hours for IrC6 • AuNP25 (0.16 nM). At the end of each 
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time point, cells were rinsed three times with PBS and imaging was carried out in 
imaging buffer (HEPES, pH 7). 
4. 5. 1. 2 Fixed cell imaging 
Coverslips (35 mm x 35 mm) were sterilised in EtOH and washed twice with PBS 
before use. Cells were seeded at a density of 100,000 cells per 35 mm coverslip, 
placed in complete DMEM and allowed to attach overnight in a humidified environment. 
For nanoparticle dosing, cell media was removed and the coverslips washed twice with 
PBS. Hela cells were dosed for 5 hours for IrC6 •AuNP13 (0.45 nM) and IrC6 
•AuNP100 (3 pM) and 3 hours for IrC6 •AuNP25 (0.16 nM). At the end of each time 
point, cells were rinsed three times with PBS. The coverslips were immersed in 4% 
paraformaldehyde (PFA) for 1 hour. The coverslips were then washed three times with 
PBS. Microscopy slides were sterilised in EtOH and air dried before use. Non-
Fluorescent hydromount was used to adhere coverslips to the microscope slide which 
were left at 4 ºC overnight. Covergrip® was used to seal the edges of the coverslip 
and left to dry for 1 hour prior to imaging.   
4. 5. 2 Microscopy techniques 
4. 5. 2. 1 Multiphoton FLIM and PLIM 
Multiphoton excitation at 760 nm was used to acquire all images. The lifetime signals 
were detected by an adapted Becker & Hickl DCS120 laser scanning system coupled 
to a SPC150 time correlated single photon counting PCI card and a PMC-100 detector. 
The same card was also used to correlate the x,y pixel positions for the FLIM 
acquisition. The multichannel lifetime collection set up in the two windows was 
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constructed around a Nikon Ti-E microscope. The multiphoton used a pulse modulated 
Titanium: Sapphire laser (Mira F-900, Coherent, UK) with 76 MHz repetition rate and 
200 fs pulse. This was used to image live HeLa cells stained with IrC6 •AuNPs. A water 
immersion x60 objective was used for all samples. Emission light was collected using 
a bandpass (BG39) filter. PLIM and FLIM data collected were analysed in SPCImage 
(Becker & Hickl software, version 5.0). The data was fitted to an exponential decay 
model.  
4. 5. 2. 2 Confocal Microscopy 
Confocal microscopy was performed using a Leica TCS SP8 upright confocal laser 
scanning system using a x40 water immersion objective lens. Solid-state laser 405 nm 
with 26 % laser intensity was used. An AOBS spectral detector and gateable hybrid 
(Hy-D) PMT detector was used with the following ex/em ranges: λexc = 405 nm, λem = 
550 - 800 nm for Iridium luminescence and λexc = 405 nm, λem = 425 - 475 nm for 
Hoechst acquisition. Z-stacks slice widths were performed as stated in the iridium and 
Hoechst channel images. Processing and visualization of 3D images was performed 
by the image processing software FIJI (ImageJ Version 1.52b). 
4. 5. 2. 3 Total Internal Reflectance Fluorescence (TIRF) Microscopy  
Total internal reflectance fluorescence (TIRF) microscopy was constructed around an 
inverted Nikon Ti-U microscope. Fluorescence excitation was obtained from an 
Omicron laser hub containing a 405 nm, 488 nm and 561 nm continuous wave lasers 
and fibre coupled to the TIRF-M unit. The laser light was focused and collimated at the 
back aperture of a x100 oil immersion, NA 1.49 objective. Fluorescence emission was 
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detected using an electron multiplying charged-coupled device (EMCCD, iXon, Andor) 
camera. Images were analysed as TIFF files in ImageJ software, version 1.49. 
4. 5 .2. 4 Transmission Electron Microscopy (TEM) 
Coverslips (12 mm x 13 mm) were sterilised in EtOH and washed twice with PBS 
before use. Cells were seeded at a density of 50,000 cells per 12 mm coverslip, placed 
in complete DMEM and allowed to attach overnight in a humidified environment. For 
nanoparticle dosing, cell media was removed and the coverslips washed twice with 
PBS. HeLa cells were dosed for 5 hours for IrC6 •AuNP13 (0.45 nM) and IrC6 
•AuNP100 (3 pM) and 3 hours for IrC6 •AuNP25 (0.16 nM). At the end of each time 
point, cells were rinsed three times with PBS. The coverslips were immersed in 2.5 % 
glutaraldehyde fixative in 100 nM phosphate buffer, wrapped in foil and left overnight 
in the fridge prior to TEM imaging.  
4. 5. 2. 5 Sample preparations for TEM 
TEM imaging was carried out on Citrate •AuNPs and IrC6 •AuNPs. For all nanoparticle 
samples 20 µL was added to a 200-mesh formvar-coated grid TEM grid and left 
overnight to dry. Samples were carried out on 4.6 nM IrC6 •AuNP13, 4.5 nM Citrate• 
AuNP13, 1.6 nM IrC6 •AuNP25, 1.6 nM Citrate •AuNP25, 30 pM IrC6 •AuNP100 and 
30 pM Citrate •AuNP100. Cells dosed with nanoparticles were grown onto cover slips 
(see cell culture and nanoparticle dosing protocol). Samples were prepared for electron 
microscopy in Materials and Metallurgy department. Samples were stained with 1% 
osmium tetroxide solution. The cells were placed in a resin, sectioned and mounted on 
a 200-mesh formvar-coated TEM grids for imaging. 
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4. 5. 3 ICP-MS sample preparations 
4. 5. 3. 1 Nanoparticle solutions 
Iridium functionalised gold nanoparticles were dissolved in 300 µL ultrapure aqua regia 
(~70% HNO3) and left to digest overnight at 80 °C. To aid digestion, these solutions 
were left to stir overnight. The following day ultrapure water was added to the samples 
until a final dilution of HNO3 to 5%. Sonication was used to aid digestion of the gold 
nanoparticles. 
4. 5 .3 .2 Cell Fractionation  
HeLa cells were cultured in T165 flasks and treated with nanoparticles (final 
concentration of 0.9 nM) for 6 and 24 hours. After treatment, the cells were washed 
three times with phosphate buffered saline (PBS, 20mL) to remove membrane bound 
nanoparticles, detached from the flask by trypsinization and resuspended in 15 mL of 
media. Cell density was calculated using a haemocytometer and each sample adjusted 
to a total of 2x107 cells. Cells were pelleted by centrifugation and cell fractionation was 
undertaken using a Mitochondrial Isolation Kit with the reagent-based method (Thermo 
Scientific) according to manufacturer’s instructions. Briefly, the cell pellet was 
resuspended in 800 µL of isolation reagent A, mixed by vortexing and incubated on ice 
for 2 minutes. Next 10 µL of reagent B was added, the sample vortexed for 5 seconds 
and incubated on ice for 5 minutes with vortexing every minute. Reagent C (800  L) 
was then added and the sample mixed by gentle inversion and centrifuged for 10 
minutes (700 g, 4°C) to pellet the cell nuclei along with any free nanoparticles not 
associated with other cellular compartments that remained in suspension after this first 
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centrifugation step. The supernatant containing the mitochondria was carefully 
transferred to a clean tube and centrifuged for 15 minutes (3000 g, 4°C), the 
supernatant removed and the mitochondrial pellet resuspended in 500 µL of reagent 
C and centrifuged at 12 000g for 5 minutes at 4°C and the pellet retained as the 
mitochondrial fraction. Finally, the supernatant from the second (mitochondrial) 
centrifugation step was centrifuged at 12 000g for 15 minutes at 4°C. The supernatant 
removed and the residual pellet retained as the vesicular fraction (containing 
endosomes, lysosomes and peroxisomes). 
4. 5 .3 .3 Cell digestion for ICP-MS 
Cell fractions were dissolved in 300 µL ultrapure aqua regia (~70% HNO3) and left to 
digest overnight at 80 °C. The following day ultrapure water was added to the samples 
until a final dilution of HNO3 to 5%. Samples were transferred to ICP-MS grade tubes 
for analysis. 
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CHAPTER 5: SELECTIVE TARGETING OF CANCER CELLS USING ANTIBODY 
FUNCTIONALISED GOLD NANOPARTICLES 
5.1 Introduction 
5. 1. 1 Angiogenesis and cancer therapies  
Angiogenesis is the formation of blood vessels from pre-existing blood vessels in the 
body. Angiogenesis starts by breaking into the wall of the pre-existing blood vessel 
which causes hypoxia.1-3 Endothelial cells are then activated by angiogenic factors 
which cause them to proliferate and migrate.4 Angiogenesis that happens in the body 
is a controlled process which is monitored by strict regulation of signalling factors that 
only occur during specific events such as wound healing in adults. However, tumour 
angiogenesis is a known process of cancer which help provide oxygen and nutrients 
to tumour cells causing the tumour to grow rapidly (Figure 5.1).  
 
Figure 5.1. Mechanism of tumour angiogenesis showing soluble angiogenic 
factors (VEGF, PDGF and FGF) which are secreted from the tumour and 
surrounding cells to induce and regulate key steps in angiogenesis.2  
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The main difference between tumour angiogenesis and physiological angiogenesis is 
the rapid and uncontrolled rate at which the former progresses. This can then lead to 
leaky and twisted vessels that are highly inflamed.5 It has been found that tumours 
grown in an environment where angiogenesis cannot occur, the tumour does not grow 
beyond 1-2 mm. This is because the lack of vascular support causes the tumours to 
become apoptotic. These are the factors which compromise the delivery of 
chemotherapeutics, and therefore research has looked at targeting angiogenesis for 
cancer therapeutics since inhibiting these angiogenic factors and molecules can halt 
angiogenesis and consequently the progression of tumours. Most commonly the 
vascular endothelial cell growth factor (VEGF) and angiopoietin (Ang) are targeted due 
to their role in upregulating angiogenesis. In 2008, the FDA approved Bevacizumab 
(Avastin) which targets VEGF proteins overexpressed on colorectal cancer 
vasculature as the first anti-angiogenic therapeutic agent using a monoclonal antibody. 
Another approach is to target tumour endothelial cells which have unique markers on 
their surface in comparison to normal endothelial cells. These are known as tumour 
endothelial markers (TEMs) which are highly expressed in human tumour vasculature 
and minimally expressed in healthy vasculature, making them attractive candidates for 
targeted cancer therapies.6 CLEC14A has been identified as a novel tumour 
endothelial marker (TEM) which has shown to be expressed strongly on tumour 
associated vessels in contrast to healthy tissue where nearly no expression is seen.7 
CLEC14A is an endothelial transmembrane glycoprotein that has shown to regulate 
endothelial cell migration and sprouting of blood vessels. CLEC14A is part of the C-
type lectin domain (CTLD) group 14 family known to mediate cellular functions such 
as angiogenesis and inflammation (Figure 5.2).8  




Figure 5.2. Schematic of CLEC14A protein with ligand binding sites.6  
 
The ability to selectively target CLEC14A and block it’s angiogenic functions could lead 
to novel anti-cancer approaches. Targeting these markers can be achieved with 
monoclonal antibodies, peptides or vaccines. Monoclonal antibodies have been 
developed as therapeutic agents for many biological applications such as cancer 
therapies, infection and inflammation.9 The ability to specifically target a cancerous cell 
over a normal cell presents a lot of challenges, and one where antibody targeting 
strategies could be beneficial. Monoclonal antibodies have a Y shaped structure 
consisting of antigen recognition sites known as Fab fragments, which can specifically 
target tumour antigens which are only present on cancerous cells (Figure 5.3). The 
antigen binding site is highly specific and varies between different types of antibodies, 
making them desirable for therapeutics.10 In 1997 Rituximab became the first FDA 
approved monoclonal antibody for the treatment of lymphoma. Since then several 
more monoclonal antibodies have been approved by the FDA for the treatment of many 
different types of cancers and solid tumours.11  




Figure 5.3. Antibody structure12 
 
There are many advantages of using monoclonal antibodies as anti-angiogenic agents 
in comparison to conventional chemotherapy drugs. Firstly, there is selective targeting 
of tumour endothelial cells present in the tumour vasculature instead of just targeting 
tumour cells alone. Secondly, tumour endothelial cells are more accessible to anti-
angiogenic therapeutic agents as they are in direct contact with blood circulating the 
body, whereas tumour cells residing inside tumour tissues are less accessible to 
administered chemotherapeutic drugs. Lastly, there is less toxicity for anti-angiogenic 
therapy agents due to the lower doses administered.13 While using monoclonal 
antibodies for cancer therapies is attractive, it comes with some limitations. Monoclonal 
antibodies have a high molecular weight and slow distribution kinetics which increases 
the chances of the antibody degrading before reaching the target tumour vessels, thus 
resulting in poor biodistribution followed by adverse side-effects and low efficiency of 
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delivery.14,15 In recent years researchers have started looking at conjugating these 
monoclonal antibodies onto nanoparticles as delivery carriers that can target the 
tumour microenvironment. Harnessing the power of nanotechnology has allowed 
researchers to develop a more efficient way of selectively targeting tumour-associated 
vasculature. 
5. 1. 2 Methods for Conjugating Antibodies onto AuNPs 
To date, there have been many methods published for the conjugation of biomolecules 
such as antibodies onto the surface of gold nanoparticles for applications such as 
biosensing, immunoassays and targeted delivery. An important consideration for these 
applications is to immobilise the antibody in the correct orientation to maintain the 
antibodies biological activity. This means having the antigen binding site free and not 
directly conjugated or close to the gold surface.16 The binding orientation of monoclonal 
antibodies is key for maintaining the functionality of the antibody for targeting 
applications. Schematic 5.1 shows the strategies that have been used to conjugate 
antibodies onto the surface of gold nanoparticles which include i) passive adsorption 
(hydrophobic attractions and electrostatic interactions), ii) covalent attachment (amino 
groups), iii) chemisorption (thiol linkers) or iiii) non-covalent attachment (protein 
intermediate).17  





Scheme 5.1. Schematic showing methods for attaching antibodies on the 
surface of gold nanoparticles.18 
 
 
Passive absorption is the simplest way of conjugating antibodies onto the surface of 
gold nanoparticles. This method relies on weak hydrophobic or electrostatic 
interactions of the antibody and the gold surface.19 For instances, positively charged 
amino groups from a monoclonal antibody have shown to attach to the surface of 
negatively charged citrate-capped gold nanoparticles, through electrostatic and 
hydrophobic interactions.20, 21 There are many limitations with these adsorption 
methods which included random orientation of antibodies on the gold surface which 
significantly reduced the amount of biologically active antibodies; binding is highly 
dependent on pH and small changes will affect the attachment on the surface; other 
biomolecules can replace the antibody on the gold surface since binding is done 
through weak interactions.22 Another approach which uses non-covalent attachment 
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of antibodies onto gold nanoparticles is through specific receptor-ligand interactions. 
For example, using biotin-streptavidin system to immobilize antibodies by using highly 
specific interactions between the biomolecules.23, 24 
Research shifted to using covalent methods for attaching antibodies onto the gold 
nanoparticle surface. The most commonly used covalent method is EDC/NHS coupling 
reaction which uses the reaction between amino groups present on the antibody and 
carboxyl groups present on the gold surface. In comparison to physical adsorption, 
these covalent methods provide strong bonding of the antibody to the gold surface 
which prevents displacement of other biomolecules, and controls the orientation of the 
antibody on the gold surface. To increase the binding and biological activity of the 
antibody (free antigen binding site), spacers have often been used. This type of 
covenant method increases the stability of the antibody and gives control of the antigen 
binding site.25 Predominately thiolated ligands are used due to their high affinity and 
strong bonding to the gold surface. These ligands have terminal carboxylic groups 
which react with the terminus amino groups present on the antibody. 
5. 1. 3 Targeting angiogenesis with nanoparticles 
5. 1. 3. 1 Passive targeting 
Nanoparticles have often been used for application within cancer research due to their 
attractive chemical and structural properties. There have been many types of 
nanoparticles studied for biological applications, however inorganic nanoparticles such 
as gold nanoparticles offer many additional benefits for imaging and cancer therapy. 
Gold nanoparticles have desirable properties such as large surface area, tuneable size 
and shape and their surface can be easily functionalised for selective targeting of 
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cancer. There are two methods in which these gold nanoparticles have been used to 
target tumour cells, passive and active targeting. Passive targeting allows 
nanoparticles to accumulate into the tumour microenvironment through the tumour’s 
leaky vessels and is heavily reliant on the nanoparticles’ size and shape. Active 
targeting uses nanoparticles functionalised with biorecognition molecules to selectively 
target tumour cells for uptake into tumours (Figure 5.4).26 These methods will be 
discussed and compared to understand more about the desirable properties of 
nanoparticles and why they are good candidates for cancer therapies.  
 
Figure 5.4. Example of passive and active targeting of tumour vasculature using 
Quantum Dots (QD). A) Permeation and retention of QD probes via leaky tumour 
vasculatures (passive targeting) and B) High affinity binding of QD-antibody 
conjugates to tumour antigens (active targeting).26 
 
 
Most types of nanoparticles have shown to accumulate directly into the tumour 
microenvironment which is dictated by the enhanced permeability and retention effect 
(EPR). The EPR effect allows for the accumulation of nanoparticles within the tumour 
microenvironment because of the tumour’s leaky vasculature and poor lymphatic 
drainage system. This makes it possible for nanoparticles to passively target tumour 
vessels during this period of increased permeability due to the leaky nature of the 
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vessels. It has been shown that nanoparticles in the size range of 40-200 nm have 
optimal for passive uptake because of longer circulation times and therefore increase 
accumulation into the tumour microenvironment through EPR effect.27 Studies have 
also shown that larger pores can be found on tumour vessels which allows for 
penetration of larger nanoparticles such as liposomes up to the size of 400 nm.28 
Li et al. showed the passive targeting of gold nanoparticles into the tumour 
microenvironment.29 The gold nanoparticles acted as a drug carrier to deliver 
recombinant human endostatin (rhES) which could passively target the tumour site. 
rhES is a well-known vascular angiogenesis-disrupting agent that has been used to 
treat non-small lung cancer (NSCLC) in the clinic.30 These anti-angiogenic treatments 
are known to “starve” tumours and induce tumour cell death by blocking specific 
angiogenesis signal pathways. Improvements to the in vivo efficiency of rhES and 
reduction of the dosing frequency was done by using gold nanoparticles (AuNPs) as a 
drug-delivery system. AuNPs can accumulate in the tumour microenvironment and be 
retained at high concentrations by passive uptake. This research successfully showed 
an enhanced concentration of rhES being delivered to the tumour site through 
conjugation onto the nanoparticle carriers. This then promoted the decrease in hypoxia 
and leaking which showed the improvements in therapeutic efficiency that these 
nanocarriers have achieved. Further studies showed that AuNPs without any 
modifications could decrease the expression of VEGF in tumours. This led to the 
normalisation of tumour vasculature through the decrease of hypoxia and the 
strengthening of the tumour vascular wall (Figure 5.5).31 




Figure 5.5. Gold nanoparticles as potential candidates for normalising tumour 
vasculature. A) CD31 staining showed the tumour vessels decreased after 
treatment with AuNPs, scale bar 100 m. B) FITC-conjugated lectins (green) and 
CD61 (red) staining indicated improved perfusion in tumours after treatment with 
AuNPs, scale bar 200 m. C) FITC-dextran (green) and CD31 (red) shows 
decreased number of sites of vascular leakage after treatment with AuNPs, scale 
bar 200 m.31 
 
Another group showed that small 5 nm AuNPs could interact selectively with heparin-
binding glycoproteins such as VEGF165 and BFGF to inhibit their activity. AuNPs could 
directly bind heparin-growth factors through cysteine residues in the heparin-binding 
domain, creating a strong bond between gold and thiol/amine groups present. This 
lead to inhibition of VEGF-induced angiogenesis which was shown in endothelial and 
fibroblast cells.32 The fact that these AuNPs could be used to inhibit signalling events 
and growth factors known to promote angiogenesis is a significant step forward in 
developing effective therapeutic delivery agents through nanotechnology. 
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5. 1. 3. 2 Active targeting 
Targeting strategies have been further developed over the past few years to enhance 
the selective uptake of nanoparticles into the tumour cells.33 Nanoparticles can be 
easily modified to selectively target tumour cells by the attachment of biorecognition 
molecules such as antibodies to the surface which can target specific markers 
overexpressed by cancer cells. This type of targeting is known as active targeting 
which increases the specificity and efficiency in targeting tumours in comparison to 
passive targeting. Nanoparticles functionalised with antibodies could potentially 
function as targeted vessels as these biomolecules can interact with receptors on the 
cell membrane allowing for selective uptake of these nanoparticles into cells. El-Sayed 
et al. studied spherical AuNPs conjugated with EFGR antibodies and observed 
differences in binding patterns between non-cancerous and cancerous cell types. They 
showed that conjugated nanoparticles bound specifically to the surface receptors 
present on the cancerous cells whereas the binding in the noncancerous cells 
appeared to be non-specific and random. The ability to distinguish between cancerous 
and noncancerous cells shows the power of using these targeted gold nanoparticles 
for cancer diagnostic applications.34 
Additionally, the surface of the gold can be modified with drugs or small molecules 
such as DNA, siRNA or peptides for targeted delivery inside the tumour cells. Bartczak 
et al. demonstrated this by conjugating peptides to the surface of AuNPs to selectively 
activate or inhibit angiogenesis. The results showed that for the AuNPs functionalised 
with the activation peptide showed capillary formation after 2 hours of incubation. This 
showed an increased amount of angiogenesis in comparison to untreated cells. 
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However, the gold nanoparticles functionalised with the inhibitor peptide showed no 
angiogenesis occurring at any of the time points studied (Figure 5.6).35   
 
Figure 5.6. Peptide-coated gold nanoparticles for activation and inhibition of 
angiogenesis. a) Phase-contract images show endothelial cells grown on 
reduced serum matrix gel after treatment with P1-OEG-NPs (activators), P2-
OEG-NPs (mutants) and P3-OEG-NPs (inhibitors) compared with untreated 
endothelial cells (ECs) for 2, 4 and 8 hours after incubation. 35     
 
 
Furthermore, luminescent probes can be conjugated onto the nanoparticle surface to 
allow for visualisation of tumour vessels whilst also being able to target the 
microenvironment.36 Nanoparticles are advantageous to use as delivery carriers as 
they often have low cytotoxicity and do not provoke an immune response, allowing for 
a higher density of therapeutic agents to be functionalised onto the gold’s surface 
before administration.  
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5. 1. 4 SiRNA delivery strategies 
Short interfering RNAs (SiRNA) are small double stranded RNAs which are about 21 
– 22 nucleotides long and have 2-base 3’ overhangs that are known to regulate gene 
expression.37 Since this fundamental area of research started over a couple of decades 
ago, the basic principles of RNA interference and gene silencing are now well 
understood.38 The mechanism sees double-stranded RNA interacting with a protein 
complex known as Dicer to generate short interfering RNAs (SiRNA). These SiRNA 
complexes then bind with proteins to form an RNA-induced silencing complex (RISC). 
This SiRNA/RISC complex binds the complementary sequence of the target mRNA 
and unwinds the double strand into single stranded fragments. These mRNA 
fragments are then degraded within the cell (Figure 5.7).39 The ability to silence genes 
makes these excellent candidates for targeted cancer therapies. 
 
 
Figure 5.7. Schematic for RNA-mediated gene silencing in Eukaryotes.39 
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Despite the advantages of using SiRNA complexes as potential cancer therapeutic 
agents, the delivery into cells is hard enough since SiRNA complexes are degraded 
upon entry into the cell. SiRNA suffers from poor intracellular uptake and degradation 
in vivo, which has made this form of cancer therapeutics very challenging. 40 Therefore, 
for effective pharmacological use of SiRNA in cells “carriers” that can efficiently 
delivery SiRNA to the intended site are needed.41 Nanoparticles are advantageous as 
“carriers” because their size and surface charge can be easily modified to overcome 
the cell membrane barrier for efficient uptake. Nanoparticles have shown to remain in 
circulation for longer periods of time, via the EPR effect, making delivery to tumour 
cells more efficient. The surface of the nanoparticle can be functionalised with target-
specific ligands, which allows for targeted delivery of SiRNA. There have been many 
types of nanoparticles investigated for SiRNA delivery into cells. There are two 
mechanisms for delivering SiRNA into cells using nanotechnology, 1) SiRNA 
complexes are contained within the nanoparticles or 2) SiRNA complexes are 
conjugated to the surface of the nanoparticle (Figure 5.8).42 
 
Figure 5.8. Functionalising nanoparticles with SiRNA can be achieved through 
conjugation to the surface of the nanoparticles or containment within the 
nanoparticle. Both methods are effective ways of delivering SiRNA into cells 
with degradation.42 
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To date, extensive studies have been carried out using both organic and inorganic 
nanoparticles for the delivery of SiRNA into cells. Organic based nanomaterial such as 
liposomes and chitosan nanoparticles can be synthesised to entrap SiRNA within the 
core, thus protecting the SiRNA from enzymatic degradation.43-45 Inorganic 
nanoparticles made from gold has been explored for delivery SiRNA into cells because 
the gold surface can be further functionalised with imaging probes which allows for 
both targeting and imaging. Gold nanoparticles have shown to be biocompatible and 
easily taken up by both cancer cells. Mirkin et al. functionalised the surface of gold 
nanoparticles with SiRNA molecules and thiol-modified oligonucleotides. It was found 
that the additional coverage of the gold surface with the oligonucleotides protected the 
SiRNA molecules from degradation within cells. They showed these SiRNA 
functionalised gold nanoparticles were taken up readily into cancer cells, despite the 
high overall negative charge of the particles which was expected to prevent their 
uptake into cells.46 Mirkin et al. then went on to look at improving the delivery of nucleic 
acid functionalised gold nanoparticles by adding a targeting antibody (HER2 mAb) onto 
the surface of the gold. This work showed impressive results with HER2 mAb 
functionalised gold nanoparticles showing higher selectively, faster uptake and more 
efficient gene knockdown in comparison to gold nanoparticles without the targeting 
antibody (Figure 5.9).47 It was also shown that in cells that did not express HER2, no 
selectively was seen from the targeting gold nanoparticles. 




Figure 5.9. Antibody functionalised gold nanoparticles for the delivery of nucleic 
acids for cellular targeting. (a) anti-HER2-pNA-AuNPs. The number of AuNPs per 
cell for (b) 4 C and (c) 37 C after 4 hours of incubation. Confocal images of 
SKOV3 cells after incubation for 4 hours with 5 nmol/ L anti-HER2-pNA-AuNPs 
at (d) 4 C and (e) 37 C.48 
 
 
The ability to easily functionalise the surface of gold nanoparticles with targeting 
vectors and imaging probes is a significant step forwards in developing novel 
constructs for efficiently targeting diseases such as cancer whilst being able to 
visualise the effect. 
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5. 2 Chapter summary 
Iridium(III) coated gold nanoparticles of various sizes were found to be suitable 
multiphoton lifetime imaging probes, due to their desirable long-luminescence lifetime 
which could be detected in cancer cells. The results showed that the iridium lifetimes 
were sensitive to changes in the local environment which was used to map localisation 
patterns. It was found that fluorescence lifetime imaging could be used to detect the 
unique SPR signal from the gold nanoparticles separately from the long-lived iridium 
signal, allowing for multichannel detection using lifetime microscopy. This chapter will 
explore the iridium(III) functionalised gold nanoparticles ability to selectively target 
cancer cells which will be monitored by multiphoton lifetime imaging. An anti-CLEC14A 
antibody (AbH) will be chemically modified for the attachment onto gold nanoparticles 
and the anti-angiogenic properties and selective targeting abilities assessed through 
changes in the probe’s luminescence lifetime. Thiolated SiRNA will be conjugated onto 
the gold nanoparticle surface and the delivery into cancer cells will be assessed for 
gene silencing applications. The ability to deliver SiRNA selectively into cancer cells 
will be explored through attachment of both AbH and SiRNA onto the gold surface. 
These functionalized nanoparticles have been shown in Scheme 5.2. These 
functionalised nanoprobes have clear potential as cancer therapeutic agents and the 
ability to monitor uptake and targeting patterns in vitro by multiphoton lifetime imaging 
shows the design and synthesis of novel cancer targeting nanoprobes. 




Scheme 5.2. Schematic showing gold nanoparticles functionalised with AbH, 
SiRNA and both which will be discussed in detail within this chapter. 
5. 3 Results and discussion 
The method for conjugating AbH, SiRNA and both AbH/SiRNA will be discussed in 
each sub chapter. The gold nanoparticles used for these experiments, unless stated 
otherwise, are monodisperse 13, 25 and 100 nm citrate stabilised AuNPs (AuNP13, 
AuNP25 and AuNP100 respectively). These particles were synthesised and 
characterised according to the methods described in Chapter 4. For these experiments 
the citrate coated AuNP25 were concentrated up to 8 nM before the addition of AbH 
or SiRNA, unless stated otherwise. The purification of these functionalised 
nanoparticles requires 3 washing steps to remove any excess biomolecules in solution, 
therefore it was found that the stock concentration of AuNP25 (1.6 nM) was reduced 
too much after purification that it was not suitable for cell dosing experiments. 
5. 3. 1 Synthesis of IrC6 •AbH •AuNPs 
5. 3. 1. 1 Chemical Modification of Antibody for attachment onto AuNPs 
For attachment onto gold nanoparticles the monoclonal antibodies were functionalised 
with a hydrazide linker containing a thiol group for conjugation onto the gold surface. 
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The high affinity between the thiol group and the gold surface creates a strong 
attachment of the antibody to the gold surface. The hydrazide linker provides enough 
distance from the gold surface to stop the antibody adsorbing onto the gold surface. 
The synthesis of the antibody-hydrazide conjugate (AbH) was followed using a method 
by Kumar et al. in Nature Protocols.49 The carbohydrates on the base of the antibody 
were oxidised using sodium periodate (Scheme 5.3, Top). To confirm the oxidation 
reaction was successful a Purpald test was conducted, in which the colour turned 
purple after 5 minutes. The Purpald test verifies the oxidation of carbohydrates to 
aldehydes which is indicated by a change in colour from colourless to purple, 
confirming oxidation of the antibody. The Purpald reagent will only react with the 
oxidised antibody (aldehyde) present in the solution causing the colour to change. After 
successful oxidation of the antibody, the hydrazide linker was conjugated to the 
aldehyde on the antibody, via a hydrazide click reaction (Scheme 5.3, bottom).  
 
Scheme 5.3. Modifying monoclonal antibodies with a hydrazide linker to produce 
antibody-hydrazide (AbH). (Top) Oxidation of the carbohydrate on monoclonal 
antibody to produce an aldehyde. (Bottom) Chemical modification of the 
aldehyde with a hydrazide linker to produce AbH. 
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The antibody was characterised by UV/Vis absorption, showing a peak at 280 nm 
(Figure 5.10). This absorption peak is characteristic of an antibody which contains 
amino acids that absorb in this region.  
 
Figure 5.10. Absorption spectrum of 100 g mL-1 AbH in HEPES buffer (pH 7.5). 
5. 3. 1 .2 Attachment of AbH onto AuNPs 
The Nature Protocol49 which described the chemical modification of the antibody was 
followed for the conjugation of AbH onto AuNPs. The AuNPs were synthesised at 13 
nm, 25 nm and 100 nm following previously described methods in Chapter 350.  The 
protocol outlines the addition of 100 L AbH into a solution of 1 mL AuNPs in water, 
giving a final antibody concentration of 100 g/ mL-1. However, after following these 
steps visible aggregation occurred upon addition of AbH into AuNPs. To move forward 
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with this protocol, the point of aggregation had to be determined. This was done by 
titrating the AbH into a solution of AuNP25. The spectra showed the characteristic 
antibody peak at 280 nm, which proved the presence of AbH in the solution of gold 
nanoparticles (Figure 5.11, arrow). However, the results also showed complete 
aggregation of gold particles after the addition of only 10 L AbH. This was identified 
by the broadening of the SPR peak seen through UV/Vis spectroscopy. The broadened 
SPR peak was compared to the citrate coated AuNP25, where clear deviations could 
be seen (Figure 5.11, blue line). There was also a shift in SPR and a visual change in 
colour from red to purple. 
 
Figure 5.11. Absorbance spectrum of 2 nM AuNP25 in water (black), addition of 
5 L AbH (red) and addition of 10 L AbH (blue), showing aggregation of 
particles.  
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The only deviation from the nature protocol was the method of synthesis for gold 
nanoparticles. Therefore, gold nanoparticles were synthesised according to the nature 
protocol to yield 18 nm AuNPs, using Frens’ method of synthesis.51 Upon addition of 
AbH into a solution of 18 nm AuNPs complete aggregation could be seen, therefore 
yielding the same outcome as the previous method. The method was then optimised 
for conjugation of the antibody onto our previously synthesised gold nanoparticles 
(AuNP25). Since aggregation was occurring upon addition of AbH into citrate coated 
AuNP25, it was decided to first partially coat the gold surface with PEG-SH (230 MW) 
before addition of the antibody (Scheme 5.4). The partial coating of the gold 
nanoparticles with PEG-SH was determined by a UV/Vis titration (Figure 5.12).  
 
 
Scheme 5.4. Schematic for the procedure of coating AuNPs with PEG-SH and 
modified monoclonal antibodies (AbH). 
 




Figure 5.12. (Left) UV/Vis titration of 28 M PEG-SH into 2 mM AuNP25 (2 mL) in 




A solution of PEG-SH in water was titrated in 2 L, 5 L and 10 L aliquots into an 
aqueous solution of AuNP25 (2 mL) and the SPR shift was monitored. The shift in SPR 
indicated that a modification had occurred on the gold surface, and this shift would stop 
once the surface has been saturated with PEG-SH. The SPR shifted from 517 nm to 
520 nm upon addition of 0.01 M to 0.5 M PEG-SH into AuNP25. PEG-SH was added 
up to a concentration of 2 M, but no further shift was seen. This identified a 
concentration of 0.5 M PEG-SH was needed to fully saturate the gold surface.  
Therefore, partial coating of AuNPs (13 nm, 25 nm and 100 nm) with 0.25 M PEG-
SH was carried out for these experiments. The PEG coated gold nanoparticles were 
centrifuged for 30 minutes at 13.3 RPM to remove any excess PEG-SH in solution. 
This produced 4.5 nM PEG •AuNP13, 1.6 nM PEG •AuNP25 and 30 pM PEG 
•AuNP100 in water. Next a titration of AbH was carried out in 5 – 20 L aliquots into 
the aqueous solution of PEG •AuNP13, PEG •AuNP25 and PEG •AuNP100 
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respectively up to a final volume of 100 L AbH or a final concentration of 100 g/ mL-
1 in accordance to the Nature Protocol. The shift was monitored to identify the 
conjugation of antibody onto the gold surface and to observe any changes which could 
be indicative of particle aggregation. Addition of 100 L AbH into PEG •AuNP13, PEG 
•AuNP25 and PEG •AuNP100 resulted in a 4 nm (524 nm), 2 nm (521 nm) and 2 nm 
(556 nm) shift in max (H2O), respectively (Figure 5.13). 
 
Figure 5.13. UV/Vis titration of AbH (1 mg/ mL-1) into (Left) 4.5 nM PEG •AuNP13, 
(Middle) 1.6 nM PEG •AuNP25 and (Right) 30 pm PEG •AuNP100 in water giving 
a final AbH concentration of 100 g/ mL. The SPR region is shown in the inset to 
highlight the shift in SPR. 
 
The antibody coated gold particles were purified using Millipore filters (300 kDa 
MWCO) to produce 3.5 nM AbH •AuNP13, 1.3 nM AbH •AuNP25 and 25 pM AbH 
•AuNP100. Upon isolation of these nanoparticles the SPR max (H2O) maximum 
remained unchanged confirming that no aggregation occurred after coating with the 
monoclonal antibody (Appendix). The particles were sized by DLS to further show that 
no aggregation had occurred during coating with AbH. The results can be seen in 
Table 5.1 and Figure 5.14. The attachment of the antibody onto the gold nanoparticles 
was confirmed by the increase in size both by number and intensity distribution. Further 
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evidence was the increase in PDI, which is sensitive to the antibody being present on 
the gold surface. 
Table 5.1. Dynamic Light Scattering (DLS) for AbH • AuNP13, AbH • AuNP25 and 
AbH • AuNP100 in water. Results displayed are Size by Number Distribution, 
Size by Intensity Distribution and Polydispersity Index (PDI). 
 
 Number Distribution (nm) Intensity Distribution (nm) PDI 
AbH •AuNP13 22  7 41  15 0.26 
AbH •AuNP25 28  8 60  25 0.21 
AbH •AuNP100 115  28 143  32 0.04 
 
Figure 5.14. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 
AbH •AuNP13 (red), AbH •AuNP25 (green) and AbH •AuNP100 (Blue).  
 
Zeta-potentials (-potential) were measured and found be -39  21 mV, -36  23 mV 
and -40  26 mV for AbH •AuNP13, AbH •AuNP25 and AbH •AuNP100 respectively 
(Figure 5.15).  The results showed a negligible decrease in negative potential in 
comparison to the PEG stabilised nanoparticles which were found to be -43  21 mV, 
-44  19 mV and -41  27 mV for PEG •AuNP13, PEG •AuNP25 and PEG •AuNP100 
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respectively. This is to be expected as both the PEG complexes and the antibody  have 
an overall negative charge, therefore upon displacement of the PEG complexes the 
overall negative charge is not expected to change. 
 
Figure 5.15. DLS data showing the absolute Zeta-Potential measurements for 
AbH • AuNP13 (red), AbH • AuNP25 (green) and AbH • AuNP100 (blue) in water.  
5. 3 .1. 3 Attachment of IrC6 onto AbH •AuNPs 
A solution of IrC6 in MeOH (1 mM) was titrated into AbH •AuNP13, AbH •AuNP25 and 
AbH •AuNP100 in 1 – 2 L aliquots (Scheme 5.5). 
 
Scheme 5.5. Schematic showing coating of AbH •AuNPs with IrC6 to produce 
IrC6 •AbH •AuNP25.  
 
The IrC6 probe was added to a final concentration of 5 M, 7 M and 5 M for AbH 
•AuNP13, AbH •AuNP25 and AbH •AuNP100 respectively (Figure 5.16). This addition 
of 1mM IrC6 into the colloidal solution of gold resulted in a 4 nm (528 nm), 4 nm (527 
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nm) and 1 nm (558 nm) shift in max (H2O) for AbH • AuNP13, AbH • AuNP25 and AbH 
• AuNP100 respectively. 
 
Figure 5.16. UV/Vis titration of IrC6 into (left) 3.4 nM AbH • AuNP13, (middle) 1 
nM AbH • AuNP25 and (right) 24 pM AbH • AuNP100. The SPR region is shown 
in the inset to highlight the shift in SPR. 
 
The iridium coated nanoparticles were centrifuged three times using a Millipore filter 
(100 kDa MWCO) for 5 minutes at 2000 g giving a final product of 3 nM IrC6 •AbH 
•AuNP13, 1 nM IrC6 •AbH •AuNP25 and 20 pM IrC6 •AbH •AuNP100 in water. The 
absorbance was measured after purification and it was found that the SPR max (H2O) 
remained unchanged, showing non-aggregation of these particles after centrifugation 
(Appendix). DLS was carried out to measure the size of these functionalised 
nanoparticles in solution. The results can be seen in Table 5.2 and Figure 5.17. An 
increase in size and PDI when coated with IrC6 can be seen in which the results 
showed a 10 nm increase in size in comparison to the antibody coated particles (AbH 
•AuNPs). This increase in size is greater than previously seen with IrC6 coated Zonyl 
particles, where the size increased by a couple of nanometres upon addition of IrC6. 
This could be because the iridium(III) complex is interacting with the antibody attached 
to the gold nanoparticle surface causing a large increase in the hydrodynamic size.  
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Table 5.2. DLS results for IrC6 •AbH •AuNP13, IrC6 •AbH •AuNP25 and IrC6 •AbH 
•AuNP100 in water. Results displayed are Size by Number Distribution, Size by 
Intensity Distribution and Polydispersity Index (PDI). 
 
 Number Distribution (nm) Intensity Distribution (nm) PDI 
IrC6 •AbH •AuNP13 36  12 88  40 0.26 
IrC6 •AbH •AuNP25 38  10 62  23 0.22 
IrC6 •AbH •AuNP100 127  32 158  40 0.05 
 
 
Figure 5.17. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 




-potential for the IrC6 •AbH •AuNPs were measured and found to be -28  19 mV, -
30  11 mV and -31  20 mV for IrC6 •AbH •AuNP13, IrC6 •AbH •AuNP25 and IrC6 
•AbH •AuNP100 respectively (Figure 5.18). The results showed a decrease in 
negative potential in comparison to the AbH •AuNPs, which had a -potential of -39  
21 mV, -36  23 mV and -40  26 mV for AbH •AuNP13, AbH •AuNP25 and AbH 
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•AuNP100 respectively. This was to be expected as IrC6 in solution holds an overall 
positive charge.  
 
Figure 5.18. DLS data showing the absolute -potential measurements for IrC6 • 
AbH • AuNP13 (red), IrC6 • AbH • AuNP25 (green) and IrC6 • AbH • AuNP100 
(blue) in water.  
 
 
Elemental composition of the nanoparticles by inductively coupled plasma mass 
spectroscopy (ICP-MS) was carried out to calculate the number of IrC6 per AbH• 
AuNPs (Table 5.3). This was done by dissolving the coated AuNPs in ultrapure Aqua 
Regia, until the nanoparticles were fully digested. The metal content for each 
iridium(III) functionalised nanoparticles was then calculated from the iridium 
concentration detected from ICP-MS.   
Table 5.3. Elemental composition of nanoparticles by ICP-MS, showing number 
of IrC6 complexes per AuNP. 
 
Sample IrC6 per AbH •AuNP 
IrC6 •AbH •AuNP13 680 
IrC6 •AbH •AuNP25 800 
IrC6 •AbH •AuNP100 7550 
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The results show a high coating of iridium(III) complexes onto AbH •AuNPs, with 
hundreds of IrC6 being detected. The number of IrC6 complexes per AbH •AuNPs is 
much less than seen for Zonyl coated particles where thousands of complexes were 
detected per AuNP. This is due to a lower concentration of IrC6 added to AbH •AuNPs. 
It was found that the concentration of IrC6 added to Z •AuNPs was 11 M, 20 M and 
15 M for Z • AuNP13, Z • AuNP25 and Z • AuNP100 respectively. In comparison, 
the total concentration of IrC6 added to AbH •AuNPs which was 6 M, 7 M and 5 M 
for AbH •AuNP13, AbH •AuNP25 and AbH •AuNP100 respectively. One of the 
advantages of using multiphoton lifetime imaging over emission based microscopy is 
detection of the luminescence lifetimes which is independent of probe concentration. 
5. 3. 2 Synthesis of IrC6 •SiRNA •AuNPs 
5. 3. 2. 1 Conjugation of SiRNA onto AuNPs 
The monodisperse AuNPs (13 nm, 25 nm and 100 nm) were coated with SiRNA for 
delivery into cancer endothelial cells for gene silencing applications. SiRNA was 
chemically modified with a thiol group on the 5’ end for attachment onto the gold 
surface (Appendix). The scheme for attaching SiRNA onto the surface of gold 
nanoparticles can be seen below. 
 




Scheme 5. 6. Schematic for the procedure of coating AuNPs with Thiolated 
SiRNA to produce SiRNA •AuNPs. 
 
The coating of SiRNA was carried out on a solution of AuNP13, AuNP25 and 
AuNP100. A solution of SiRNA (100 M) was added in 10 L, 3 L and 10 L aliquots 
for AuNP13, AuNP25 and AuNP100 respectively. The SiRNA was added to a final 
volume of 30 L and a concentration of 1.5 M for all three sizes. Addition of 30 L 
SiRNA into AuNP13, AuNP25 and AuNP100 resulted in a 1 nm shift in max (H2O) for 
all three sizes. This resulted in a shift from 516 nm to 517 nm, 518 nm to 519 nm and 
550 nm to 551 nm for AuNP13, AuNP25 and AuNP100 respectively (Figure 5.19). 
Appearance of a peak at 260 nm along with the shift in SPR confirms the presence of 
SiRNA on the gold nanoparticles. 
 
 




Figure 5.19. UV/Vis titration of SiRNA (100 M) into (left) 4.5 nM AuNP13, (middle) 
1.7 nM AuNP25 and (right) 30 pm AuNP100 in water. Region of interest of at 260 
nm showing absorbance from SiRNA.  
 
These SiRNA coated nanoparticles were purified three times using Millipore filters (10 
kDa MWCO) to produce 4 nM SiRNA •AuNP13, 6 nM SiRNA •AuNP25 and 25 pM 
SiRNA •AuNP100. Upon isolation of the SiRNA coated nanoparticles the SPR max 
(H2O) maximum remained unchanged showing that no aggregation occurred after 
purification (Appendix). After purification, the absorbance peak at 260 nm remained for 
all three sizes of nanoparticles, confirming the conjugation of SiRNA to the surface of 
gold nanoparticles (Figure 5.20, arrows). 




Figure 5.20. Normalised UV/Vis plots of 4 nM SiRNA •AuNP13 (green), 6 nM 
SiRNA •AuNP25 (red) and 27 pM SiRNA •AuNP100 (blue) after purification. 
SiRNA absorbance at 260 nm showed with arrows. 
 
The SiRNA •AuNPs were sized by DLS to show that coating of the nanoparticles with 
SiRNA did not affect the stability of the nanoparticles. The results can be seen in Table 
5.4 and Figure 5.21. The results showed a small increase in hydrodynamic size and 
PDI which is to be expected upon addition of SiRNA into the solution of gold 
nanoparticles as this confirms conjugation onto the gold surface. 
Table 5.4. Dynamic Light Scattering (DLS) for SiRNA •AuNP13, SiRNA •AuNP25 
and SiRNA •AuNP100 in water. Results displayed are Size by Number 
Distribution, Size by Intensity Distribution and Polydispersity Index (PDI). 
 
 Number Distribution (nm) Intensity Distribution (nm) PDI 
SiRNA •AuNP13 22  7 41  15 0.26 
SiRNA •AuNP25 28  8 60  25 0.21 
SiRNA •AuNP100 115  28 143  32 0.04 
 




Figure 5.21. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 
SiRNA • AuNP13 (red), SiRNA • AuNP25 (green) and SiRNA • AuNP100 (Blue).  
 
-potential were measured and found to be -68  30 mV, -58  22 mV and -58  28 mV 
for SiRNA •AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively (Figure 
5.22). The results showed an increase in negative potential in comparison to the citrate 
stabilised nanoparticles, which indicates an increase in stability of the nanoparticles in 
solution. This large increase in negative potential was to be expected due to the high 
negative charge of the SiRNA which were conjugated to the gold nanoparticles. This 
same increase in negative potential was also seen for the Zonyl coated gold 
nanoparticles. 




Figure 5.22. DLS data showing the absolute -potential measurements for SiRNA 
• AuNP13 (red), SiRNA • AuNP25 (green) and SiRNA • AuNP100 (blue) in water.  
 
5. 3. 2. 2 Attachment of IrC6 onto SiRNA •AuNPs 
A solution of IrC6 in MeOH (1 mM) was titrated into an aqueous solution of 4 nM 
SiRNA•AuNP13, 6 nM SiRNA •AuNP25 and 25 pm SiRNA •AuNP100 in 2 L, 5 L 
and 10 L aliquots respectively (Scheme 5.7). The shift in SPR showed modifications 
onto the gold surface. 
 
Scheme 5.7. Schematic for the procedure of coating SiRNA •AuNPs with IrC6 to 
produce IrC6 • SiRNA • AuNPs.  
 
IrC6 (1 mM) was added up to a final concentration of 20 M, 24 M and 18 M for 
SiRNA •AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively (Figure 5.23). 
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This addition of 1mM IrC6 into the colloidal solution of SiRNA •AuNPs resulted in an 8 
nm (525 nm), 7 nm (526 nm) and 5 nm (556 nm) shift in max (H2O) for SiRNA • 
AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively. 
 
Figure 5.23. UV/Vis titration of IrC6 (1 mM) into (left) 4 nM AuNP13, (middle) 1.4 
nM AuNP25 and (right) 27 pm AuNP100 in water. The SPR region is shown in the 
inset to highlight the shift in SPR. 
 
These functionalised nanoparticles were purified by centrifuging three times using a 
Millipore filter (10 kDa MWCO) for 3 minutes at 2000 g to produce 3 nM IrC6 •SiRNA 
•AuNP13, 4.5 nM IrC6 •SiRNA •AuNP25 and 15 pM IrC6 •SiRNA •AuNP100 
respectively. The SPR was checked after purification and it was found that the SPR 
max (H2O) remained unchanged, showing non-aggregation of these particles after 
centrifugation (Appendix). DLS was carried out to measure the hydrodynamic size of 
the functionalised nanoparticles in solution and to show the stability in solution, the 
results are shown in Table 5.5 and Figure 5.24. There is an increase in both size by 
number and intensity for the IrC6 • SiRNA •AuNPs in comparison to the SiRNA 
•AuNPs. This is comparable to the increase in size that was seen when IrC6 was 
added to Zonyl coated nanoparticles. There has been no significant increase in PDI 
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for the IrC6 • SiRNA •AuNPs showing high stability of the functionalised gold 
nanoparticles in solution. 
Table 5.5. DLS results for IrC6 •AbH •AuNP13, IrC6 •AbH •AuNP25 and IrC6 •AbH 
•AuNP100 in water. Results displayed are Size by Number Distribution, Size by 
Intensity Distribution and Polydispersity Index (PDI). 
 




IrC6 • SiRNA •AuNP13 32  10 50  23 0.25 
IrC6 • SiRNA •AuNP25 36  13 58  29 0.23 
IrC6• SiRNA•AuNP100 127  32 163  45 0.05 
 
Figure 5.24. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 
IrC6 •SiRNA •AuNP13 (green), IrC6 •SiRNA •AuNP25 (red) and IrC6 •SiRNA 
•AuNP100 (Blue).  
 
-potentials for IrC6 • SiRNA •AuNPs were measured and found to be -34  25 mV, -
35  12 mV and -38  17 mV for IrC6 • SiRNA •AuNP13, IrC6 • SiRNA •AuNP25 and 
IrC6 • SiRNA •AuNP100 respectively (Figure 5.25). The results indicate highly stable 
nanoparticles in solution with an overall negative charge similar for all three sizes. The 
results showed a decrease in negative -potential in comparison to the SiRNA •AuNPs 
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in solution, which were found to be -68  30 mV, -58  22 mV and -58  28 mV for 
SiRNA •AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively. This 
decrease in negative potential was to be expected due to the positive charge of the 
IrC6 on the gold nanoparticles, which had an overall positive charge of +1.  
 
Figure 5.25. DLS data showing the absolute -potential measurements for IrC6 • 
SiRNA •AuNP13 (red), IrC6 • SiRNA •AuNP25 (green) and IrC6 • SiRNA •AuNP100 
(blue) in water.  
 
Elemental composition of IrC6 •SiRNA •AuNP13 was carried out by inductively 
coupled plasma mass spectrometry (ICP-MS) to calculate the number of IrC6 
complexes per SiRNA •AuNPs (Table 5.6).  
Table 5.6. Elemental composition of nanoparticles by ICP-MS, showing number 
of IrC6 complexes per SiRNA •AuNPs. 
 
Sample ID IrC6 per SiRNA •AuNPs 
IrC6 •SiRNA•AuNP13 2400 
IrC6 •SiRNA•AuNP25 4100 
IrC6 •SiRNA•AuNP100 27000 
 
The results showed a high coating of IrC6 onto SiRNA •AuNPs, with thousands of IrC6 
complexes per SiRNA •AuNPs. This showed an increase in IrC6 complexes per SiRNA 
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coated gold nanoparticle in comparison to Zonyl coated gold nanoparticles, which were 
found to have 1400, 3200 and 22,000 IrC6 complexes per Z •AuNP13, Z •AuNP25 
and Z •AuNP100 respectively. The higher loading of IrC6 onto SiRNA coated 
nanoparticles is due to the increased stability when coating the gold nanoparticle with 
the negative SiRNA complex. This was also supported by the -potential 
measurements. The higher negative charge of the aqueous solution of SiRNA •AuNPs 
meant that more positive iridium could be added before the nanoparticles destabilised.  
5. 3. 3 Synthesis of IrC6 •AbH/SiRNA •AuNPs 
5. 3. 3. 1 Conjugation of AbH onto SiRNA •AuNPs 
In this section, monodisperse AuNPs (13, 25 and 100 nm) were coated with AbH and 
SiRNA before the addition of IrC6. Addition of AbH onto SiRNA coated nanoparticles 
allows for targeted delivery of SiRNA into cancer cells. In theory, these nanoparticles 
should deliver the SiRNA in a more efficient manner than gold nanoparticle particles 
coated with just SiRNA. These particles are prone to entrapment into endosomes and 
lysosomes which would stop SiRNA from being delivered and potentially cause 
degradation of the SiRNA from the acidic nature of the lysosomes.   
Monodisperse AuNPs (13 nm, 25 nm and 100 nm) were pre-coated with SiRNA as 
described in the section 5. 3. 2.1 of this chapter. The SiRNA coated gold nanoparticles 
were purified and isolated to provide 4 nM SiRNA •AuNP13, 6 nM SiRNA •AuNP25 
and 25 pm SiRNA •AuNP100. A solution of AbH (1 mg/ mL-1) was titrated into the 
SiRNA •AuNPs. The attachment of AbH on SiRNA •AuNPs can be seen in Scheme 
5.8. 




Scheme 5.8. Schematic for the procedure of coating SiRNA •AuNPs with AbH to 
produce AbH•SiRNA •AuNPs. 
 
A solution of AbH (1 mg/ mL-1) was added in 5 L, 5 L and 10 L aliquots for SiRNA 
•AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively. The AbH was added 
to a final volume of 30 L and a concentration of 30 g/ mL-1 for all three sizes. Addition 
of 30 L AbH into SiRNA •AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 resulted 
in a 1 nm shift in max (H2O) for all three sizes. This resulted in a shift from 518 to 519 
nm, 518 to 519 nm and 557 to 558 nm for SiRNA •AuNP13, SiRNA •AuNP25 and 
SiRNA •AuNP100 respectively (Figure 5.26). 
 
Figure 5.26. UV/Vis titration of AbH (1 mg/ mL-1) into (left) 6 nM SiRNA •AuNP13 
(middle) 1.4 nM SiRNA •AuNP25 and (right) 25 pm SiRNA •AuNP100 in water.  
 
These nanoparticles were purified three times using Millipore filters (300 kDa MWCO) 
to produce 3.5 nM AbH/SiRNA •AuNP13, 3.5 nM AbH/SiRNA •AuNP25 and 17 pM 
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AbH/SiRNA •AuNP100. After purification, the SPR max (H2O) maximum of these 
functionalised gold nanoparticles remained unchanged showing that no aggregation 
had occurred during the purification step (Appendix). The particles were sized by DLS 
to show that coating of the nanoparticles with AbH/SiRNA did not affect the overall 
stability of these nanoparticles in solution (Table 5.7 and Figure 5.27).  
Table 5.7. Dynamic Light Scattering (DLS) for AbH •SiRNA•AuNP13, AbH 
•SiRNA•AuNP25 and AbH •SiRNA•AuNP100 in water. Results displayed are Size 
by Number Distribution, Size by Intensity Distribution and Polydispersity Index 
(PDI). 
 
 Number Distribution (nm) 
Intensity Distribution 
(nm) PDI 
AbH/SiRNA •AuNP13 32  17 49  20 0.32 
AbH/SiRNA •AuNP25 35  16 55  24 0.35 
AbH/SiRNA •AuNP100 129  33 136  33 0.04 
 
Figure 5.27. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 
AbH •SiRNA•AuNP13 (red), AbH •SiRNA•AuNP25 (green) and AbH 
•SiRNA•AuNP100 (blue) in water. 
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The results showed a large increase in size when compared to the SiRNA coated 
nanoparticles. This is to be expected due to the large size of the monoclonal 
antibodies. These results showed the largest PDI of 0.32 and 0.35 in comparison to 
AbH •AuNPs and SiRNA •AuNPs, which had PDI of <0.3 after coating. This increase 
in PDI shows that having both SiRNA and the monoclonal antibodies conjugated to the 
surface of the gold nanoparticles, could lead to faster destabilisation in solution in 
comparison to the other functionalised nanoparticles.  
-potentials were measured and found to be -36  19 mV, -39  20 mV and -43  19 
mV for AbH/SiRNA •AuNP13, AbH/SiRNA •AuNP25 and AbH/SiRNA •AuNP100 
respectively (Figure 5.28). The overall negative potential of the AbH/SiRNA •AuNPs 
didn’t increase as much as that seen for the SiRNA coated nanoparticles, which 
displayed -potentials of -68  30 mV, -58  22 mV and -58  28 mV for SiRNA 
•AuNP13, SiRNA •AuNP25 and SiRNA •AuNP100 respectively. This could mean that 
addition of the antibody to the negatively charged solution of SiRNA •AuNPs causes 
displacement of SiRNA molecules on the surface of the gold nanoparticles. 
 
Figure 5.28. DLS data showing the absolute -potentials measurements for IrC6 
• AbH •AuNP13 (red), IrC6 • AbH •AuNP25 (green) and IrC6 • AbH •AuNP100 
(blue) in water.  
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5. 3. 3. 2 Attachment of IrC6 onto AbH/SiRNA •AuNPs 
A solution of IrC6 in MeOH (1 mM) was titrated into an aqueous solution of 3.5 nM 
AbH/SiRNA •AuNP13, 3.5 nM AbH/SiRNA •AuNP25 and 17 pM AbH/SiRNA 
•AuNP100 (Scheme 5.9). The IrC6 was titrated in aliquots of 2 L, 2 L and 2.5 L for 
AbH/SiRNA •AuNP13, AbH/SiRNA •AuNP25 and AbH/SiRNA •AuNP100 
respectively. The shift in SPR shows modifications onto the gold surface. 
 
Scheme 5.9. Schematic for the procedure of coating SiRNA •AuNPs with IrC6 to 
produce IrC6 • AbH/SiRNA •AuNPs.  
 
IrC6 (1 mM) was added up to a final concentration of 9 M, 21 M and 12.5 M for 
AbH/SiRNA •AuNP13, AbH/SiRNA •AuNP25 and AbH/SiRNA •AuNP100 
respectively (Figure 5.29). This addition of 1mM IrC6 into the colloidal solution of 
AbH/SiRNA •AuNPs resulted in a 4 nm (525 nm), 6 nm (525 nm) and 2 nm (560 nm) 
shift in max (H2O) for AbH/SiRNA •AuNP13, AbH/SiRNA •AuNP25 and AbH/SiRNA 
•AuNP100 respectively.  
 




Figure 5.29. UV/Vis titration of IrC6 (1 mM) into (left) 3.5 nM AbH/SiRNA •AuNP13, 
(middle) 3.5 nM AbH/SiRNA •AuNP25 and (right) 17 pM AbH/SiRNA•AuNP100 in 
water. The SPR region is shown in the inset to highlight the shift in SPR. 
 
These functionalised nanoparticles were purified by centrifuging three times using a 
Millipore filter (300 kDa MWCO) for 3 minutes at 2000 g to produce 3 nM IrC6 
•AbH/SiRNA •AuNP13, 2 nM IrC6 •AbH/SiRNA •AuNP25 and 12 pM IrC6 •AbH/SiRNA 
•AuNP100 respectively. The SPR was checked after purification and it was found that 
the SPR max (H2O) remained unchanged, positively identifying that these gold 
nanoparticles did not aggregate after centrifugation (Appendix). DLS was carried out 
to measure the size of these functionalised nanoparticles and to identify the stability of 
in solution, the results are shown in Table 5.8 and Figure 5.30. The results showed an 
increase in size by both number and intensity in comparison to AbH/SiRNA•AuNPs in 
solution. The increase is significantly larger in comparison to the other two iridium 
functionalised nanoparticles (SiRNA and AbH). This is to be expected due to both AbH 
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Table 5.8. DLS results for IrC6 • AbH/SiRNA • AuNP13, IrC6 • AbH/SiRNA • 
AuNP25 and IrC6 • AbH/SiRNA • AuNP100 in water. Results displayed are Size 
by Number Distribution, Size by Intensity Distribution and Polydispersity Index 
(PDI). 
 
 Number Distribution (nm) 
Intensity Distribution 
(nm) PDI 
IrC6 •AbH/SiRNA •AuNP13 32  13 48  20 0.36 
IrC6 •AbH/SiRNA •AuNP25 40  15 54  33 0.36 
IrC6 •AbH/SiRNA •AuNP100 147  48 162  52 0.06 
 
 
Figure 5.30. Dynamic Light Scattering (DLS) Data showing sizing by Number 
Distribution (top) and Intensity Distribution (bottom). Results displayed are for 
IrC6 •AbH/SiRNA •AuNP13 (red), IrC6 •AbH/SiRNA •AuNP25 (green) and IrC6 
•AbH/SiRNA •AuNP100 (blue) in water. 
 
There is no significant increase in PDI in comparison to the AbH/SiRNA •AuNPs. It 
should be noted that only a single peak is seen in the distribution graph for size by 
intensity for these functionalised nanoparticles. A second peak within the intensity 
distribution graph has previously been seen for Zonyl coated gold nanoparticles when 
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there has been excess of Zonyl present in the solution (Appendix). Since a second 
peak has not been detected for these nanoparticles it can be assumed that there is no 
free antibody or SiRNA present in solution. 
-potentials of the IrC6 •AbH/SiRNA •AuNPs were measured and found to be -31  11 
mV, -33  16 mV and -39  15 mV for IrC6 •AbH/SiRNA •AuNP13, IrC6 •AbH/SiRNA 
•AuNP25 and IrC6 •AbH/SiRNA •AuNP100 respectively (Figure 5.31).  
 
Figure 5.31. DLS data showing the absolute -potentials measurements for IrC6 
•AbH/SiRNA •AuNP13 (red), IrC6 •AbH/SiRNA •AuNP25 (green) and IrC6 
•AbH/SiRNA •AuNP100 (blue) in water.  
 
These results show highly stable nanoparticles in solution with an overall similar 
negative charge for all three sizes. The results show a decrease in negative potential 
in comparison to AbH/SiRNA •AuNPs, which had zeta-potentials of -36  19 mV, -39 
 20 mV and -43  19 mV for AbH/SiRNA •AuNP13, AbH/SiRNA •AuNP25 and 
AbH/SiRNA •AuNP100 respectively. This is due to the conjugation of the positive 
iridium complex onto the gold nanoparticles in the solution which caused an overall 
decrease in negative potential. 
Elemental composition of the nanoparticles by inductively coupled plasma mass 
spectroscopy (ICP-MS) was carried out to calculate number of IrC6 complexes per 
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AbH/SiRNA •AuNPs. The results show a high coating of iridium complexes onto AbH 
•SiRNA•AuNPs, with thousands of iridium complexes per AbH •SiRNA•AuNPs (Table 
5.9). The amount of IrC6 attached to the AbH/SiRNA coated gold nanoparticles is 
similar to that previously seen for IrC6 •SiRNA •AuNPs. 
Table 5.9. Elemental composition of nanoparticles by ICP-MS, showing number 
of IrC6 complexes per AbH/SiRNA •AuNP13. 
 
Sample IrC6 per AuNPs 
IrC6 •AbH/SiRNA •AuNP13 1000 
IrC6 •AbH/SiRNA •AuNP25 3500 
IrC6 •AbH/SiRNA •AuNP100 25000 
 
This shows that the SiRNA coating provides extra stability for the nanoparticles by 
increasing the overall negative charge of the aqueous solution. This allows for a higher 
concentration of positive IrC6 to be added to the solution AbH/SiRNA coated gold 
nanoparticles before aggregation occurs. 
5. 3. 4 Photophysical characterisations of functionalised nanoprobes 
The photophysical properties of gold nanoparticles functionalised with SiRNA, AbH 
and AbH/SiRNA were investigated. The luminescence properties were characterised 
by steady state and time resolved spectroscopy. The luminescence spectra of IrC6 
•SiRNA •AuNPs, IrC6 •AbH •AuNPs and IrC6 •AbH/SiRNA •AuNPs in water were 
recorded and the results displayed in Figure 5.32. The results will be compared to 
Zonyl coated gold nanoparticles (IrC6 •AuNPs) and IrC6 in water. 




Figure 5.32. Steady-state emission spectrum exc = 375 nm (solid line) and 
excitation spectra (dotted line). (A) 3 nM IrC6 •SiRNA •AuNP13 (em = 595 nm), 
(B) 3 nM IrC6 •AbH •AuNP13 (em = 580 nm), (C) 3 nM IrC6 •AbH/SiRNA •AuNP13 
(em = 580 nm), (D) 3 nM IrC6 •SiRNA •AuNP25 (em = 595 nm), (E) 2 nM IrC6 •AbH 
•AuNP25 (em = 580 nm), (F) 2 nM IrC6 •AbH/SiRNA •AuNP25 (em = 580 nm), (G) 
15 pM IrC6 •SiRNA •AuNP100 (em = 600 nm), (H) 15 pM IrC6 •AbH •AuNP100 (em 
= 595 nm) and 12 pM IrC6 •AbH/SiRNA•AuNP100 (em = 595 nm). Spectra 
corrected for PMT and instrument response. 
 
 
All sets of nanoparticles for all three sizes showed to be highly emissive upon excitation 
at 375 nm, but differences were seen in the emission max between the different surface 
coatings (Table 5.10). The excitation spectra displayed the characteristic bands of the 
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iridium complex which are responsible for the observed emission. The excitation 
spectra are similar for all sets of functionalised nanoparticles and for all three sizes. 
Table 5.10. Emission max (nm) taken upon excitation at 375 nm for 13 nm, 25 nm 
and 100 nm AuNPs coated with SiRNA, AbH and SiRNA/AbH.  
 
 AuNP13 (max nm) AuNP25 (max nm) AuNP100 (max nm) 
IrC6 •AbH 580 580 595 
IrC6 •SiRNA 595 595 600 
IrC6 •AbH/SiRNA 580 580 595 
 
A surface coating with AbH showed an emission max of 580 nm for IrC6 •AbH 
•AuNP13 and IrC6 •AbH •AuNP25, and an emission max of 595 nm for IrC6 •AbH 
•AuNP100. The emission max for IrC6 •AbH •AuNP13 and IrC6 •AbH •AuNP25 was 
found to be the same as the free metal complex in solution. The monoclonal antibody 
is around 12 nm in size, therefore the fact that no shift in emission max was seen could 
be indicative of the interaction of the antibody with the surface of these smaller sized 
nanoparticles. This could show that the antibody wraps around the nanoparticles which 
in turn causes less interaction with the IrC6 complexes.  This is different for IrC6 •AbH 
•AuNP100 which showed a 15 nm red shift in emission max in comparison to the IrC6 
in solution. It is unlikely that the antibody (12 nm) would be able to wrap around these 
larger 100 nm nanoparticles, and therefore a shift in emission is seen indicating a 
greater interaction between the antibody and the  IrC6 complexes. A surface coating 
with SiRNA showed an emission max of 595 nm for IrC6 •SiRNA •AuNP13 and IrC6 
•SiRNA •AuNP25, and an emission max of 600 nm for IrC6 •SiRNA •AuNP100. The 
emission has red shifted by 15 nm for IrC6 •SiRNA •AuNP13 and IrC6 •SiRNA 
•AuNP25 and by 20 nm for IrC6 •SiRNA •AuNP100 in comparison to IrC6 in water, 
which has an emission max of 580 nm. This same affect was seen when gold 
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nanoparticles were coated with Zonyl FSA, where a 10 nm shift was seen in the 
emission max in comparison to IrC6 in solution. When gold nanoparticles were coated 
with both AbH and SiRNA there was an emission max of 580 nm for IrC6 •AbH/SiRNA 
•AuNP13 and IrC6 •AbH/SiRNA •AuNP25, again this shows no shift in emission in 
comparison to IrC6 in solution. This same affect was seen for the 13 nm and 25 nm 
particles which were coated with AbH. The emission max for IrC6 •AbH/SiRNA 
•AuNP100 was found to be 595 nm, which showed a 15 nm red shift in emission in 
comparison to IrC6 in solution. This same trend was seen for the 100 nm particles 
coated with AbH. The luminescence lifetimes of these functionalised nanoparticles are 
summarised in the table below (Table 5.11).  
Table 5.11. Luminescence lifetimes of iridium(III) functionalised gold 
nanoparticles coated with SiRNA, AbH or SiRNA/AbH. Iridium functionalised 
gold nanoparticles coated with Zonyl FSA have been shown for comparison. 
Luminescence lifetimes were fitted with a 2 between 1 and 1.1.   
 
 AuNP13 ( ns) AuNP25 ( ns) AuNP100 ( ns) 
IrC6 •AbH 
60 (5 %) 
210 (32 %) 
720 (63 %) 
50 (4 %) 
190 (30 %) 
700 (65 %) 
20 (3 %) 
130 (30%) 
710 (67 %) 
IrC6 •SiRNA 
30 (1 %) 
110 (42 %) 
500 (57 %) 
10 (1 %) 
170 (33 %) 
570 (67 %) 
50 (2 %) 
240 (34 %) 
540 (64 %) 
IrC6 •AbH/SiRNA 
40 (3 %) 
160 (24 %) 
640 (72 %) 
40 (1 %) 
130 (32 %) 
620 (67%) 
30 (1 %) 
180 (21 %) 
600 (79 %) 
IrC6 •Zonyl 
50 (5 %) 
180 (48 %) 
340 (47 %) 
40 (5 %) 
160 (42 %) 
330 (53 %) 
25 (3 %) 
140 (43 %) 
340 (54 %) 
 
All the lifetimes detected were found to have three lifetime components. The 
luminescence lifetimes recorded for IrC6 •AbH •AuNPs are similar for all three sizes 
of nanoparticles. A short lifetime component of 20 – 60 ns was observed at a small 
percentage of 3 – 5 %. The long component was found to be 720 ns, 700 ns and 710 
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ns for IrC6 •AbH •AuNP13, IrC6 •AbH •AuNP25 and IrC6 •AbH •AuNP100 
respectively. This showed an increase in luminescence lifetimes of 112 %, 112 % and 
109 % for IrC6 •AbH •AuNP13, IrC6 •AbH •AuNP25 and IrC6 •AbH •AuNP100 
respectively when compared to the Zonyl coated nanoparticles. In comparison to IrC6 
in solution (3 = 430 ns) an increase of 67 %, 63 % and 65 % for IrC6 •AbH •AuNP13, 
IrC6 •AbH •AuNP25 and IrC6 •AbH •AuNP100. The coating with AbH resulted in the 
largest increase in luminescence lifetimes when compared to coatings with SiRNA and 
SiRNA/AbH.  This increase in luminescence lifetimes would indicate interactions 
between the IrC6 with AbH conjugated to the gold nanoparticles, however this doesn’t 
correlate with emission studies which showed no shift in max. 
The luminescence lifetimes for IrC6 •SiRNA •AuNPs are similar for all three sizes of 
nanoparticles. A short lifetime component of 10 - 50 ns was observed at a small 
percentage of 1 – 2 %, which was also present for the lifetime recorded for the Zonyl 
FSA coated nanoparticles. The long component was found to be 500 ns, 570 ns and 
540 ns for IrC6 •SiRNA •AuNP13, IrC6 •SiRNA •AuNP25 and IrC6 •SiRNA• AuNP100 
respectively. This showed an increase in luminescence lifetimes of 47 %, 73 % and 59 
% for IrC6 •SiRNA •AuNP13, IrC6 •SiRNA •AuNP25 and IrC6 •SiRNA •AuNP100 
respectively when compared to the Zonyl coated particles. In comparison to IrC6 in 
solution, the luminescence lifetimes increased by 16 %, 33 % and 26 % for IrC6 •SiRNA 
•AuNP13, IrC6 •SiRNA •AuNP25 and IrC6 •SiRNA •AuNP100 respectively. This 
increase in luminescent lifetime shows interactions of the IrC6 complex with the SiRNA 
•AuNPs. 
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The luminescence lifetimes for IrC6 •AbH/SiRNA •AuNPs are similar for all three sizes 
of nanoparticles. A short lifetime component of 30 – 40 ns was observed at a small 
percentage of 1 – 3 %. The long component was found to be 640 ns, 620 ns and 600 
ns for IrC6 •AbH/SiRNA •AuNP13, IrC6 •AbH/SiRNA •AuNP25 and IrC6 •AbH/SiRNA 
•AuNP100 respectively. This showed an increase in luminescence lifetimes of 88 %, 
88 % and 76 % for IrC6 •AbH/SiRNA •AuNP13, IrC6 •AbH/SiRNA •AuNP25 and IrC6 
•AbH/SiRNA •AuNP100 respectively when compared to the Zonyl coated particles. In 
comparison to IrC6 in solution, the luminescence lifetimes showed an increase of 49 
%, 44 % and 40 % for IrC6 •AbH/SiRNA •AuNP13, IrC6 •AbH/SiRNA •AuNP25 and 
IrC6 •AbH/SiRNA •AuNP100 respectively. This increase in luminescent lifetime shows 
that the iridium complex is interacting with the surfactant, which increases the 
luminescence lifetime in solution. 
5. 3. 5 Mapping localisation and uptake into cancer cells using multiphoton 
lifetime imaging 
Multiphoton fluorescence and phosphorescence lifetime imaging was carried out, in 
which the short-lived picosecond lifetimes from the gold was detected in one channel 
and the long-lived iridium signal was detected in the second channel. The lifetimes 
obtained from the two channels were analysed and the differences between the 
surface coatings were compared.  The long-lived lifetimes detected in the PLIM 
channel were fitted to three components for all samples and the lifetimes displayed in 
the resulting PLIM image were taken from the 3 lifetime component.  
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5. 3. 5. 1 Multichannel detection of IrC6 •AbH •AuNPs in cancer cells  
Analysis of the short-lived and long-lived signals of IrC6 •AbH •AuNPs in Hela cells 
can be seen below for the three different sizes (Figure 5.33, 5.34 and 5.35). The PLIM 
images revealed strong phosphorescence signal within HeLa cells for all three sizes 
of AbH coated nanoparticles. The uptake of the AbH coated nanoparticles show a 
similar pattern of uptake for all three sizes of nanoparticles, with uptake being mainly 
within the cytoplasm of the cell. Future work would be carried out to confirm whether 
these nanoparticles localised within endosomes or lysosomes within the cytoplasm. 
The luminescence lifetimes detected for IrC6 •AbH •AuNP13 in Hela Cells ranged from 
620 – 2500 ns. The PLIM images show only green (600 – 690 ns) and red (700 – 1000 
ns) lifetimes detected within the cells (Figure 5.33).  
 
Figure 5.33. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.3 nM IrC6 •AbH •AuNP13 for 
24 hours. (Left) FLIM image showing detection of lifetimes in the range 20 – 1000 
ps. (Middle) Intensity image and (Right) Mapped PLIM images showing detection 
of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns (green) and 450 – 
590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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Analysis of the PLIM image shows luminescence lifetimes longer than those recorded 
for IrC6 •AbH •AuNP13 in solution, which had a long component of 720 ns in water. 
This extension in luminescence lifetimes is present in all the cells (displayed in red) 
with only some areas showing the shorter nanosecond lifetimes being detected which 
are displayed in green (600 – 690 ns) and in blue (450 – 590 ns) in the image. This 
follows a similar trend to that seen for the Zonyl coated nanoparticles (IrC6 •AuNP13), 
where uptake into the cytoplasm showed long nanosecond lifetimes.  
The FLIM image shows detection of short-lived lifetimes in the range of 20 – 1000 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, the 
characteristic SPR peak is present in the lifetime decay. These results show that the 
short-lived lifetimes from the gold have been detected within the cytoplasm of the cells 
and fully co-localise with the long-lived signal from the iridium seen in the PLIM 
channel. This can be seen for a specific coordinate within the HeLa cells which shows 
lifetimes detected within the PLIM and FLIM channel fully co-localise with each other, 
therefore identifying uptake of intact IrC6 •AbH •AuNP13 (Appendix). This is due to 
the high loading and long incubation time of IrC6 •AbH •AuNP13, which was dosed at 
a concentration of 0.3 nM for 24 hours. The luminescence lifetimes were detected 
through multichannel lifetime imaging. These lifetime images are shown below for IrC6 
•AbH•AuNP25 in Hela Cells (Figure 5.34). 




Figure 5.34. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.2 nM IrC6 •AbH•AuNP25 for 
24 hours. (Left) FLIM image showing detection of lifetimes in the range 20 – 1000 
ps. (Middle) Intensity image and (Right) Mapped PLIM images showing detection 
of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns (green) and 450 – 
590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 – 590 ns) to longer nanosecond lifetimes in green 
(600 – 690 ns) and red (700 – 1000 ns).  However, the lifetimes detected in the sample 
show mostly longer lifetimes (red) localised throughout the cytoplasm of the HeLa cells. 
Some lifetimes in the 600 – 690 ns range (green) were detected around the nuclear 
and inner cell membrane. This is a similar trend to 13 nm AbH coated nanoparticles 
which showed mostly long nanosecond lifetimes being detected in the cytoplasm (red) 
and some shorter nanosecond being detected in some cells within the image, 
displayed in green. Analysis of the PLIM image shows lifetimes which are longer than 
the IrC6 •AbH •AuNP25 in solution, which has a long component of 700 ns in water. 
This extension of the luminescent lifetime is present in all the cells with most lifetimes 
being detected in the 700 – 2000 ns range, which appears as red in the image. This 
shows that upon uptake into cells the probe is interacting with cellular proteins, causing 
an extension in the luminescent lifetime. This was seen for the Zonyl coated particles 
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(IrC6 •AuNPs) where long luminescence lifetimes of 650 – 790 ns were detected within 
the cytoplasm and nucleus of HeLa cells, which was an extension from the luminescent 
lifetime in solution (~330 ns).  
The FLIM image shows detection of short-lived lifetimes in the range of 50 – 1300 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, as there 
is a characteristic peak from the surface plasmon resonance band seen in the lifetime 
decay. These results showed that the short-lived lifetimes from the gold have been 
detected within the cytoplasm of the cells and fully co-localise with the long-lived signal 
from the iridium seen in the PLIM channel. This can be seen for a specific coordinate 
within the HeLa cells showing both PLIM and FLIM lifetimes being detected, therefore 
identifying full localised iridium functionalised nanoparticles (Appendix). The lifetimes 
detected through multichannel lifetime imaging for IrC6 •AbH •AuNP100 in Hela Cells 
are shown in Figure 5.35. 
 
Figure 5.35. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 1.5 pM IrC6 •AbH •AuNP100 
for 24 hours. (Left) FLIM image showing detection of lifetimes in the range 50 – 
1300 ps. (Middle) Intensity image and (Right) Mapped PLIM images showing 
detection of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns (green) 
and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 – 590 ns) to longer nanosecond lifetimes in green 
(600 – 690 ns) and red (700 – 1000 ns). The lifetimes detected in the sample show 
mostly shorter lifetimes displayed in green (600 – 690 ns) localised throughout the 
cytoplasm and inner cell membranes and some areas of red (700 – 1000 ns) lifetimes 
being detected in a few HeLa cells. This shows a similar trend to the 13 nm and 25 nm 
AbH coated nanoparticles. Analysis of the PLIM image shows lifetimes which are 
longer than the IrC6 •AbH•AuNP100 in solution, which has a long component of 710 
ns in water. This extension of the luminescent lifetime is present in all the cells with 
most lifetimes being detected in the 700 – 3000 ns range, which appears as red in the 
image.  
The FLIM image shows detection of short-lived lifetimes in the range of 50 – 1300 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, as there 
is a characteristic peak from the surface plasmon resonance of the gold. The FLIM 
image shows clustering of nanoparticles within the cytoplasm of the cells, which can 
be seen in orange in the FLIM image. These clusters can be seen in all cells within the 
sample. This visual clustering of nanoparticles was not seen for the 13 nm and 25 nm 
AbH coated nanoparticles. The analysis of the FLIM lifetimes and the visual clustering 
seen in the cells, shows that 100 nm particles are easily detected using fluorescence 
lifetime imaging due to their size and strong plasmon resonance. Uptake of 13 nm and 
25 nm particles could show a similar pattern of clustering within the cytoplasm, but 
since the FLIM signal is much weaker, these clusters are not visually seen in the 
images. The corresponding PLIM images show that these clusters of nanoparticles 
have long luminescence lifetimes which are greater than the lifetimes of aggregated 
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nanoparticles (~300 ns in water), these can be seen in green and red in the PLIM 
image. The short-lived lifetimes from the gold have been detected within the cytoplasm 
of the cells and fully co-localise with the long-lived signal from the iridium seen in the 
PLIM channel. This can be seen for a specific coordinate within the HeLa cells showing 
both PLIM and FLIM lifetimes being detected, therefore identifying full localised iridium 
functionalised nanoparticles (Appendix). The same trend was seen for the 13 nm and 
25 nm AbH coated nanoparticles and has been attributed to the long 24 hour 
incubation time which has allowed for accumulation of nanoparticles into cells. 
5. 3. 5. 2 Multichannel detection of IrC6 •SiRNA •AuNPs in cancer cells  
Analysis of the short-lived and long-lived signals of IrC6 •SiRNA •AuNPs in Hela cells 
can be seen below for the three different sizes (Figure 5.36, 5.37 and 5.38). The 
luminescence lifetimes from the fluorescence channel (FLIM) can be seen on the left-
hand side of the intensity image. The short-lived lifetimes detected were similar for all 
three sizes of nanoparticles. The lifetimes from the phosphorescence channel (PLIM) 
can be seen to the right of the intensity images, the colour in the images represents a 
range of lifetimes detected from the sample. The PLIM images revealed strong 
phosphorescence signal within HeLa cells for all three sizes of SiRNA coated 
nanoparticles. The luminescence lifetimes detected in the PLIM channel were mapped 
and found to range from short nanosecond lifetimes (blue) to long nanosecond 
lifetimes (red). The uptake of the SiRNA coated nanoparticles show a similar pattern 
of uptake for all three sizes of nanoparticles, with uptake being mainly within the 
cytoplasm of the cell. The lifetimes detected for IrC6 •SiRNA •AuNP13 in Hela Cells 
ranged from 620 – 2500 ns. The PLIM images show only green (600 – 690 ns) and red 
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(700 – 1000 ns) lifetimes detected within the cells, with no shorter lifetimes being 
detected in the range of 450 – 590 ns (blue) (Figure 5.36).  
 
Figure 5.36. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.3 nM IrC6 •SiRNA •AuNP13 
for 24 hours. (Left) FLIM image shows detection of lifetimes in the range 20 – 
2500 ps. (Middle) Intensity image and (Right) Mapped PLIM images showing 
detection of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns (green) 
and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
Analysis of the PLIM image shows lifetimes which are longer than the IrC6 •SiRNA 
•AuNP13 in solution, which has a long component of 500 ns in water. This extension 
of the luminescent lifetime is present in all the cells with no short nanosecond lifetimes 
(450 – 590 ns) being detected in the sample, which would appear blue in the image. 
The data shows similar uptake and luminescence lifetimes detection within cancer cells 
in comparison to IrC6 •AbH •AuNP13. However, this does differ from the uptake of 
Zonyl coated particles, IrC6 •AuNP13, in cancer cells where lifetimes were detected in 
the range of 450 – 1500 ns and short nanosecond lifetimes (blue) were detected in the 
cytoplasm of HeLa cells as clusters of nanoparticles. Interactions with cellular proteins 
could cause an extension in the luminescent lifetime, as previously seen for IrC6 
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•AuNP13 in which the luminescence lifetime increased in cellular culture media and 
serum. 
The FLIM image showed detection of short-lived lifetimes in the range of 20 – 1300 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, as there 
is a characteristic peak from the surface plasmon resonance of the gold. These results 
show that the short-lived lifetimes from the gold have been detected within the 
cytoplasm of the cells and fully co-localise with the long-lived signal from the iridium 
seen in the PLIM channel. This can be seen for a specific coordinate within the HeLa 
cells showing both PLIM and FLIM lifetimes being detected, therefore identifying full 
localised iridium functionalised nanoparticles (Appendix). This is due to the high 
loading and long incubation time of IrC6 •SiRNA •AuNP13, which was dosed at a 
concentration of 0.3 nM for 24 hours. These results were similar for IrC6 •AuNP13 in 
Hela cells which showed fully localised FLIM and PLIM signal in the cells which was 
attributed to high loading of nanoparticles into HeLa cells (0.45 nM for 5 hours). Since 
strong FLIM and PLIM signal was seen after 5 hours dosing with Zonyl coated particles, 
these results are expected from a 24-hour incubation time for the SiRNA coated 
particles. The lifetimes detected for IrC6 •SiRNA •AuNP25 in Hela Cells are shown in 
Figure 5.37. 




Figure 5.37. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.3 nM IrC6 •SiRNA •AuNP25 
for 24 hours. (Left) FLIM image showing detection of lifetimes in the range 20 – 
1300 ps. (Middle) Intensity image and (Right) Mapped PLIM images showing 
detection of lifetimes in the range of 700 – 2000 ns (red), 600 – 690 ns (green) 
and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 – 590 ns) to longer nanosecond lifetimes in green 
(600 – 690 ns) and red (700 – 1000 ns). The luminescence lifetimes detected in the 
sample show mostly longer lifetimes displayed in red localised throughout the 
cytoplasm of the cell with areas of green (450 – 590 ns) and blue (600 – 690 ns) 
lifetimes being detected around the inner cell membrane of HeLa cells. This differs 
from the lifetimes detected for IrC6 •SiRNA •AuN13, which showed more 600 – 690 
ns lifetimes in green throughout the cytoplasm of the cells and no short nanosecond 
lifetimes detected in the sample. Analysis of the PLIM image shows lifetimes which are 
longer than the IrC6 •SiRNA •AuNP25 in solution, which has a long component of 570 
ns in water. This extension of the luminescent lifetime is present in all the cells with 
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most lifetimes being detected in the 700 – 2000 ns range, which appears as red in the 
image. This extension in luminescence lifetime has been seen for all the nanoparticles 
analysis with HeLa cells, and strongly indicates interactions of the iridium probe with 
cellular proteins. The FLIM image shows detection of short-lived lifetimes in the range 
of 20 – 1600 ps. The fitting of the lifetime decays suggests this signal is coming the 
characteristic surface plasmon resonance band of the gold. These results show that 
the short-lived lifetimes from the gold have been detected within the cytoplasm of the 
cells and fully co-localise with the long-lived signal from the iridium seen in the PLIM 
channel. This can be seen for a specific coordinate within the HeLa cells showing both 
PLIM and FLIM lifetimes being detected, therefore identifying full localised iridium 
functionalised nanoparticles (Appendix). The same trend was seen for the 13 nm 
SiRNA coated nanoparticles and has been attributed to the long 24 hour incubation 
time which has allowed for accumulation of nanoparticles into cells. The lifetimes 
detected for IrC6 •SiRNA •AuNP100 in Hela Cells are shown in Figure 5.38. 
 
Figure 5.38. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 1.5 nM IrC6 •SiRNA•AuNP100 
for 5 hours. (Left) FLIM image showing detection of lifetimes in the range 20 – 
2500 ps. (Middle) Intensity image and (Right) Mapped PLIM images showing 
detection of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns (green) 
and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 – 590 ns) to longer nanosecond lifetimes in green 
(600 – 690 ns) and red (700 – 1000 ns). The lifetimes detected in the sample show 
mostly longer lifetimes displayed in red localised throughout the cytoplasm which are 
longer than the IrC6 •SiRNA •AuNP100 in solution, which has a long component of 
540 ns in water. This extension of the luminescent lifetime is present in all the cells 
with most lifetimes being detected in the 700 – 2000 ns range. Interestingly, the PLIM 
images show high uptake of IrC6 •SiRNA •AuNP100 in the cytoplasm of the cells, 
which appear to be non-aggregated nanoparticles since they are coloured in red. This 
pattern in uptake differs from IrC6 •AuNP100, which saw these 100 nm nanoparticles 
localising around the outer membrane, with minimal uptake into the cells. This was 
attributed to the large size of these nanoparticles hindering uptake into HeLa cells. The 
fact that multichannel lifetime imaging has detected IrC6 •AbH •AuNP100 within the 
cytoplasm of HeLa cells, could be attributed to the SiRNA coating increasing the 
uptake efficiency of these nanoparticles. 
The FLIM image shows clustering of nanoparticles within the cytoplasm of the cells, 
which can be seen in orange in the FLIM image. These clusters can be seen in all cells 
within the sample. This amount of clustering of nanoparticles within HeLa cells was not 
seen for the 13 nm and 25 nm particles. Analysis of the short picosecond lifetimes 
showed stronger signal detected in comparison to that seen from the 25 nm particles 
(Appendix). The analysis of the FLIM lifetimes and the visual clustering seen in the 
cells, shows that these 100 nm particles are easily detected using fluorescence lifetime 
imaging due to their size and strong plasmon resonance. The corresponding PLIM 
images show that these clusters of nanoparticles have long luminescence lifetimes 
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which are greater than the lifetimes of aggregated nanoparticles (~300 ns in water), 
these can be seen mainly in red within the PLIM image. The short-lived lifetimes from 
the gold have been detected within the cytoplasm of the cells and fully co-localise with 
the long-lived signal from the iridium seen in the PLIM channel. This can be seen for a 
specific coordinate within the HeLa cells showing both PLIM and FLIM lifetimes being 
detected, therefore identifying fully localised iridium functionalised nanoparticles 
(Appendix). This trend was seen for IrC6 •AbH •AuNP100 where clustering of 
nanoparticles could be seen within the cytoplasm of HeLa cells, which had short 
nanosecond lifetimes detected (600 – 690 ns). 
5. 3. 5. 3 Multichannel detection of IrC6 •AbH/SiRNA •AuNPs in cancer cells 
Analysis of the short-lived and long-lived signals of IrC6 •AbH/SiRNA•AuNPs in Hela 
cells can be seen below for the three different sizes (Figure 5.39, 5.40 and 5.41). The 
PLIM images revealed strong phosphorescence signal within HeLa cells for IrC6 
•AbH/SiRNA•AuNP25 and IrC6 •AbH/SiRNA•AuNP100, however the PLIM signal 
detected for IrC6 •AbH/SiRNA•AuNP13 was extremely weak. The uptake of the 
AbH/SiRNA coated nanoparticles show a similar pattern of uptake for IrC6 
•AbH/SiRNA•AuNP13 and IrC6 •AbH/SiRNA•AuNP25, with uptake being mainly 
within the cytoplasm of the cell. However, the uptake of IrC6 •AbH/SiRNA•AuNP100 
appears to be around the cell’s outer membrane. The shows a similar pattern of uptake 
as seen for IrC6 •AuNP100 in HeLa cells after only 5 hours of incubation with the 
nanoparticles. The lifetimes detected for IrC6 •AbH/SiRNA •AuNP13 in Hela Cells 
ranged from 450 – 950 ns. The PLIM signal detected for IrC6 •AbH/SiRNA •AuNP13 
was extremely weak so to fit the lifetime decay, the binning had to be increased to 
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maximum (10 binning). Analysis of the PLIM image shows mainly short nanosecond 
lifetimes being detected (450 – 590 ns), which are coloured in blue in the image (Figure 
5.39) This differs from the lifetimes detected for IrC6 •AbH •AuNP13 which showed 
mostly long nanosecond lifetime being detected in red (700 – 1000 ns) and IrC6 
•SiRNA•AuNP13 which showed long nanosecond lifetimes being detected in green 
(600 – 690 ns) and red (700 – 1000 ns) throughout the cytoplasm. This shows that 
there is no extension of lifetimes for the nanoparticles which have been internalised in 
the HeLa cells for IrC6 •AbH/SiRNA •AuNP13.   
 
Figure 5.39. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.3 nM IrC6 •AbH/SiRNA 
•AuNP13 for 24 hours. (Left) FLIM image showing detection of lifetimes in the 
range 20 – 1000 ps. (Middle) Intensity image and (Right) Mapped PLIM images 
showing detection of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns 
(green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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Analysis of the PLIM image shows mainly lifetimes which are shorter than the IrC6 
•AbH/SiRNA •AuNP13 in solution, which has a long component of 640 ns in water. 
The predominate lifetimes present in the sample are within the range of 450 – 590 ns 
(blue). This is the opposite to that seen for IrC6 •AbH •AuNP13 and IrC6 •SiRNA 
•AuNP13, which showed extension of the luminescent lifetimes when internalised into 
HeLa cells. The presence of both AbH and SiRNA onto the gold surface, could have 
slowed the uptake into cells due to steric hindrance. Therefore, the amount of IrC6 
•AbH/SiRNA •AuNP13 present in the cells is lower than that seen from previous sets 
of nanoparticles. Since both FLIM and PLIM signal is detected in the cells, it is 
assumed that there is no free IrC6 present within the cells, and that detection of these 
long and short lived signals are coming from fully coated gold nanoparticles.  
The FLIM image shows detection of short-lived lifetimes in the range of 300 – 900 ps. 
In comparison to the other sets of coated nanoparticles, which displayed strong FLIM 
signal from the gold nanoparticles, the FLIM signal detected for IrC6 •AbH/SiRNA 
•AuNP13 was extremely weak. However, the characteristic peak from the surface 
plasmon resonance of the gold was still present within the cells. A comparison of the 
FLIM and PLIM signal detected for IrC6 •AbH/SiRNA •AuNP13 and IrC6 •SiRNA 
•AuNP13, can be found in the Appendix. However, the short-lived lifetimes that have 
been detected within the cytoplasm of the cells appear to fully co-localise with the long-
lived signal from the iridium seen in the PLIM channel. This can be seen for a specific 
coordinate within the HeLa cells showing both PLIM and FLIM lifetimes being detected, 
therefore identifying full localised iridium functionalised nanoparticles (Appendix). 
Since these nanoparticles were dosed under the same conditions as IrC6 •SiRNA 
•AuNP13 and IrC6 •AbH •AuNP13 (0.3 nM or 24 hours), the FLIM and PLIM signal 
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detected within the cell should be a lot stronger. This could be an indication of the 
nanoparticle surface coating affecting the mechanism of uptake into the cells. The 
luminescence lifetimes detected for IrC6 •AbH/SiRNA •AuNP25 in Hela Cells are 
shown in Figure 5.40. 
 
Figure 5.40. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 0.2 nM IrC6 •AbH/SiRNA 
•AuNP25 for 24 hours. (Left) FLIM image showing detection of lifetimes in the 
range 60 – 1600 ps. (Middle) Intensity image and (Right) Mapped PLIM images 
showing detection of lifetimes in the range of 700 – 1000 ns (red), 600 – 690 ns 
(green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 – 590 ns) to longer nanosecond lifetimes in green 
(600 – 690 ns) and red (700 – 1000 ns). The predominant lifetimes detected in the cell 
appear to be from the long nanosecond lifetimes, displayed in red. The lifetimes 
detected appear to be localised through the cytoplasm of the cells. Some 
luminescence lifetimes in the 600 – 690 ns range were detected around the nuclear 
and inner cell membrane. This pattern of uptake is similar to that seen for IrC6 •AbH 
•AuNP25 and the IrC6 •AbH •AuNP13 in HeLa cells, which showed mostly long 
nanosecond lifetimes being detected in the cytoplasm (red) and some shorter 
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nanosecond lifetimes being detected around the cell inner and outer membranes 
(green). Analysis of the PLIM image shows lifetimes which are longer than the IrC6 
•AbH •AuNP25 in solution, which has a long component of 620 ns in water. This shows 
that upon uptake into cells the probe is interacting with cellular proteins, causing an 
extension in the luminescent lifetime. This extension in the luminescent lifetime was 
seen for the Zonyl coated particles (IrC6 •AuNPs), SiRNA coated particles (IrC6 
•SiRNA •AuNPs) and antibody coated nanoparticles (IrC6 •AbH •AuNPs), where long 
luminescence lifetimes of 650 – 790 ns were detected within the cells. However, this 
long extension of the luminescent lifetime was not seen for the IrC6 •AbH/SiRNA 
•AuNP13 in HeLa cells. The same trend was seen for IrC6 •AuNP25 in HeLa cells in 
comparison to IrC6 •AuNP13, which showed a higher uptake for 25 nm particles than 
for the 13 nm particles, which had weaker PLIM and FLIM signals detected in cells. 
The strong signal detected for both the long and short lived lifetimes within HeLa cells 
for all sets of 25 nm gold nanoparticles studied, identify these sized nanoparticles as 
promising candidates for lifetime imaging within cancer cell lines. 
The FLIM image shows detection of short-lived lifetimes in the range of 60 – 1500 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, as there 
is a characteristic peak from the surface plasmon resonance of the gold. These results 
show that the short-lived lifetimes from the gold have been detected within the 
cytoplasm of the cells and fully co-localise with the long-lived signal from the iridium 
seen in the PLIM channel (Appendix). This same trend has been seen for SiRNA 
coated particles (IrC6 •SiRNA •AuNPs) and antibody coated nanoparticles (IrC6 •AbH 
•AuNPs). There appears to be no visual clustering of nanoparticles within the cells 
which is to be expected due to the smaller diameter of the nanoparticles in comparison 
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to 100 nm nanoparticles. The lifetimes detected for IrC6 •AbH/SiRNA •AuNP100 in 
Hela Cells ranged as shown in Figure 5.41.  
 
Figure 5.41. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection. HeLa cells incubated with 1.2 pM IrC6 
•AbH/SiRNA•AuNP100 for 24 hours. (Left) FLIM image showing detection of 
lifetimes in the range 30 – 3500 ps. (Middle) Intensity image and (Right) Mapped 
PLIM images showing detection of lifetimes in the range of 700 – 1000 ns (red), 
600 – 690 ns (green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
The PLIM image displays all the lifetime ranges detected in HeLa cells from short 
nanosecond lifetimes in blue (450 - 590 ns) to longer nanosecond lifetimes in green 
(600-690 ns) and red (700 – 1000 ns). The PLIM signal detected in this sample was 
weaker than previously seen for IrC6 •AbH •AuNP100 and IrC6 •SiRNA •AuNP100 in 
HeLa cells. The pattern of uptake is confined mainly to the cell membranes, which was 
seen for IrC6 •SiRNA•AuNP100 and IrC6 •AbH•AuNP100. There appear to be two 
cells that have phosphorescence lifetimes detected in the long nanosecond range (700 
– 1000 ns) and one cell present that has phosphorescence lifetimes detected in the 
short nanosecond range (450 – 590 ns) with all nanoparticles being localised around 
the cell membrane. It is unclear why the pattern of luminescence lifetimes detected is 
different from one cell to the other, this could be an indication of non-uniform coating 
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of nanoparticles with iridium due to the large amount of SiRNA and AbH present on 
the gold surface. Another reason could be the cultured HeLa cells themselves affecting 
uptake into one specific cell. The PLIM images show luminescence lifetimes which are 
longer than the IrC6 •AbH/SiRNA •AuNP100 in solution, which had a long component 
of 600 ns in water. However, this extension of the luminescent lifetime is not present 
in all the cells, with one cell showing only shorter nanosecond lifetimes (blue). 
The FLIM image shows detection of short-lived lifetimes in the range of 30 –3500 ps. 
The fitting of the lifetime decays suggests this signal is coming from the gold, as there 
is a characteristic peak from the SPR of the gold nanoparticles. The FLIM image shows 
that all nanoparticles detected within the sample are present as clusters, which are 
coloured in orange. These clusters can be seen in all cells within the sample, localised 
around the cell membrane. This trend was seen for IrC6 •AbH •AuNP100 and IrC6 
•SiRNA •AuNP100 where clustering of nanoparticles could be seen within the 
cytoplasm of HeLa cells. However, with IrC6 •AbH •AuNP100 and IrC6 •SiRNA 
•AuNP100, short-lived signal from the gold was also present in areas where there was 
no clustering of nanoparticles visually seen. The corresponding PLIM images show 
that these clusters of nanoparticles have long luminescence lifetimes which are greater 
than the lifetimes of aggregated nanoparticles (~300 ns in water). The short-lived 
lifetimes from the gold have been detected around the cell membrane and fully co-
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5. 3. 5. 4 Lifetime analysis showing nuclear uptake of IrC6 •AbH •AuNP25, IrC6 
•SiRNA •AuNP25 and IrC6 •AbH/SiRNA •AuNP25 into cancer cells 
Further lifetime analysis was carried out on the nuclear region of HeLa cells dosed with 
IrC6 •AbH •AuNP25, IrC6 •SiRNA •AuNP25 and IrC6 •AbH/SiRNA •AuNP25, to 
identify whether these functionalised nanoparticles localised within the nucleus. The 
nucleus of the cells analysed have been highlighted by a red box present on both the 
phosphorescence and fluorescence lifetime images. Unfortunately, for these 
preliminary experiments no Z-stacks were acquired for any of the images. To identify 
true uptake into the nucleus, future work would entail carrying out PLIM and FLIM Z-
stacks throughout the cells for all functionalised nanoprobes. Since the outline of the 
nucleus can be seen in the images, it is assumed that this plane is located somewhere 
within the nucleus. Analysis of the lifetimes within the nucleus of cells dosed with IrC6 
•AbH •AuNP25, can be seen in Figure 5.42 below. 




Figure 5.42. Hela cells dosed with 0.2 nM IrC6 •AbH •AuNP25 for 24 hours, (Top, 
right) Short-lived lifetimes showing gold signal, tm: 20 – 1000 ps. (Top, right) 
Long-lived lifetimes showing iridium signal in nucleus, blue: 450 – 590 ns, green: 
600 – 690 ns and red: 700 – 1000 ns. (Bottom, left) Inset of red box on FLIM image 
showing gold detection in the nucleus. (Bottom, right) Inset of red box on PLIM 
image showing iridium signal in the nucleus. exc = 760 nm, scale bar = 20 μm. 
 
The PLIM images show long-lived signal from the iridium within the nucleus of the cells, 
which are displayed in red. Shorter lifetimes in green and blue can be seen in patches 
within the inner nuclear membrane. Lifetimes detected in the range 600 – 690 ns 
(green) can also be seen around the cell outer nuclear membrane. The long-lived 
lifetimes appear strongly in the nucleus and co-localise with the short-lived signal from 
the gold, thus positively identifying fully functionalised gold nanoparticles within the 
nucleus of HeLa cells. It should be noted that no clusters of nanoparticles can be seen 
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within the nucleus. The short-lived and long-lived lifetimes were extracted from a 
specific coordinate within the nucleus of the HeLa cell analysed, this can be found in 
the Appendix. The results show both the long lifetime decay from the iridium, and the 
characteristic SPR peak from the gold, both within the same coordinate of the cell. This 
further confirms uptake of fully coated IrC6 •AbH •AuNP25 within the nucleus. The 
uptake pattern of HeLa cells dosed with IrC6 •SiRNA •AuNP25 differs from the nuclear 
uptake for IrC6 •AbH •AuNP25 which can be seen below (Figure 5.43). 
 
Figure 5.43. Hela cells dosed with 0.3 nM IrC6 •SiRNA •AuNP25 for 24 hours, 
(Top, right) Short-lived lifetimes showing gold signal, tm: 20 – 1300 ps. (Top, 
right) Long-lived lifetimes showing iridium signal in nucleus, blue: 450 – 590 ns, 
green: 600 – 690 ns and red: 700 – 1000 ns. (Bottom, left) Inset of red box on 
FLIM image showing gold detection in the nucleus. (Bottom, right) Inset of red 
box on PLIM image showing iridium signal in the nucleus. exc = 760 nm, scale 
bar = 20 μm. 
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The lifetimes detected within the nucleus of cells dosed with 0.3 nM IrC6 •SiRNA 
•AuNP25 for 24 hours, show mostly longer luminescence lifetimes in the range of 700 
– 1000 ns (red). There are some areas of shorter lifetimes detected in the range of 450 
– 590 ns (blue), however no lifetimes in the range of 600 – 690 ns (green) were 
detected within the nucleus. The long-lived lifetimes for iridium appear a lot stronger 
within the nucleus in comparison to cells dosed with IrC6 •AbH •AuNP25. This long-
lived signal presented in red can also be seen around the outer nuclear membrane of 
the cell. The short-lived lifetimes from the gold were detected within the cell and co-
localise with the long-lived lifetimes from the iridium complex on the nanoparticles. This 
co-localisation of the two signals confirms uptake of fully functionalised gold 
nanoparticles within the nucleus of HeLa cells. The short-lived and long-lived lifetimes 
were extracted from a specific coordinate within the nucleus of the HeLa cell analysed, 
this can be found in the Appendix. The results show both the long lifetime decay from 
the iridium, and the characteristic SPR peak from the gold, both within the same 
coordinate. This further confirms uptake of fully coated IrC6 •SiRNA •AuNP25 within 
the nucleus. The third set of functionalised nanoparticles (IrC6 •AbH/SiRNA •AuNP25) 
were found to localise within the nucleus of HeLa cells. The lifetimes detected within 
the nucleus of HeLa cells for these nanoparticles appears to follow the same pattern 
as seen for IrC6 •AbH •AuNP25 (Figure 5.44). 





Figure 5.44. Hela cells dosed with 0.2 nM IrC6 •AbH/SiRNA •AuNP25 for 24 hours, 
(Top, right) Short-lived lifetimes showing gold signal, tm: 60 – 1600 ps. (Top, 
right) Long-lived lifetimes showing iridium signal in nucleus, blue: 450 – 590 ns, 
green: 600 – 690 ns and red: 700 – 1000 ns. (Bottom, left) Inset of red box on 
FLIM image showing gold detection in the nucleus. (Bottom, right) Inset of red 
box on PLIM image showing iridium signal in the nucleus. exc = 760 nm, scale 
bar = 20 μm. 
 
The PLIM images show that most of the lifetimes detected within the HeLa cells are 
the long luminescence lifetimes from iridium in the range of 700 – 1000 ns, presented 
in red. Shorter lifetimes in green and blue were detected within certain areas of the 
nucleus. This is similar to the uptake of IrC6 •AbH •AuNP25 into the nucleus of HeLa 
cells based on the lifetime analysis. This is to be expected since both nanoparticles 
have been functionalised with the monoclonal antibody. The PLIM images showed 
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lifetimes within the range of 500 – 690 ns being detected around the nuclear outer 
membrane. The FLIM images show short-lived lifetimes detected from the gold 
nanoparticles within the nucleus of HeLa cells. These short-lived lifetimes appear to 
fully co-localise with the long-lived signal from the iridium, thus positively identifying 
fully functionalised gold nanoparticles within the nucleus of HeLa cells. The short-lived 
and long-lived lifetimes were extracted from a specific coordinate within the nucleus of 
the HeLa cell analysed, this can be found in the Appendix. The results show both the 
long lifetime decay from the iridium, and the characteristic SPR peak from the gold, 
both within the same coordinate. This further confirms uptake of fully coated IrC6 
•AbH/SiRNA •AuNP25 within the nucleus. This work has allowed for multichannel 
detection of iridium functionalised gold nanoparticles within the nucleus of cancer cells, 
which has currently have been investigated. 
5. 3. 6 Selective targeting of functionalised nanoprobes into endothelial cells 
These gold nanoparticles have been functionalised with monoclonal antibodies that 
selectively target CLEC14a which is a known tumour endothelial marker. The targeting 
abilities of these functionalised nanoprobes were assessed using multiphoton lifetime 
imaging by monitoring the lifetime changes upon uptake into HUVEC cells. HUVEC 
cells were used in these experiments due to the presence of CLEC14a on their 
surface.7 Multiphoton lifetime imaging was carried out on live HUVEC cells dosed with 
functionalised nanoparticles and the localisation patterns were assessed by detecting 
the lifetime changes within the cells. This was done by looking at the uptake of IrC6 
•AbH •AuNP25 into HUVEC cells and identifying whether the antibody conjugated 
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onto the surface of gold nanoparticles has any affect up the uptake into these 
endothelial cells. The results can be seen in Figure 5.45 below. 
 
 
Figure 5.45. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection in HUVEC cells. HUVEC cells were incubated with 0.2 nM 
IrC6 •AbH •AuNP25 for 24 hours. (Left) FLIM image showing detection of 
lifetimes in the range 100 – 2300 ps. (Middle) Intensity image and (Right) Mapped 
PLIM images showing detection of lifetimes in the range of 700 – 1000 ns (red), 
600 – 690 ns (green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
 
The phosphorescence lifetime images show uptake of IrC6 •AbH •AuNP25 into 
HUVEC cells, with mostly long-lived luminescence lifetimes in the range of 700 – 1000 
ns being detected. This follows the same trend as seen for IrC6 •AbH •AuNP25 into 
HeLa cells under the same dosing conditions, where most lifetimes detected were 
present in this range. Interestingly, there appears to be a lot more clusters of 
nanoparticles around the cell inner and outer membrane, which was not seen for IrC6 
•AbH •AuNP25 in HeLa cells. The lifetimes for these clusters can be seen in blue and 
have been detected in the range of 450 – 590 ns, identifying these as non-aggregated 
nanoparticles. The fluorescence lifetime images show detection of the short-lived 
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lifetimes from the gold, which co-localises with the long-lived signal from the iridium(III) 
complexes. The clustering of nanoparticles can be seen in bright orange in the FLIM 
image, showing strong signal detected from the gold, which is confirmed by the lifetime 
decay plot showing the SPR band of the gold. The uptake into HeLa cells for these 
antibody functionalised nanoprobes showed no clustering of nanoparticles and no 
lifetimes were detected within the range of 450 – 590 ns. This shows that the uptake 
of IrC6 •AbH •AuNP25 into HUVEC is specific to these endothelial cells. This high 
clustering around the cell surface could be an indication of selective targeting of the 
antibody with the CLEC14a, tumour endothelial marker, since this pattern of uptake is 
only seen within HUVEC cells. Next, the uptake of IrC6 •SiRNA •AuNP25 into HUVEC 
cells was assessed through multiphoton lifetime imaging, to confirm their potential as 
delivery carriers for gene silencing applications (Figure 5.46). 
 
 
Figure 5.46. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection in HUVEC cells. HUVEC cells were incubated with 0.3 nM 
IrC6 •SiRNA •AuNP25 for 24 hours. (Left) FLIM image showing detection of 
lifetimes in the range 50 – 2100 ps. (Middle) Intensity image and (Right) Mapped 
PLIM images showing detection of lifetimes in the range of 700 – 1000 ns (red), 
600 – 690 ns (green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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The phosphorescence lifetime images show uptake of IrC6 •SiRNA •AuNP25 into 
HUVEC cells, with mostly long-lived luminescence lifetimes in the range of 450 – 590 
ns being detected in the cells. The phosphorescence lifetimes detected were very 
weak and the binning had to be increased to the maximum to fit the lifetime decays. 
This differs for the uptake and signal found for IrC6 •AbH •AuNP25 in HeLa cells under 
the same dosing conditions, where strong signal was detected, and lifetimes were 
mostly in the range of 700 -1000 ns. There appears to be some clusters of 
nanoparticles within the cytoplasm of HUVEC cells, which can be seen on the 
fluorescence lifetime image. Analysis of these cluster reveal lifetimes in the range of 
450 – 590 ns. This is different for the uptake of IrC6 •SiRNA •AuNP25 into HeLa cells 
were the clusters of nanoparticles showed longer lifetimes in the range of 600 – 690 
ns and 700 – 1000 ns.  The fluorescence lifetime images show detection of the short-
lived lifetimes from the gold, which co-localises with the long-lived signal from the 
iridium(III) complexes. This confirms uptake of fully functionalised nanoparticles into 
cancer cells. The clustering of nanoparticles can be seen in bright orange in the FLIM 
image, and appears to by localised within a small section of the cytoplasm of HUVEC 
cells. The weak PLIM signal detected for these SiRNA coated nanoparticles suggests 
ineffective uptake into HUVEC cells after 24 hours. This differs from the uptake seen 
in HeLa cells where strong PLIM signal could be seen after 24 hours suggesting high 
uptake into these cells. The inefficient uptake into cancer endothelial cells could be 
due to the high negative charge on the IrC6 •SiRNA •AuNP25, which was found to be 
-58 mV in solution. It is known that the surface of vascular endothelial cells is negatively 
charged,52 and therefore the inefficient uptake into HUVEC cells could be due to 
electrostatic repulsion. This has previously been shown where the internalisation of 
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magnetite nanoparticles into human endothelial cells (HUVEC) was shown to be 
dependent on the nanoparticles surface charge.53 They found that the uptake of 
positively charged nanoparticles into HUVEC cells was much greater than 
nanoparticles containing a negative surface change. They also found that normal 
cancer cells the uptake was indifferent to surface charge. This agrees with the results 
seen for the uptake of IrC6 •SiRNA •AuNP25 into HUVEC cells. The last experiment 
focuses of the uptake of IrC6 •AbH/SiRNA •AuNP25 into HUVEC cells, to identify the 
selective delivery of SiRNA into endothelial cells. (Figure 5.47). However, to fully prove 
this process is selective, future work would include using positive and negative controls 
for CLEC14a expressing and non-expressing cells which would be dosed with these 
nanoparticles.
 
Figure 5.47. Two-photon lifetime images showing detection of the short-lived 
fluorescence (FLIM) and long-lived phosphorescence (PLIM) lifetimes for 
multichannel detection in HUVEC cells. HUVEC cells were incubated with 0.2 nM 
IrC6 •AbH/SIRNA •AuNP25 for 24 hours. (Left) FLIM image showing detection of 
lifetimes in the range 40 – 1600 ps. (Middle) Intensity image and (Right) Mapped 
PLIM images showing detection of lifetimes in the range of 700 – 1000 ns (red), 
600 – 690 ns (green) and 450 – 590 ns (blue). exc = 760 nm, scale bar = 10 μm.  
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The phosphorescence lifetime images show uptake of IrC6 •AbH/SiRNA •AuNP25 into 
HUVEC cells, with mostly long-lived luminescence lifetimes in the range of 600 – 690 
ns being detected in the cells. There are some areas containing the longer 
luminescence lifetimes in the range for 700 – 1000 ns (red) within the cell. There are 
also some shorter lifetimes detected which can be seen in blue. This is similar to the 
uptake pattern found for IrC6 •AbH/SiRNA •AuNP25 in HeLa cells under the same 
dosing conditions, where the predominant lifetimes in the cells were found to be in the 
range of 600 – 690 ns. The lifetime images show no clustering of nanoparticles within 
the HUVEC cells, which was the same for IrC6 •AbH/SiRNA •AuNP25 in HeLa cells. 
However, this is different from the results seen for both IrC6 •AbH •AuNP25 and IrC6 
•SiRNA •AuNP25 in HUVEC cells where visual clustering could be seen in the FLIM 
images. This could show that SiRNA hinders the antibodies ability to selectively target 
CLEC14a and therefore the mechanism is not through receptor-mediated 
internalisation but rather through normal endocytosis of nanoparticles as seen for IrC6 
•AbH/SiRNA •AuNP25 in HeLa cells. The fluorescence lifetime images show detection 
of the short-lived lifetimes from the gold, which co-localises with the long-lived signal 
from the iridium(III) complexes. This confirms uptake of fully functionalised 
nanoparticles into cancer cells. The lifetime analysis from both the FLIM and PLIM 
channels revealed strong signal detected for both gold and iridium. This shows efficient 
uptake of nanoparticles into the HUVEC cells, though not through selective uptake. 
Since these were preliminary experiments, further work would need to be carried out 
to identify the true selective targeting abilities of these functionalised nanoparticles into 
cancer vasculature. 
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5. 4 Conclusions 
Gold nanoparticles were functionalised with monoclonal antibodies and SiRNA for 
selective targeting of cancer cells. The nanoparticles were synthesised and 
functionalised with iridium(III) complexes, which have shown to undergo multiphoton 
excitation and contain long-luminescence lifetimes desirable to lifetime imaging 
techniques. The photophysical properties of the iridium(III) functionalised nanoprobes 
revealed long-luminescence lifetimes and high photostability. Their uptake into cancer 
cells was monitored by multiphoton lifetime imaging where the gold and iridium signal 
could be detected separately in two channels. The uptake of IrC6 •AbH •AuNPs, IrC6 
•SiRNA •AuNP25 and IrC6 •AbH/SiRNA •AuNP25 into cancer cells was found to be 
within the cytoplasm of the cells, with high signal detected for both the gold and iridium. 
Future experiments would have to be designed to identify whether these functionalised 
gold nanoparticles are localising within endosomes or lysosomes within the cytoplasm. 
This could be done through confocal and lifetime microscopy by using endosomal and 
lysosomal cellular stains to look at co-localisation in the fluorescence signal and the 
lifetime changes within these vesicles. The PLIM images showed long-lived lifetimes 
mainly present in the range of 700 – 1000 ns and lifetimes which were longer than the 
functionalised nanoprobes in solution. Investigation of the lifetime was carried out to 
reveal nuclear uptake of IrC6 •AbH •AuNP25, IrC6 •SiRNA •AuNP25 and IrC6 
•AbH/SiRNA •AuNP25 within HeLa cells. The targeting abilities of these functionalised 
nanoprobes were investigated within HUVEC cells, which contain CLEC14a on their 
surface. The results showed uptake of IrC6 •AbH•AuNP25, which showed long-lived 
luminescence lifetime detected in the cytoplasm of cells. A high degree of clustering 
could be seen around the cell inner and outer membrane suggesting a difference in 
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uptake mechanism when compared with IrC6 •AbH •AuNP25 in HeLa cells. It was 
found that the uptake of IrC6 •SiRNA •AuNP25 into HUVEC cells was inefficient with 
weak PLIM signal detected inside the endothelial cells. Lastly, uptake of IrC6 
•AbH/SiRNA •AuNP25 into HUVEC cells showed similar patterns to that seen for IrC6 
•AbH/SiRNA •AuNP25 in HeLa cells. There was no clustering of nanoparticles seen 
around the cell membranes, suggesting the addition of SiRNA to the AbH coated gold 
nanoparticles, changes the uptake mechanism. These were preliminary experiments 
to assess uptake into these endothelial cells. This work would be continued to assess 
the true targeting abilities by looking at uptake of IrC6 •AbH •AuNP25 in both HUVEC 
cells and HUVEC cells over-expressing CLEC14a on their surface membrane. 
Secondly, live cell time-lapse experiments and lifetime z-stacks would be taken to 
identify uptake mechanisms and localisation patters within HUVEC cells. To assess 
delivery of SiRNA into endothelial cells gene knockdown experiments would be carried 
out. To complete this work, uptake into angiogenic vasculature would be carried out 
by injecting nanoparticles into tumour bearing mice and two-photon lifetime imaging 
would be carried out on tumour tissue sections to positively identify selective targeting 
of tumour vasculature. 
5. 5 Experimental section 
5. 5. 1 Synthesis of AbH  
The method for conjugation of a hydrazide linker to a monoclonal antibody (AbH) was 
based on the nature protocol by Kumar et al.49 CRT3 monoclonal antibody (100L, 1 
mg/ mL-1) was centrifuged in a Vivaspin®6 filter (10 kDa) at 2000 g for 3 minutes. 
Sodium Phosphate (Na2PO4, pH 7.5) was added to a final volume of 100 L. The 
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antibody was oxidised by adding 10 L NaIO4 (100 mM) to the solution and left to stir 
in the dark for 30 minutes at room temperature. The reaction was quenched with PBS 
(500 L, 0.1 M, pH 7). A Purpald test was done to confirm oxidation of the 
carbohydrate. 10 mg Purpald was dissolved in 1mL NaOH (1 mM). The antibody 
solution (20 L) was mixed with freshly prepared Purpald solution (60 L). The 
solution turned purple after 5 minutes, confirming presence of aldehyde.  
Hydrazide linker (2 L, 46.5 mM) was added to the antibody solution and left to stir in 
the dark for 1 hour at room temperature. HEPES buffer (1 mL, 40 mM) was added and 
the entire volume filtered in a Vivaspin®6 tube (10 kDa MWCO) for 5 minutes at 2,000 
g. The solution was centrifuged in a Vivaspin®6 filter for 5 minutes at 2000 g. HEPES 
buffer (40 mM) was added to a volume of 1 mL and centrifuged at the same conditions, 
this was repeated 3 times. The remaining solution was made to a final volume of 100 
L in 40 mM HEPES buffer, giving 100 L/ mL-1 AbH solution. 
5. 5. 2 Synthesis of IrC6 •AbH •AuNPs 
PEG •AuNP13. 28 M PEG-SH (230 mW) in ultrapure water (20L) was added to 4.5 
nM AuNP13 (2 mL) and sonicated for 15 minutes. This was centrifuged at 10, 000 g 
for 20 minutes, the supernatant was decanted, and the pellet was resuspended in 
ultrapure water (2 mL) to form PEG  •AuNP13. max(H2O): 520 nm (SPR). Diameter 19 
 3 nm (DLS number distribution), PDI = 0.21. -potential = - 43 ± 21 mV.  
AbH •AuNP13. 100 L/ mL-1 AbH in HEPES buffer (100L) was added to 4.5 nM PEG 
•AuNP13 (2 mL) and incubated at RT for 1 hour whilst stirring. These nanoparticles 
were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. 
The supernatant was removed from the bottom of the tube and 1 mL HEPES buffer 
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added. This was repeated three times to remove any excess antibody in solution, and 
left in a final volume of 2 mL. This formed 4 nM AbH  •AuNP13. max(H2O): 524 nm 
(SPR). Diameter 22  7 nm (DLS number distribution), PDI = 0.26. -potential = - 39 ± 
21 mV.  
IrC6 •AbH •AuNP13. IrC6 (8 L, 1 mM) was titrated into 4 nM solution of AbH •AuNP13 
(2 mL) with stirring in between. These nanoparticles were purified using Vivaspin®20 
tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was removed from 
the bottom of the tube and 1 mL HEPES buffer added. This was repeated three times 
to remove any excess probe in solution, and left in a final volume of 2 mL forming 3 
nM IrC6 •AbH •AuNP13. max(H2O): 528 nm (SPR). Diameter 36  12 nm (DLS number 
distribution), PDI = 0.26. -potential = -28 ± 19 mV. ICP-MS results show 680 
complexes per AbH •AuNP13. 
PEG •AuNP25. 28 M PEG-SH (230 mW) in ultrapure water (20L) was added to 8 
nM AuNP25 (2 mL) and sonicated for 15 minutes. This was centrifuged at 10, 000 g 
for 20 minutes, the supernatant was decanted and the pellet was resuspended in 
ultrapure water (2 mL) to form PEG  •AuNP25. max(H2O): 519 nm (SPR). Diameter 21 
 9 nm (DLS number distribution), PDI = 0.130. -potential = - 44 ± 19 mV.  
AbH •AuNP25. 100 L/ mL-1 AbH in HEPES buffer (100L) was added to 8 nM PEG 
•AuNP13 (2 mL) and incubated at RT for 1 hour whilst stirring. These nanoparticles 
were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. 
The supernatant was removed from the bottom of the tube and 1 mL HEPES buffer 
added. This was repeated three times to remove any excess antibody in solution, and 
left in a final volume of 2 mL. This formed 6 nM AbH  •AuNP25. max(H2O): 521 nm 
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(SPR). Diameter 28  8 nm (DLS number distribution), PDI = 0.21. -potential = - 36 ± 
23 mV.  
IrC6 •AbH •AuNP25. IrC6 (8 L, 1 mM) was titrated into 6 nM solution of AbH •AuNP25 
(2 mL) with stirring in between. These nanoparticles were purified using Vivaspin®20 
tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was removed from 
the bottom of the tube and 1 mL HEPES buffer added. This was repeated three times 
to remove any excess probe in solution, and left in a final volume of 2 mL forming 2 
nM IrC6 •AbH •AuNP25. max(H2O): 528 nm (SPR). Diameter 38  10 nm (DLS number 
distribution), PDI = 0.22. -potential = -30 ± 11 mV. ICP-MS results show 800 
complexes per AbH •AuNP25. 
PEG •AuNP100. 28 M PEG-SH (230 mW) in ultrapure water (20L) was added to 30 
pM AuNP100 (2 mL) and sonicated for 15 minutes. This was centrifuged at 10, 000 g 
for 20 minutes, the supernatant was decanted and the pellet was resuspended in 
ultrapure water (2 mL) to form PEG  •AuNP100. max(H2O): 554 nm (SPR). Diameter 
107  27 nm (DLS number distribution), PDI = 0.025. -potential = - 41 ± 27 mV.  
AbH •AuNP100. 100 L/ mL-1 AbH in HEPES buffer (100L) was added to 30 pM PEG 
•AuNP13 (2 mL) and incubated at RT for 1 hour whilst stirring. These nanoparticles 
were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. 
The supernatant was removed from the bottom of the tube and 1 mL HEPES buffer 
added. This was repeated three times to remove any excess antibody in solution, and 
left in a final volume of 2 mL. This formed 25 pM AbH  •AuNP100. max(H2O): 556 nm 
(SPR). Diameter 115  28 nm (DLS number distribution), PDI = 0.04. -potential = - 40 
± 26 mV.  
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IrC6 •AbH •AuNP100. IrC6 (9 L, 1 mM) was titrated into 25 pM solution of AbH 
•AuNP100 (2 mL) with stirring in between. These nanoparticles were purified using 
Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was 
removed from the bottom of the tube and 1 mL HEPES buffer added. This was 
repeated three times to remove any excess probe in solution, and left in a final volume 
of 2 mL forming 15 pM IrC6 •AbH •AuNP100. max(H2O): 558 nm (SPR). Diameter 127 
 32 nm (DLS number distribution), PDI = 0.05. -potential = -40 ± 26 mV. ICP-MS 
results show 7550 complexes per AbH •AuNP100. 
5. 5. 3 Synthesis of IrC6 •SiRNA •AuNPs 
SiRNA •AuNP13. 100 M SiRNA in HEPES buffer (30L) was added to 4.5 nM 
AuNP13 (2 mL) and incubated at RT for 30 minutes whilst stirring. These nanoparticles 
were purified using Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 2, 000 g. The 
supernatant was removed from the bottom of the tube and 1 mL HEPES buffer pH 7.4 
was added and centrifuged. This was repeated three times to remove any excess 
SiRNA in solution, and left in a final volume of 2 mL. This formed 4 nM SiRNA  
•AuNP13. max(H2O): 517 nm (SPR). Diameter 24  5 nm (DLS number distribution), 
PDI = 0.24. -potential = - 68 ± 30 mV.  
IrC6 •SiRNA •AuNP13. IrC6 (20 L, 1 mM) was titrated into 4 nM solution of SiRNA 
•AuNP13 (2 mL) with stirring in between. These nanoparticles were purified using 
Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was 
removed from the bottom of the tube and 1 mL HEPES buffer pH 7.4 was added and 
centrifuged. This was repeated three times to remove any excess probe in solution, 
and left in a final volume of 2 mL forming 3 nM IrC6 •SiRNA •AuNP13. max(H2O): 525 
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nm (SPR). Diameter 34  10 nm (DLS number distribution), PDI = 0.25. -potential = -
34 ± 25 mV. ICP-MS results show 2400 complexes per AbH •AuNP13. 
SiRNA •AuNP25. 100 M SiRNA in HEPES buffer (30L) was added to 8 nM AuNP13 
(2 mL) and incubated at RT for 30 minutes whilst stirring. These nanoparticles were 
purified using Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 2, 000 g. The 
supernatant was removed from the bottom of the tube and 1 mL HEPES buffer pH 7.4 
was added and centrifuged. This was repeated three times to remove any excess 
SiRNA in solution, and left in a final volume of 2 mL. This formed 6 nM SiRNA  
•AuNP25. max(H2O): 519 nm (SPR). Diameter 26  7 nm (DLS number distribution), 
PDI = 0.19. -potential = - 58 ± 22 mV.  
IrC6 •SiRNA •AuNP25. IrC6 (24 L, 1 mM) was titrated into 6 nM solution of SiRNA 
•AuNP25 (2 mL) with stirring in between. These nanoparticles were purified using 
Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was 
removed from the bottom of the tube and 1 mL HEPES buffer pH 7.4 was added and 
centrifuged. This was repeated three times to remove any excess probe in solution, 
and left in a final volume of 2 mL forming 3 nM IrC6 •SiRNA •AuNP25. max(H2O): 526 
nm (SPR). Diameter 36  13 nm (DLS number distribution), PDI = 0.23. -potential = -
35 ± 12 mV. ICP-MS results show 4100 complexes per AbH •AuNP25. 
SiRNA •AuNP100. 100 M SiRNA in HEPES buffer (30L) was added to 30 pM 
AuNP100 (2 mL) and incubated at RT for 30 minutes whilst stirring. These 
nanoparticles were purified using Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 
2, 000 g. The supernatant was removed from the bottom of the tube and 1 mL HEPES 
buffer pH 7.4 was added and centrifuged. This was repeated three times to remove 
any excess SiRNA in solution, and left in a final volume of 2 mL. This formed 25 pM 
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SiRNA  •AuNP100. max(H2O): 551 nm (SPR). Diameter 103  21 nm (DLS number 
distribution), PDI = 0.04. -potential = - 58 ± 28 mV.  
IrC6 •SiRNA •AuNP100. IrC6 (18 L, 1 mM) was titrated into 25 pM solution of SiRNA 
•AuNP100 (2 mL) with stirring in between. These nanoparticles were purified using 
Vivaspin®6 tube (10 kDa MWCO) for 20 minutes at 2, 000 g. The supernatant was 
removed from the bottom of the tube and 1 mL HEPES buffer pH 7.4 was added and 
centrifuged. This was repeated three times to remove any excess probe in solution, 
and left in a final volume of 2 mL forming 15 pM IrC6  •SiRNA •AuNP100. max(H2O): 
556 nm (SPR). Diameter 127  32 nm (DLS number distribution), PDI = 0.05. -
potential = -38 ± 17 mV. ICP-MS results show 27, 000 complexes per SiRNA 
•AuNP100. 
5. 5. 4 Synthesis of IrC6 •AbH/SiRNA •AuNPs 
AbH/SiRNA •AuNP13. 100 L/ mL-1 AbH in HEPES buffer (30L) was added to 4 nM 
SiRNA •AuNP13 (2 mL) and incubated at RT for 1 hour whilst stirring. These 
nanoparticles were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes 
at 2, 000 g. The supernatant was removed from the bottom of the tube and 1 mL 
HEPES buffer added. This was repeated three times to remove any excess antibody 
in solution, and left in a final volume of 2 mL. This formed 3.5 nM AbH/SiRNA  
•AuNP13. max(H2O): 519 nm (SPR). Diameter 35  7 nm (DLS number distribution), 
PDI = 0.35. -potential = - 36 ± 19 mV.  
IrC6 •AbH/SiRNA •AuNP13. IrC6 (9 L, 1 mM) was titrated into 3.5 nM solution of 
AbH/SiRNA •AuNP13 (2 mL) with stirring in between. These nanoparticles were 
purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The 
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supernatant was removed from the bottom of the tube and 1 mL HEPES buffer added. 
This was repeated three times to remove any excess antibody in solution, and left in a 
final volume of 2 mL forming 3 nM IrC6 •AbH/SiRNA •AuNP13. max(H2O): 525 nm 
(SPR). Diameter 35  7 nm (DLS number distribution), PDI = 0.36. -potential = -31 ± 
11 mV. ICP-MS results show 1,000 complexes per AbH/SiRNA •AuNP13. 
AbH/SiRNA •AuNP25. 100 L/ mL-1 AbH in HEPES buffer (30L) was added to 6 nM 
SiRNA •AuNP25 (2 mL) and incubated at RT for 1 hour whilst stirring. These 
nanoparticles were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes 
at 2, 000 g. The supernatant was removed from the bottom of the tube and 1 mL 
HEPES buffer added. This was repeated three times to remove any excess antibody 
in solution, and left in a final volume of 2 mL. This formed 3.5 nM AbH/SiRNA  
•AuNP25. max(H2O): 519 nm (SPR). Diameter 37  6 nm (DLS number distribution), 
PDI = 0.32. -potential = - 39 ± 20 mV.  
IrC6 •AbH/SiRNA •AuNP25. IrC6 (21 L, 1 mM) was titrated into 3.5 nM solution of 
AbH/SiRNA •AuNP25 (2 mL) with stirring in between. These nanoparticles were 
purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The 
supernatant was removed from the bottom of the tube and 1 mL HEPES buffer added. 
This was repeated three times to remove any excess antibody in solution, and left in a 
final volume of 2 mL forming 2 nM IrC6 •AbH/SiRNA •AuNP25. max(H2O): 525 nm 
(SPR). Diameter 33  16 nm (DLS number distribution), PDI = 0.36. -potential = -33 
± 16 mV. ICP-MS results show 4,100 complexes per AbH/SiRNA •AuNP25. 
AbH/SiRNA •AuNP100. 100 L/ mL-1 AbH in HEPES buffer (30L) was added to 25 
pM SiRNA •AuNP100 (2 mL) and incubated at RT for 1 hour whilst stirring. These 
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nanoparticles were purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes 
at 2, 000 g. The supernatant was removed from the bottom of the tube and 1 mL 
HEPES buffer added. This was repeated three times to remove any excess antibody 
in solution, and left in a final volume of 2 mL. This formed 17 pM AbH/SiRNA  
•AuNP100. max(H2O): 558 nm (SPR). Diameter 113  21 nm (DLS number 
distribution), PDI = 0.36. -potential = - 43 ± 19 mV.  
IrC6 •AbH/SiRNA •AuNP100. IrC6 (12.5 L, 1 mM) was titrated into 17 pM solution of 
AbH/SiRNA •AuNP100 (2 mL) with stirring in between. These nanoparticles were 
purified using Vivaspin®20 tube (300 kDa MWCO) for 20 minutes at 2, 000 g. The 
supernatant was removed from the bottom of the tube and 1 mL HEPES buffer added. 
This was repeated three times to remove any excess antibody in solution, and left in a 
final volume of 2 mL forming 12 pM IrC6 •AbH/SiRNA •AuNP100. max(H2O): 560 nm 
(SPR). Diameter 145  32 nm (DLS number distribution), PDI = 0.06. -potential = -39 
± 15 mV. ICP-MS results show 27,000 complexes per AbH/SiRNA •AuNP100. 
5. 5. 5 Cell culture and nanoparticle dosing 
5. 5. 5. 1. HeLa cells 
Human cervical epithelioid cancer cells (HeLa cells) obtained from Public Health 
England (catalogue number 93021013) were used in all experiments. HeLa cells were 
maintained and grown in complete Dulbecco’s Modified Eagle Medium (DMEM) 
without phenol red supplemented with 10% Fetal Bovine Serum (FBS), 2 mM 
glutamine, 100 units/mL penicillin and 0.4 mg/mL streptomycin. Cells were grown as 
monolayer in vented cap T75 flasks at 37 C in a humidified atmosphere of 5 % CO2 
incubator. A day prior to dosing with nanoparticles, HeLa cells were counted with 
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Biorad automated cell counter and viability determined by trypan blue exclusion. Cells 
were seeded at a density of 100,000 cells per 35 mm MaTek glass dishes and allowed 
to attach overnight in a humidified 5 % CO2 atmosphere. For nanoparticle dosing, cell 
media was removed and the dishes washed twice with phosphate buffered saline 
(PBS) at pH 7. HeLa cells were dosed for 24 hours for IrC6 •AbH •AuNP13 (0.3 nM), 
IrC6 •SiRNA •AuNP13 (0.3 nM), IrC6 •AbH/SiRNA •AuNP13 (0.3 nM) IrC6 •AbH 
•AuNP25 (0.2 nM), IrC6 •SiRNA •AuNP25 (0.3 nM), IrC6 •AbH/SiRNA •AuNP25 (0.2 
nM), IrC6 •AbH •AuNP100 (1.5 pM), IrC6 •SiRNA •AuNP100 (1.5 pM) and IrC6 
•AbH/SiRNA •AuNP100 (1.2 pM). At the end of each time point, cells were rinsed three 
times with PBS and imaging was carried out in imaging buffer (HEPES, pH 7). 
5. 5. 5. 2. HUVEC cells 
HUVEC cells were isolated from umbilical cords. HUVEC cells were extracted, 
maintained and grown in complete M199 complete media without phenol red and 
supplemented with 10% Fetal Calf Serum (FCS), 4 mM glutamine, 100 units/mL 
penicillin, 0.4 mg/mL streptomycin and 10 % endothelial cell growth supplement. 
HUVEC cells were grown as monolayer in vented cap T75 flasks coated with 1 % 
gelatin at 37 C in a humidified atmosphere of 5 % CO2 incubator. HUVEC cells were 
passaged 1 in 3 upon reaching 70 – 80 % confluency. A day prior to dosing 
with nanoparticles, HUVEC cells were seeded at a density of 300,000 cells per 35 mm 
MaTek glass dishes and allowed to attach overnight in a humidified 5 % CO2 
atmosphere at 37 C. For nanoparticle dosing, cell media was removed and the dishes 
washed twice with phosphate buffered saline (PBS) at pH 7. HeLa cells were dosed 
for 24 hours for IrC6 •AbH •AuNP13 (0.3 nM), IrC6 •SiRNA •AuNP13 (0.3 nM), IrC6 
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•AbH/SiRNA •AuNP13 (0.3 nM) IrC6 •AbH •AuNP25 (0.2 nM), IrC6 •SiRNA •AuNP25 
(0.3 nM), IrC6 •AbH/SiRNA •AuNP25 (0.2 nM), IrC6 •AbH •AuNP100 (1.5 pM), IrC6 
•SiRNA •AuNP100 (1.5 pM) and IrC6 •AbH/SiRNA •AuNP100 (1.2 pM). At the end of 
each time point, cells were rinsed three times with PBS and imaging was carried out 
in imaging buffer (HEPES, pH 7). 
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CHAPTER 6. GENERAL CONCLUSIONS AND FUTURE WORK 
IrC6 was designed based on a previously synthesised iridium(III) complex (IrbpySS) 
in which the phenyl pyridine ligand was modified with a hexyl chain to increase the 
hydrophobicity of the complex. These iridium(III) complexes were synthesised and 
characterised by NMR and MS. These iridium(III) complexes showed desirable 
photophysical properties such as long-lived luminescence lifetimes, emission in the 
visible range and high photostability. The IrC6 complex was found to undergo 
multiphoton excitation with high two-photon absorption cross-sections. It was found 
that the complex without the hydrophobic chain (IrbpySS) did not undergo multiphoton 
excitation. The reasons for this are unclear since both complexes displayed similar 
photophysical properties for absorption, excitation and luminescence lifetimes. This 
would be fully investigated in future work, to identify the properties of IrC6 that causes 
it to undergo multiphoton excitation whilst IrbpySS did not. Since IrbpySS did not 
undergo multiphoton excitation, IrC6 was chosen for the multiphoton lifetime imaging 
experiments and was conjugated to the surface of monodisperse 13 nm, 25 nm and 
100 nm gold nanoparticles. The photophysical properties of these luminescent 
nanoparticles revealed long luminescence lifetimes in the hundreds of nanosecond 
range, showed emission in the visible range and high photostability in solution. 
These iridium(III) coated nanoparticles were investigated as multiphoton lifetime 
imaging probes. Multiphoton lifetime imaging revealed uptake of these luminescent 
nanoprobes into cancer cell lines. It was found that detection of the long-lived iridium 
signal could be completely gated from background autofluorescence. These 
experiments revealed changes in lifetimes of the iridium(III) coated nanoparticles 
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depending on where they localised within the cell. This allowed for mapping of 
localisation patterns based on the long-lived lifetimes from iridium being sensitive to 
the cell microenvironment. The multiphoton lifetime images showed localisation of the 
iridium(III) functionalised nanoparticles was mainly within the cytoplasm of cells, but 
some nuclear localisation was also seen. It was not determined during these 
experiments if these functionalised nanoparticles were localising within vesicles 
(endosomes or lysosomes) or free within the cytoplasm of the cells. For future work, 
this would be investigated using endosomal and lysosome markers, which would allow 
for visualisation of the uptake of nanoparticles into these cellular compartments 
through changes in the iridium(III) lifetimes (multiphoton lifetime imaging) or co-
localisation in fluorescence (confocal microscopy). 
The fluorescence lifetime images revealed strong signal from the gold, by detecting 
the SPR band in the lifetime decay. This allowed for detection of the iridium signal in 
one channel, and the gold signal in a separate channel. This is the first time 
multichannel detection of short-lived and long-lived signals has been done. With this 
technique, the short-lived lifetimes from the gold and the long-lived lifetimes from the 
iridium(III) complex could be overlaid to reveal uptake of fully coated nanoprobes into 
cancer cells. The phosphorescence lifetime images showed longer lifetimes detected 
within the cells than seen for the metal complex and luminescent nanoprobes in 
solution. Lifetime analysis revealed the extension in luminescence lifetime was due to 
the nanoprobes interactions with biomolecules such as proteins within the cells.  
Upon successful application of these iridium(III) coated nanoprobes as multiphoton 
lifetime imaging probes, their targeting abilities were assessed. For these experiments 
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gold nanoparticles were functionalised with monoclonal antibodies which selectively 
targeted the tumour endothelial marker, CLEC14A and SiRNA molecules for targeted 
delivery into endothelial cells. Lifetime imaging revealed uptake of these functionalised 
nanoprobes into both cancer cells and endothelial cells. Long luminescence lifetimes 
were detected within the cytoplasm and nucleus of the cancer cells. Investigation of 
the selective targeting towards CLEC14A on the surface of endothelial cells was done 
on 25 nm gold nanoparticles. These preliminary results looked promising with long and 
short lived signals being detected in two separate channels. The lifetime images 
revealed that the uptake of gold nanoparticles was mainly within the cytoplasm of the 
endothelial cells with no aggregation occurring upon uptake. The antibody 
functionalised nanoprobes showed localisation around the membrane, proposing 
interactions of the antibody with CLEC14A present on the surface of the endothelial 
cells. Nanoprobes coated with SiRNA showed weak signal detected within the cells, 
possibly due to the high negative charge of the nanoparticles. The nanoprobes 
functionalised with both biomolecules showed a different pattern of uptake in 
comparison to the antibody only functionalised nanoprobes. This could be due to the 
SiRNA molecule hindering the antibodies selectivity towards the endothelial marker. 
Further work would need to be carried out to assess the true targeting and delivery 
mechanism of these functionalised nanoprobes. To investigate the selective delivery 
of SiRNA, SiRNA gene knockdown experiments would need to be designed. To assess 
these nanoparticles targeting abilities, uptake into angiogenic tumour vasculature 
would also need to be carried out. This would involve tumour bearing mice being 
injected with iridium(III) functionalised gold nanoparticles and two-photon lifetime 
imaging being carried out on tumour tissue sections to positively identify selective 
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targeting of tumour vasculature. The ability for multiphoton lifetime imaging to detect 
extensions in the long-lived iridium signal based on changes in the microenvironment, 
alongside detection of the short-lived signal from the gold in a separate channel proves 






NMR and Mass Spectra 
 




































Figure 7.9. Structure of 4,4’-di-(N-(Boc)-5-amino-1-pentoxy)-2,2’-bipyridine 
 
 




Figure 7.11. 13C NMR 4,4’-di-(N-(Boc)-5-amino-1-pentoxy)-2,2’-bipyridine (CDCl3). 
 





Figure 7.13. Structure of 4,4’-di-(5-amino-1-pentoxy)-2,2’-bipyridine 
 




Figure 7.15. MS 4,4’-di-(5-amino-1-pentoxy)-2,2’-bipyridine (CDCl3). 
 










Figure 7.18. 13C NMR 4,4’-di-(5-lipoamido-1-pentoxy)-2,2’-bipyridine (bpySS) 
(CDCl3). 
 














Figure 7.22. MS iridium dimer (CDCl3). 
 




Figure 7.24. 1H NMR IrbpySS (d6-acetone). 
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Figure 7.25. 13C NMR IrbpySS (d6-acetone). 
 







Figure 7.27. Steady-state emission spectrum (A) 30 µM IrbpySS lexc = 375 nm, 
(B) 30 µM IrbpySS lexc = 405 nm, (C) 30 µM IrC6 lexc = 375 nm and (D) 30 µM IrC6 






Figure 7.28. Aggregated nanoparticles. Absorption spectra of IrC6 •AuNP25 in 
water after visual aggregation in solution by turning from red to purple. Particles 
show clear aggregation with the SPR lmax shifting from 525 nm to 654 nm along 
with peak broadening. 






𝑁 = 30.89602	𝐷) 
Where: 
N is the number of Atoms per AuNP 
r is the density of gold (19.3 g/cm3) 
D is the core diameter of the AuNPs taken from TEM (nm) 
M is the atomic weight of gold (197 g/mol1) 




Nanoparticle Diameter (nm) Number of Gold atoms per AuNP (N) 
15 1.04 x 105 
25 4.82 x 105 
95 2.64 x 107 
 
Calculating number of AuNPs per HeLa cell using data from ICP-MS 
Concentrations detected in ICP-MS were 77 µg/L, 172 µg/L and 1485 µg/L for IrC6 




Number of gold atoms calculated: 7.04 x 1014, 1.57 x 1015 and 1.36 x 1016 for IrC6 
•AuNP13, IrC6 •AuNP25 and IrC6 •AuNP100 respectively. 




Number of AuNPs calculated: 6.7 x 109, 3.26 x 109 and 5.13 x 108 for IrC6 •AuNP13, 
IrC6 •AuNP25 and IrC6 •AuNP100 respectively. 




Number of AuNPs per cell (1 x 105) was calculated: 67,000, 26,000 and 5100 for IrC6 





Figure 7.30. Quantum Yield Calculations 
Spectral scans of the emission region (E), recorded from 450 – 700 nm and excitation 
scatter region (S), recorded from 365 – 385 nm of the sample (s) and reference 
standard or solvent (r).  
 
 
Figure 7.31. Absorption spectra of (left) sample, IrC6 •AuNP25 (dotted line) and 
reference, Z •AuNP25 (solid line). (Right) Expanded region showing SPR overlap 
of sample and reference. 
 
Quantum yield experiments were carried out using an integrated sphere attachment 
on Edinburgh Instruments FLS920 spectrometer, the equation above is applied for 
calculating the Quantum Yield. For molecular complex a sample of IrC6 in water (1% 
MeOH in water) and reference solvent of 1% MeOH in water was used. A different 
method was applied for the functionalised gold nanoparticles. A sample of IrC6 •AuNPs 
and a reference standard of Z •AuNP25 was used. The reference standard was diluted 
until the SPR peak of the gold matched that of the sample SPR peak, which was 






Spectral scans of the emission region (E), recorded from 450 – 700 nm and excitation 
scatter region (S), recorded from 365 – 385 nm of the sample (s) and reference 
standard or solvent (r).  
 
 
Figure 7.32. UV/Vis showing purified AbH •AuNPs for (left) 4 nM AbH •AuNP13, 





Figure 7.33. UV/Vis showing purified IrC6 •AbH •AuNPs for (left) 3 nM IrC6 •AbH 
•AuNP13, (middle) 2 nM IrC6 •AbH •AuNP25 and (right) 15 pm IrC6 •AbH 











Figure 7.35. UV/Vis showing purified SiRNA •AuNPs for (left) 4 nM SiRNA 




Figure 7.36. UV/Vis showing purified IrC6 •SiRNA •AuNPs for (left) 3 nM IrC6 
•SiRNA •AuNP13, (middle) 3 nM IrC6 •SiRNA •AuNP25 and (right) 15 pm IrC6 
•SiRNA •AuNP100 in water. 
 
 
Figure 7.37 UV/Vis showing purified AbH/SiRNA •AuNPs for (left) 3.5 nM 
AbH/SiRNA •AuNP13, (middle) 3.5 nM AbH/SiRNA •AuNP25 and (right) 17 pm 






Figure 7.38 UV/Vis showing purified IrC6 •AbH/SiRNA •AuNPs for (left) 3 nM IrC6 
•AbH/SiRNA •AuNP13, (middle) 2 nM IrC6 •AbH/SiRNA •AuNP25 and (right) 12 




Figure 7.39. Dynamic Light Scattering (DLS) showing size by intensity for IrC6  
•AuNP25. Two peaks have been intentified in the size distribution graph. The 












Figure 7.40. Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH •AuNP13 
analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs showing 
iridium gold nanoparticles. Intensity images can be seen in grey, left of both the FLIM and 
PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which is 
attributed to the short-lived signal from the gold. Lifetime decay is fitted to one component 
to give a c2 of 1.38. (Right) PLIM image shows lifetime decay characteristic of the long-lived 




Figure X.17 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH •AuNP25 
analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs showing 
iridium gold nanoparticles. Intensity images can be seen in grey, left of both the FLIM and 
PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which is 
attributed to the short-lived signal from the gold. Lifetime decay is fitted to one component 
to give a c2 of 1.96. (Right) PLIM image shows lifetime decay characteristic of the long-lived 






Figure X.18 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH •AuNP100 
analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs showing 
iridium gold nanoparticles. Intensity images can be seen in grey, left of both the FLIM and 
PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which is 
attributed to the short-lived signal from the gold. Lifetime decay is fitted to one component 
to give a c2 of 1.44. (Right) PLIM image shows lifetime decay characteristic of the long-lived 




Figure 7.41 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •SiRNA 
•AuNP13 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.41. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 





Figure 7.42 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •SiRNA 
•AuNP25 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.28. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 




Figure 7.43 Two-photon fluorescence lifetimes of IrC6 •SiRNA •AuNP25 and 
IrC6 •SiRNA •AuNP100 analysed on SPCImage (Becker & Hickl software, 
version 5.0). Binning had to be increased to 10 to fit lifetimes detected for IrC6 
•SiRNA •AuNP25, in comparison to IrC6 •SiRNA •AuNP100. Red boxes are 
drawn over areas showing weak vs strong signal from the gold. Both the 
lifetime decays show a sharp peak in the lifetime decay plot which is attributed 
to the short-lived signal from the gold. (Top) Lifetime decay for IrC6 •SiRNA 
•AuNP25 is fitted to one component to give a c2 of 1.27. (Bottom) Lifetime 





Figure 7.44 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •SiRNA 
•AuNP100 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.51. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 
to give a c2 of 1.20. 
 
 
Figure 7.45 Two-photon fluorescence and phosphorescence lifetimes of IrC6 
•SiRNA •AuNP13 and IrC6 •AbH/SiRNA •AuNP13 analysed on SPCImage 
(Becker & Hickl software, version 5.0). Red boxes are drawn over areas 
showing weak vs strong signal from the gold and iridium. (Left) Fluorescence 
lifetime decays for (Top) IrC6 •SiRNA •AuNP13 and (Bottom) IrC6 •AbH/SiRNA 
•AuNP13.Both the lifetime decays show a sharp peak in the lifetime decay plot 
which is attributed to the short-lived signal from the gold. (Left) 
Phosphorescence Lifetime decay for (Top) IrC6 •SiRNA •AuNP13 and (Bottom) 





Figure 7.46 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH/SiRNA 
•AuNP13 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.70. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 
to give a c2 of 1.11. 
 
Figure 7.47 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH/SiRNA 
•AuNP25 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.48. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 




Figure 7.48 Two-photon fluorescence and phosphorescence lifetimes of IrC6 •AbH/SiRNA 
•AuNP100 analysed on SPCImage (Becker & Hickl software, version 5.0). Blue cross hairs 
showing iridium gold nanoparticles. Intensity images can be seen in grey, left of both the 
FLIM and PLIM images. (Left) FLIM image shows a sharp peak in the lifetime decay plot which 
is attributed to the short-lived signal from the gold. Lifetime decay is fitted to one 
component to give a c2 of 1.30. (Right) PLIM image shows lifetime decay characteristic of 
the long-lived signal from the iridium complex. Lifetime decay is fitted to three components 
to give a c2 of 1.28. 
 
 
 
 
